



Clinical application of circulating tumor cells in patients with 







PhD Tesis, 2015 







Clinical application of circulating tumor cells in patients with metastatic castration-






Memoria que presenta: 
Luis León Mateos 








Fdo. Luis León Mateos 




El Doctor Rafael López López profesor asociado de ciencias de la salud, en el 
departamento de Medicina de la Universidad de Santiago de Compostela, Jefe de 
Servicio de Oncología Médica del Hospital Clínico Universitario de Santiago de 
Compostela,  el Doctor Ihab Abdulkader profesor asociado de ciencias de la salud, en 
el departamento de Medicina de la Universidad de Santiago de Compostela, Adjunto en 
el  Servicio de Anatomía Patológica del Hospital Clínico Universitario de Santiago de 
Compostela  y la Doctora Laura Muinelo Romay investigadora del laboratorio de 





Que el presente trabajo titulado “Clinical application of circulating tumor cells in 
patients with metastatic castration-resistant prostate cancer” se ha realizado bajo su 
dirección por el licenciado en Medicina Luis León Mateos y se encuentra en 
condiciones de presentarse y defenderse como tesis doctoral ante el tribunal 
correspondiente en la Universidad de Santiago de Compostela.  
 
 
Para que así conste, se expide el presente certificado en Santiago de Compostela 
















“The answer is blowing in the wind” 




Por mis padres. 
Para Javier, Sabela, Miguel, Pedro. 
A Bea.  
 





Background. Prostate cancer (PCa) is the most common diagnosed male malignancy in 
the Western world. One third of patients will develop metastatic castration resistant 
prostate cancer (mCRPC). 
To monitor systemic disease, the study of circulating tumor cells (CTCs) can be a 
supplement or an alternative to the serum PSA and imaging methods. In the present 
study we assessed the value of CTC count and molecular characterization to manage 
mCRPC patients. 
Methods. Blood samples from 29 mCRPC patients treated with first line taxanes were 
analyzed at four different time points. Samples were first processed by the Cellsearch 
platform. Besides we did a CTC isolation and a gene expresson analysis by RT-qPCR at 
baseline in 29 mCPRC. In addition a whole gene expression analysis was carried out on 
blood samples extracted from 9 patients and from 6 healthy donors. 
Results. CTC count worked as a prognostic factor: median OS was 16 months for those 
patients with ≥5 CTCs at baseline versus not reached for those < 5 CTCs. In addition to 
the CTC count we identified a molecular CTCs-signature that could be useful for the 
initial diagnosis, prognosis and therapy monitoring. Thus, high levels of AR, CYP19 
and GDF15 were associated with poor PFS rates while AR, GDF15 and BIRC5 were 
also found as consistent predictors of OS in the univariate analysis. Finally after the 
global gene expression approach we found a general stress-survival phenotype in the 
CTC population of mCRPC patients partially based on cell proliferation, apoptosis, 
adhesion and migration. 
Conclusions. In our cohort CTC count using CellSearch technology has prognostic 
value. In parallel, we have also demonstrated the feasibility of an alternative method of 
CTC isolation and gene expression analysis, identifying a panel of genes with 
prognostic relationship and deserves to be explored for the treatment monitoring. 
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1. Prostate cancer overview.  
1.1 Epidemiology.   
Prostate cancer is the most prevalent male urogenital malignancy and the second leading 
cause of cancer death among men in industrialized countries, with 1.1 million new cases 
and 307,500 estimated deaths to have occurred in 2012. Age-standardized incidence and 
mortality per 100,000 inhabitants per year were 96.0 and 19.3 in Europe and 96.8 and 
15.2 in Spain, respectively.  
About two-thirds of these cases were diagnosed in economically developed countries, 
with the highest incidence in Northern and Western Europe, Northern America, 
Oceania, and some Caribbean island nations, and lowest in Asia. Much of the variation 
reflects differences in the use of prostate specific antigen (PSA) testing the aging 
population, the use of improved diagnostic techniques, programs for early detection and 
increased surgical procedures performed on benign prostate disease  (1). 
 
 
Figure 1.1 Prostate Cancer. SEER incidence and US death rates (1975-2011). 
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Death rates for prostate cancer have been decreasing in Northern America, Oceania, and 
Northern and Western Europe. This decrease has been attributed mainly to improved 
treatment and/or early detection, although the specific contribution of PSA testing is 
debated. In the other hand, in some Asian and Central and Eastern European countries 
mortality rates are increasing (1). Risk factors associated with  economic development 
as increased consumption of animal fat or physical inactivity may be responsible for this 
trend. 
1.2 Risk factors.  
The only well-established risk factors for prostate cancer are increasing age, race, a 
family history of the disease and certain inherited genetic conditions. In fact more than 
65% of all prostate cancer cases in the United States are diagnosed in men over the age 
of 65 years, and 97% occur in men 50 and older  (2). African American men are more 
likely to develop prostate cancer compared with Caucasian men and are nearly 2.5 times 
as likely to die from the disease. Conversely, Asian men who live in Asia have the 
lowest risk. The reason for the high prostate cancer risk among some populations of 
African descent is still poorly understood, though it may in part reflect differences in 
genetic susceptibility (3).  
Genetic studies suggest that strong familial predisposition may be responsible for 5%-
10% of all prostate cancers. Compared with men that have no familiy history, those with 
one first-degree relative with prostate cancer have twice the risk; this risk is five times 
greater in men with two first-degree relatives affected. Germline mutations in the 
BCRA gene increase not only the risk of prostate cancer, but a more agressive disease 
with poor clinical outcome (4). Other studies suggest that a diet high in processed meat 
or dairy foods may increase risk, that obesity increases the risk of aggressive prostate 
cancer and that smoking is associated with prostate cancer death, but not incidence.  
Prevention and early detection. 
Lifestyle modifications such as smoking cessation, exercise and weight control could be 
contribute to reduce the risk of developing prostate cancer. Early detection of prostate 
cancer by prostate-specific antigen screening is controversial, because it is difficult to 
establish if early diagnosis is related to a benefit in overall survival, and side effects 
associated with a possible treatment are not negligible (5).  Changes in PSA velocity or 
PSA doubling time, frequency of screening, and the use of other biomarkers have the 
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potential to minimise the overdiagnosis associated with PSA screening. Several new 
biomarkers for individuals with raised PSA concentrations or those diagnosed with 
prostate cancer will try to distinguish the more aggressive subtypes of prostate cancer 
and can help select in which tumors treatment should start early and in which patients 
the onset of therapy could be delayed.  
Several pharmacological agents such as aspirin could prevent development of prostate 
cancer. Chemoprevention studies with 5α-reductase inhibitors (finasteride and 
dutasteride) are based in the effect of this compunds to reduce the amount of certain 
male hormones in the body  (6,7) . Both drugs have been found to lower the risk of 
prostate cancer by 25% in large clinical trials, but its use is controversial due to: 1) a 
possible effect on the occurrence of more aggressive prostate cancer; 2) an increase in 
side effects and 3) no survival impact. Neither finasteride nor dutasteride are approved 
for the prevention of prostate cancer at this time.  
PSA screening has played a critical role in the downward migration of prostate cancer 
stage seen over the past decades. The risk of prostate cancer increases with increasing 
PSA, but there is no level of PSA below which the risk of prostate cancer can be 
eliminated. Besides the difficulty of finding a PSA cutoff to discriminate malignant 
tumors, many doctors argue that the benefits of early detection are, at best, moderate, 
and that early detection could results in overdetection of a  disease that would not be a 
problem for the patient if undetected or untreated (8). Besides false-positives results 
could contribute to patient anxiety and the increased costs or complications associated 
with unnecessary biopsies.  
So in the absence of benefits in survival or quality of life it is difficult to decide on 
whether to make early detection of prostate cancer. Men should consider their personal 
risk factors and discuss them with their doctors before making a decision on whether to 
perform screening with PSA. Men at high risk of developing prostate cancer (African 
Americans or men with a close relative diagnosed with prostate cancer before the age of 
65) should consider screening beginning at age 45.  
1.3 Diagnosis and staging.  
Signs and symptoms. 
Typically, prostate cancer at an early stage causes no symptoms. However, more 
advanced prostate cancer can often cause symptoms such as: 
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- Urinary discomfort, including slow or weak urinary stream. 
-  Dysuria, urinary frequency and nocturia.  
These symptoms can also occur in cases such as benign prostatic hypertrophy. 
Hematuria is also characteristic and sometimes patients may experience erectile 
dysfunction. 
In later stages, with locally advanced or metastatic disease patients may experience pain 
in the pelvis, hips, spine, rib or other areas due to the spread of cancer to the bones, 
lymph nodes or other organs. A serious complication is spinal cord compression, which 
usually present with pain in spine, numbness in legs or feet, or even paraplegia and 
urinary incontinence. 
Anatomy and histology. 
The prostate lies below the bladder and encompasses the prostatic urethra (Figure 1.2). 
It is surrounded by a capsule and is separated from the rectum by the Denonvilliers 
aponeurosis. The blood supply to the base of the bladder and prostate comes from the 
vesicoprostatic artery, wich is derived from the internal iliac. The neurovascular bundle 
lies on either side of the prostate on the rectum. It is derived from the pelvic plexus and 
is important for erectile function. 
Prostatic tumor originates in the peripheral zone of the gland, and then grows to invade 
the capsule, seminal vesicles and periprosthetic tissues. Spread to the central area is late 
and can cause urinary obstruction. 
Histological diagnosis is based in performing prostate biopsy. The system used for 
classifying the histologic characteristics of prostate cancer is the Gleason scoring 
system, which uses the glandular architecture within the tumor (Figure 1.3)  (9). The 
predominant pattern and the second-most common pattern are each given a grade of 
between 1 and 5 (1=more differentiated; 5=undifferentiated). The Gleason score is the 
sum of these 2 grades. Scoring based on the 2 most common patterns is an attempt to 
factor in the considerable heterogeneity within cases of prostate cancer. In addition, this 
scoring method was found to be superior for predicting disease outcomes compared 
with using the individual grades alone. 
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Figure 1.3. Gleason score. A. Gleason score 3, hematoxylin-eosin (HE), x10. B. Gleason score 5, 
hematoxylin-eosin, x10. 
Histological types of prostate carcinoma are: 
- Epithelial tumors: Adenocarcinoma, small cell, transitional cell, clear cell, 
carcinosarcoma. 
- Mesenchymal malignant tumor <0.3%: Rhabdomyosarcoma, Leioimiosarcoma. 
- Lymphomas. 
- Prostate metastases: lymphoma, leukemia, lung adenocarcinoma, melanoma, 
seminoma, malignant rhabdoid tumor. 
Adenocarcinoma is the most common histologic type and comprises 95% of cases of 
prostate cancer (Figure 1.4). It originates in the secretory cells of the acini and the 
ductus and it is usually multifocal and heterogeneous. More than 75% of the tumors 
appear in the peripheral zone. This produce a change in consistency, wich can be felt 
during rectal exploration/palpation. Adenocarcinoma has an infiltrative growth pattern 
(papillary, cribriform, comedo or acinar). 
Most adenocarcinomas are of the acinar type, which are usually referred to as prostate 
carcinomas. More than 1% of prostate carcinoma are made up of other variants that 
often have a poor prognosis such as ductal carcinoma, mucinous carcinoma, signet ring 
cell carcinoma and small cell carcinoma. Neuroendocrine cells are one of the epithelial 
populations in the prostate. Neuroendocrine differentiation (NED) has been observed in 
prostate cancer. In addition to small cell neuroendocrine carcinomas and carcinoid 
tumors of the prostate, prostatic adenocarcinomas may have NED. 
Diagnostic test. 
Prostate tumor diagnosis is based on three elements: elevated PSA, suspicious digital 
rectal examination (DRE) and prostate biopsy.  
A B 
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PSA. Serum PSA is a protein body-specific but not cancer-specific, which explains the 
limitations of their use in the diagnosis of prostate cancer. However, it is the most useful 
tumor marker for diagnosis and monitoring of prostate cancer. Higher PSA levels 
correlate with higher probability of detecting prostate cancer, but there is not a lower 
threshold that allows rule out malignancy  (7). The "normal" PSA values are between 0 
and 4.0 ng / ml (low probability of cancer, especially if regular DRE); PSA> 10.0 ng / 
ml is highly suggestive of cancer. In patientes with levels between 4.0-10.0 ng / ml 
diagnoses of benign and malignant conditions overlap. 
 
Figure 1.4. Prostate cancer histology. A. Prostate adenocarcinoma (acinar type), Gleason score 4+4, 
HE, x10. B. Basaloid pattern prostate adenocarcinoma, HE, x10.  C. Neuroendocrine prostate carcinoma 
HE, x10. D. Prostate adenocarcinoma (mucinous pattern), HE, x20.  
The percentage of measured PSA existing in the free form (free:total PSA ratio) is 
useful in assessing the risk of prostate cancer in patients with borderline or moderately 
increased total PSA (4.0-10.0 ng/mL) and has been used to help select men who should 
have follow-up prostate biopsy. Usually 10-40% of the total PSA circulates as free: PSA 
free/total <0.10 is associated with cancer but also should be used with caution because it 
A B 
C D 
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is affected by other factors. 
Cancer is a growth process and it is natural that we should be concerned with how PSA 
changes over time. Such change is measured by PSA velocity or PSA doubling time, 
described in general as “PSA kinetics”. PSA velocity is given in ng/ml/year and can be 
thought of as a prediction: for example, a patient with a current PSA of 4 ng/ml and a 
PSA velocity of 0.5 ng/ml/year would be expected to have a PSA of 4.5 ng/ml in 12 
months time. PSA doubling time is the number of months it would take for PSA to 
increase two-fold. Other methods have been proposed to increase the specificity of PSA, 
including age-specific PSA reference ranges and PSA density. 
Digital rectal examination.  
Digital rectal examination is physician dependent, and serial examinations are best. 
Various factors are considered when a DRE is performed. A nodule is important, but 
findings such as asymmetry, difference in texture and bogginess are important clues to 
the patient's condition and should be considered in conjunction with the PSA level. 
Change in texture over time can offer important clues about the need for intervention.  
This maneuver has low sensitivity and specificity but improves when combined with an 
elevated PSA>2 ng/mL (positive predictive value (VPP): 5-30%) (11). The finding of 
asymmetric areas of induration or palpable nodules do suspect a malignancy and 
requires performing a prostate biopsy regardless of the value of PSA and especially in 
patients over 45 years of age with other risk factors for the disease  (11). DRE can 
detect tumors in the lateral and posterior surface of the prostate gland but it´s not useful 
for 25-35% of tumors located in other locations, small tumors, T1 or non-palpable 
tumors. A pathological DRE is usually predictive of more aggressive prostate neoplasia 
(Gleason ≥ 7). 
In most patients who are diagnosed with prostate cancer, however, DRE results are 
normal and the PSA readings are abnormal. 
Prostate Biopsy.  
The number of biopsies that should be performed is debated. Sextant- versus 12 or 18-
core biopsy protocols are published in the literature. The 12- or 18-core protocols yield 
more specimens from the lateral regions and usually sample the transition zone  (11). 
Several studies have demonstrated an increase in the cancer detection rate, but others 
have not. 
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The pathology report should include the maximum extent of the cancer, Gleason 
dominant pattern and higher grade (modified Gleason) to predict the pathological stage 
and the progression free survival (PFS). 
The pathology report of a prostate biopsy should contain  (11): 
- Gleason score. 
- Number of  positive samples. 
- Percentage of cancer in positive samples. 
- Perineural invasion and extraprostatic extension. 
- Accurate histologic subtype. 
- Presence or absence of intraductal carcinoma. 
In patients with a persistently elevated PSA level in the face of negative biopsy results, 
the literature supports repeating the biopsy once or twice. Among cancer cases, 31% 
were detected on repeated biopsy and 39% were detected if the PSA value was greater 
than 20 ng/mL.  
Staging. 
The staging system for prostate cancer is based on TNM AJCC  but also takes into 
account the serum PSA and Gleason score (Table 1.1). Localized disease should be 
classified into prognostic groups for decision-making (12). A predictive model 
determines the probability of 5-year biochemical control after local treatment (90%, 
60% and 30% respectively): 
- Low risk: PSA <10 ng /ml, Gleason score ≤ 6 and T1c or T2a. 
- Intermediate risk: PSA 10-20 ng /ml, Gleason 7 and T2b. 
- High risk: PSA> 20 ng / ml, Gleason score ≥ 8 and T2c. 
Staging of the disease is determined by various factors such as life expectancy, 
comorbidities, symptoms, extent of tumor according to the DRE, PSA level and 
Gleason score. Asymptomatic patients with favorable risk and life expectancy less than 
10 years will not receive treatment and they dont need further testing. 
Men with PSA levels above 10 ng/mL, Gleason score 7 or higher, or physical findings 
that suggest stage T3 disease should undergo a staging computed tomography (CT) scan 
and a bone scan. CT scan can be used to evaluate extension into the bladder and lymph 
nodes. 
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TNM staging System for prostate cancer 
 
Primary Tumor (T) 
Clinical 
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
T1  Clinically inapparent tumor neither palpable nor visible for imaging 
 T1a Tumor incidental histologic finding in 5% or less of tissue resected 
 T1b Tumor incidental histologic finding in more than 5% of tissue resected 
 T1c Tumor identified by needle biopsy (e.g.,becasuse of elevated PSA) 
T2  Tumor confined within prostate* 
 T2a Tumor involves one-half of one lobe or less 
 T2b Tumor involves more than one-half of one lobe but not both lobes 
 T2c Tumor involves both lobes 
T3  Tumor extends through the prostatic capsule** 
 T3a Extracapsular extension (unilatera or bilaterla) 
 T3b Tumor invades the seminal vesicle(s) 
T4  Tumor is fixed or invades adjacent structures other than seminal vesicles: 
bladder, levator muscles, and/or pelvic wall 
 
Patological (pT) 
pT2  Organ confined 
 pT2a Unilateral, involving one-half one side or less 
 pT2b Unilateral, involving more than one-half of one side but not both sides 
pT3  Extraprostatic extension 
 pT3a Extraprostatic extension or microscopic invasion of the bladder neck  
 pT3b Seminal vesicle invasion  
pT4 
 
 Invasion of bladder, rectum 
 
*Note: There is no pathologic T1 classification 
**Note: Positive surgical margin should be indicated by an R1 descriptor (residual microscopic 
disease) 
 
Regional Lymph Nodes (N) 
Clinical 
Nx  Regional lymph nodes were not assessed 
N0  No regional lymph node metastases 
N1  Metastasis in regional lmph node(s) 
Pathologic  
PNX  Regional nodes not sampled  




 Metastases in regional node(s) 
 
Distant metastasis (M)* 
M0  No distant metastasis 
M1  Distant metastasis 
 M1a Non-regional lymph node(s) 
 M1b Bone(s) 
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ANATOMIC STAGE/PROGNOSTIC GROUPS* 
Group T N M PSA Gleason 
I T1a-c N0 M0 PSA<10 Gleason ≤6 
 T2a N0 M0 PSA<10 Gleason ≤6 
 T1-2a NO M0 PSA X Gleason X 
IIA T1a-c N0 M0 PSA<20 Gleason 7 
 T1a-c N0 M0 PSA<20 Gleason ≤6 
 T2a N0 M0 PSA<20 Gleason ≤7 
 T2b N0 M0 PSA<20 Gleason ≤7 
 T2b N0 M0 PSA X Gleason X 
IIB T2c N0 M0 ANY PSA Any 
Gleason 
 T1-2 N0 M0 PSA ≥20 Any 
Gleason 
 T1-2 N0 M0 Any PSA Gleason ≥8 
III T3a-b N0 M0 Any PSA Any 
Gleason 
IV T4 N0 M0 Any PSA Any 
Gleason 
 Any T N1 M0 Any PSA Any 
Gleason 
 Any T Any N M1 Any PSA Any 
Gleason 
 
Table 1.1. TNM staging system for prostate cancer**.*Note: When either PSA or 
Gleason is not available, group should be determined by T stage and/or either PSA or 
Gleason as available. 
** Adapted from NCCN guideliness. 
Magnetic resonance imaging (MRI) increases the accuracy in detecting extracapsular 
extension and seminal vesicles infiltration and can be useful in the  selection of 
candidates for local treatment (PPV 70%) , and for the preservation of the nerve bundle 
in the radical surgery patients (Figure 1.5 and 1.6) (13). Dynamic, contrast-enhanced 
MRI and MR spectroscopic imaging are complementary in local staging, but their use is 
currently limited to selected centers. Diffusion-weighted MRI appears to improve 
detection of transition-zone prostate cancer.  
Nodal staging should only be done if it will influence the therapeutic decision (not 
necessary in PSA <20 ng/mL, ≤T2a, Gleason ≤6). However patients with elevated PSA, 
T2b-T3 tumors, poorly differentiated or with perineural invasion are at high risk of 
lymph node invasion. CT scan shows superiority to MRI in the detection of nodal 
invasion, and is quite specific (90-95%) to high-risk patients. CT-guided FNA can be 
technically difficult and has many false negatives. 
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Figure 1.5. Pelvic MRI on T2 sequence. Patient with suspected prostate carcinoma (PSA 18). Pelvic MRI 
on T2 sequence shows a neoplasm invading the neurovascular left band (white arrow) and alteration of 
the bone signal (red arrows). 
The gold-standard for nodal staging is open or laparoscopic lymphadenectomy and is 
usually reserved for patients at high risk of nodal spread. It is not recommended for 
those who are going to be treated with radiotherapy. C-choline PET has low sensitivity 
for detecting lymph node involvement. 
Prostate cancer has a predilection for bone, affecting 85% of patients who die from the 
disease. Other common metastatic sites are: lymph nodes, lung, liver, brain and skin. 
PSA can be useful to determine which tests should be performed in the staging. PSA 
values > 100 ng / mL predict distant disease with a PPV of 100% 
In case of suspected metastasis or when it´s necessary to complete staging in high risk 
patients abdominopelvic CT it is recommended to rule out locoregional involvement 
and Rx chest to rule out pulmonary metastases. Spine MRI is used to study malignant 
vertebral compression in patients with vertebral pain or neurological symptoms.  
MRI is superior to bone scanning in evaluating bone metastasis but their use as routine 
total-body surveys is not yet widespread (Figure 1.7) (14). Instead, it is used to 
determine the etiology of questionable lesions found on bone scans.  
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Figure  1.6. Pelvic MRI (T2 and diffusion). Fusion of sequences T2 and diffusion imaging showing high b 
value. Color map shows malignant presacral lymph nodes and a left iliac lymph node positive (white 
arrow, right image). Diffusion is restricted in prostate tumor (white arrow, center) and bone 
involvement is confirmed (red arrow). Stage cT3cN + CM1 (bone). 
ProstaScint scanning involves the use of a murine monoclonal antibody that reacts with 
prostate-specific membrane antigen to identify cancer in the prostate and in metastatic 
deposits. F-fluorodeoxyglucose (18F-FDG) currently has no indication in the staging of 
prostate cancer. However the C-choline PET is useful in assessing local relapse of 
prostate cancer when a local salvage therapy is assessed. 
 
Figure  1.7. Assessment of bone disease in patients with prostate cancer. 61 years old man. PSA 73 
ng/mL, alkaline phosphatase 1125 UI/L. A bone scan was negative. Whole-body MRI showed multiple 
bone metastases. 
Clinical application of circulating tumor cells in patients with metastatic castration-resistant prostate cancer 
32 
Prognostic factors and biomarkers. Molecular testing.  
In the therapeutic management of patients with prostate cancer factors such as life 
expectancy and biological characteristics of the tumor should be assessed. Prostate 
cancers are best characterized by clinical stage determined by DRE, Gleason score in 
the biopsy specimen and serum PSA level. The more clinically relevant information that 
is used in the calculation of time to PSA failure, the more accurate the result.  
Several approaches based on clinical factors are used to assess the prognosis of prostate 
cancer patients. The risk stratification schemes most commonly used are those of 
D'Amico and NCCN (15-18). Stratification helps clinicians to distinguish between 
tumors with better and worse prognosis and so take treatment decisions based on this 
risk (Figure 1.8). 
The Partin tables were the first to achieve widespread use for counseling men with 
clinically localized prostate cancer (19). This tables give the probability (95% 
confidence intervals) that a patient with a certain clinical stage, Gleason score and PSA 
will have a cancer of each pathologic stage. Nomograms can be used to inform 
treatment decision-making for men contemplating active surveillance, radical 
prostatectomy, neurovascular bundle preservation or omission of pelvic lymph node 
dissection (PLND) during radical prostatectomy, brachytherapy, or external beam 
radiation therapy (EBRT). 
Given the non-related cancer causes of mortality, many men who sustain PSA failure 
will not live long enough either to develop clinical evidence of distant metastases or to 
die from prostate cancer. Not all PSA failures are clinically relevant, thus PSA doubling 
time may be a more useful measure of risk of death: men with a short PSA doubling 
time are at greatest risk of death. 
Several genomic/proteomic tests have become commercially available in recent years. 
Althougth they have not been approved by the FDA and their validation is somewhat 
limited it could help make better clinical decisions for treating PCa patients.  
The Oncotype DX was developed to test fixed paraffin-embedded tissue samples that 
were obtained by needle biopsy. The assay measures the expression of 12 cancer-related 
genes which represent four different biological pathways [cellular organization (FLNC, 
GSN, TPM2, and GSTM2); androgen pathway (AZGP1, KLK2, SRD5A2, and 
RAM13C); proliferation pathway (TPX2); and stromal response (BGN, COL1A1 and 
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SFRP4)] and five reference genes (used to normalize and control preanalytical and 
analytical variability). These genes are algorithmically combined to calculate the 
Genomic Prostate Score  (20). The combination of GPS and NCCN criteria improves 
risk discrimination of PCa into very low, low and modified intermediate risk in order to 
select appropriate candidates for active surveillance. 
The Prolaris assay produces a cell cycle progression (CCP) score from RNA expression 
levels of 31 genes involved in CPP that were selected because of correlation with 
proliferation of PCa. This molecular test  directly measures tumor cell growth 
characteristics to stratify disease risk of progression. Cooperberger et al validated CPP 
in a prostatectomy cohort  (21). They found that low expression is associated with a low 
risk of disease progression, whereas high expression is associated with increased risk of 
disease progression. This test may be useful to determine which patients need either 
close monitoring or additional therapy. 
 
Figure 1.8.  Risk stratificacion based treatment. From NCCN guideliness version 1.2015. 
2. Treatment.  
2.1 Non metastatic disease.   
Most patients present with tumors confined to the prostate (Figure 1.9). Treatment options 
vary depending on age, stage, and Gleason score, as well as other medical conditions.  
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In low risk prostate cancer, the patient decide whether he prefers an active treatment 
(surgery, brachytherapy or external beam radiotherapy(EBRT)) versus active 
surveillance. Active surveillance instead of immediate treatment is appropriate for many 
patients, particularly men with less aggressive tumors and for older men. 
Intermediate risk prostate cancer. The patient can choose from a radical prostatectomy 
with extended lymphadenectomy versus external beam therapy (3D CRT/intensity 
modulated radiotherapy (IMRT)) associated with 6 months of androgen deprivation. 
Brachytherapy is also an alternative in selected patients. The patient has moderate risk 
of erectile dysfunction regardless of the chosen method of treatment. 
High risk disease. The patient should know that it is feasible that he requires a 
multimodal treatment. The best therapy choice should be identify in a multidisciplinary 
committee: clinical characteristics of the tumor, performance status and preferences of 
the patient shoud be considered. Options are IMRT + 2-3 years of androgen deprivation 
vs radical prostatectomy with extended lymphadenectomy and potential further 
treatments depending on the surgical margins, nodal status and biochemical evolution. 
Brachyterapy has a role as dose intensification in intermediate and high risk prostate 
cancer. 
 
Figure 1.9. Prostate cancer presentation.  
 






Chapter 1. General Introduction 
35 
Active surveillance.  
Active surveillance began as a necessity due to the overtreatment of many patients with 
indolent prostate tumors, recognizing them as tumors that had not conditioned the life 
expectancy of the patients. Active surveillance differs from watchful waiting. With 
watchful waiting, patients forgo close follow-up and primary treatment. With active 
surveillance, the physician monitors the course of the disease over time and and decide 
to start treatment if the disease progresses.  
Active surveillance is increasingly being recommended for men with low-risk disease, 
which includes T1-2a disease, a Gleason score of 2-6, and a PSA level below 10 ng/mL. 
Progression of local disease may be indicated either by increased tumor volume, 
changes in the Gleason score or even by PSA doubling times.  
The optimal management of men on active surveillance is evolving, and varies 
according to different guidelines. Monitoring typically consists of PSA testing every 3 
months and repeat biopsy at 12- to 24-month intervals. Biopsy findings are the most 
important factor in deciding whether to pursue treatment. A rapid PSA level rise or 
patient choice can also prompt the physician to proceed to treatment  (22). 
Surgery.  
Radical prostatectomy (RP) involves complete resection of the prostate and seminal 
gland. The goal of radical prostatectomy is the eradication of the disease preserving the 
quality of life of patients, and so it is only appropriate for men whose tumor is confined 
to the prostate. The surgical option should not be ruled exclusively by the patient's 
age, but because of potential perioperative morbidity it should be reserved for patients 
whose life expectancy is 10 years or more. 
Radical prostatectomy is popularly associated with risk of incontinence and impotence. 
However, such complications arising from the anatomical position of the gland and so 
any prostate treatment involves a certain risk of injury to these structures and the 
development of complications. The prostate is overlapped at its distal portion with the 
external sphincter muscle and is involved in the dorsolateral area by neurovascular 
tissue responsible for erection. Prostatectomy includes the dissection of the gland 
regarding its neighboring structures (bladder, rectum, sphincter and neurovascular 
bundles) and then anastomizing the bladder to the urethra through a suture. 
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Minimally invasive techniques have shown only better intreoperative bleeding. The 
only variable that is associated with better oncological and functional results is the 
experience of the surgeon. Lymphadenectomy is associated with prostatectomy based 
on the clinical risk group of metastases: it is generally recommended when the risk of 
metastasis is more than 5%. For the calculation of risk is often used multivariate 
prediction models  (23). 
Stephenson and colleagues reported a low 15-year prostate cancer-specific mortality of 
12% in patients who underwent radical prostatectomy (5% for low-risk patients), 
despite the presence of adverse clinical features. It is unclear whether the favorable 
prognosis is due to the effectiveness of the procedure or the low lethality of cancers 
detected in the PSA era  (24). 
The SPCG-4 trial, with a median follow-up of 15 years, showed that radical 
prostatectomy was associated with a reduced risk of death (HR= 0.75; 95%CI: 0.61 to 
0.92) and the risk of death from prostate cancer (HR= 0.62; 95%CI: 0.44 to 0.87)  (25). 
However the PIVOT study, published a year later, failed to reproduce these results, 
reducing the benefit of the RP for patients with PSA> 10 ng/ml and possibly among 
those with for intermediate or high risk tumors  (26). 
Some patients at high or very high risk may still benefit from radical prostatectomy. In 
an analysis of 842 men with high-Gleason sum at biopsy who underwent to radical 
prostatectomy a PSA concentration of >10 ng/mL, clinical stage ≥ T2b, Gleason pattern 
9 or 10, increasing number of cores with high-grade cancer and >50% core involvement 
were predictive of unfavourable pathology (27). In men with favourable pathological 
findings the 10-year biochemical-free (BFS), metastasis-free (MFS) and prostate 
cancer-specific survival (CSS) were 31.0%, 60.9% and 74.8%, respectively. In contrast, 
men with unfavourable pathological findings had significantly worse 10-year BFS, MFS 
and CSS: 4.3%, 29.1% and 52.3%, respectively (all p < 0.001). 
Laparoscopic and robot-assisted radical prostatectomy are used commonly and are 
considered comparable to conventional approaches in experienced hands. Both 
techniques have comparable rates of complications and the need for additional cancer 
therapies is similar to the classic techniques. In a study conducted by Gandaglia et al 
robot-assisted radical prostatectomy was associated with lower risk of blood 
transfusions and a slightly shorter length of stay (28). 
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Robot-assisted surgery is being implemented today and the question for patients 
considering surgical treatment of their prostate cancer is not to choose a technique, but 
to choose a surgeon who is an expert at a given technique, to minimize surgical 
complication risk  (29). 
Radical prostatectomy is a salvage option for patients experiencing biochemical 
recurrence after primary RT, but morbidity (incontinence, erectile dysfunction, and 
bladder neck contracture) remains significantly higher than when radical prostatectomy 
is used as initial therapy. Biochemical recurrence-free probability after salvage radical 
prostatectomy ranged from 47% to 82% at 5 years and from 28% to 53% at 10 years 
(30). Patient selection is important and prostatectomy should only be performed by 
highly experienced surgeons.  
Regarding pelvic lymph node dissection (PLND), while extended lymphadenectomy is 
popular in Europe, standard PLND has always been preferred in the United States. An 
extended PLND reaches from the bifurcation of the common iliac artery superiorly to 
the femoral canal inferiorly; posteriorly, the obturator nerve, obturator vessels, and 
internal iliac artery are skeletonized. In standard PLND the internal iliac artery nodes 
are not removed. These approaches carry with them differing morbidities as well as the 
possibility of varied staging and curative advantages. A survival advantage with more 
extensive lymphadenectomy has been suggested by several studies, possibly due to 
elimination of microscopic metastases.  
Radiotherapy. 
Radiation therapy offers the potential for curative treatment of localized prostate cancer. 
It may be delivered in the form of external-beam radiation therapy or brachytherapy 
(insertion of radioactive seeds into the prostate gland). EBRT techniques include 3-
dimensional conformal radiation therapy (3D-CRT) and intensity-modulated radiation 
therapy. Stereotactic body radiotherapy (SBRT) is an emerging treatment technique that 
delivers highly conformal, high-dose radiation in 5 or fewer treatment fractions, which 
are safe to administer only with precise, image-guided delivery (Figure  1.10).  
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Figure 1.10. External beam radiotherapy unit. 
 
Randomized trials comparing surgery with radiation either have not yet been reported or 
have been abandoned because of poor accrual. In this context, most men with localized 
prostate cancer are encouraged to make treatment decisions based on the toxicity 
profiles of the treatments and personal preferences. The acute effects of radiation, 
defined as occurring up to 6 months after treatment, include urinary obstructive 
symptoms, bowel symptoms and fatigue  (31,32) . Late toxicities may include sexual 
dysfunction, persistent bowel problems (intermittent rectal bleeding, tenesmus and 
urgency) and urinary obstructive symptoms. An increased risk of bladder, colon or 
rectum tumors  can occur after prostate radiation therapy.  
Doctors commonly use risk groups based on clinical and pathologic information known 
at the time of diagnosis to guide treatment decisions. The risk groups are commonly 
defined by the tumor (T)-classification, the Gleason score, and the PSA level at 
diagnosis (Table 1.2). 
Significant progress has also been made in the use of genetic signatures from tumor 
tissue in providing additional prognostic information, but we need large prospective 
studies to know wheter these emerging tests can be  used to select patients who need 
radical therapy, e.g radiotherapy. 
The use of EBRT to the prostate for men with prostate cancer has been established by 
two randomized controlled trials. Both studies were done mainly in men with high-risk 
or locally advanced disease. The National Cancer Institute of Canada-PR3 trial assigned 
1205 prostate cancer patients between 1995 and 2005 to lifelong androgen deprivation  
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Table 1.2. Group risk classifcation. 
D´AMICO CURRENT 
Low risk Very low risk 
 Gleason ≤6, and  T1c, and 
 PSA <10 ng/mL, and  Gleason ≤6, and 
 ≤T2a  PSA<10 ng/mL, and 
  PSA density <0.15 ng/mL, and 
  ≤2 cores positive, and 
  ≤50% cancer in each core 
 Low risk  
 ≤T2a, and 
 Gleason ≤6, and     
 PSA< 10 ng/mL 
Intermediate risk Favorable intermediate risk 
 Gleason 7, or   T2b-T2c, or 
 PSA 10-20 ng/mL  Gleason 7, or 
 T2b  PSA 10-20 ng/mL 
 Unfavorable intermediate risk 
 Primary Gleason grade 4, or 
 ≥50% cores positive, or  
 Multiple intermediate risk factors 
High risk High risk 
 Gleason 8-10, or ≥T2c, or  Gleason 8-10, or T3a, or 
 PSA> 20 ng/mL, or  PSA > 20 ng/mL 
 Very high risk 
  ≥T3b 
PSA: prostate specific antigen  
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therapy (luteinizing hormone-releasing hormone agonist or antagonist or bilateral 
orchiectomy), with or without radiotherapy  (33). The addition of radiotherapy 
significantly reduced 7-year overall mortality from 34% to 26% (HR 0.77 [95% CI 
0.61–0.98], p=0.033). The SPCG-7 trial randomly assigned 875 patients between 1996 
and 2002 to hormonal treatment alone (3 months of total androgen blockade followed 
by flutamide alone) or to the same hormonal treatment combined with radiotherapy 
(34). Radiotherapy significantly improved 10 year overall mortality (30% vs 39%, 
p=0.004). Side effects of radiation therapy were mild in both studies, rectal bleeding as 
the most significant complication. Long-term androgen deprivation plus radical 
radiotherapy are now a standard of care for high-risk and locally advanced prostate 
cancer. As a consequence of these trials, hormone therapy as exclusive treatment is not 
recommended for men with localised or locally advanced disease.  
Level I evidence supports the use of higher doses in the 75.6-Gy to 79.2-Gy range as a 
standard treatment of localized prostate cancer (35-38). Observational data suggest that 
IMRT reduces the risk of important late toxicities over 3DCRT, although treatment cost 
is increased (Figure 1.11)  (39). This increase in cost has led to a call for greater 
comparative effectiveness research in prostate cancer in the setting of  less costly 
options. 
Moderately hypofractionated image-guided IMRT regimens (2.4–4 Gy per fraction over 
4-6 weeks) have been tested in randomized trials and efficacy and toxicity have been 
similar to conventionally fractionated IMRT  (40,41). Given the atractiviness of this 
approach to patient convenience and reduced cost and the successes of hypofractionated 
treatment in breast cancer, it is considered that this treatment modality may actually be 
useful (42). However, long-term efficacy results from non-inferiority trials are needed 
before moderate hypofractionation can confidently be widely adopted.  
The same consideration applies to the case of extreme hypofractionation. A randomized 
phase 2 study is currently underway through the RTOG (NCT01434290) comparing 
five 7.25-Gy fractions with twelve 4.3-Gy fractions. In the International Standard 
Randomized Controlled Trial Number 45905321 open in Sweden 592 men with 
intermediate-risk prostate cancer will be randomized to 78 Gy in 2-Gy fractions versus 
7 fractions of 6.1 Gy to a total dose of 42.7 Gy.  
 




Figure 1.11. External beam radiotherapy in prostate cancer. IMRT planning. 
 
Brachytherapy is generally used only in men with early stage PCa. Its use is also limited 
by other factors. For men who have had a transurethral resection of the prostate (TURP) 
or for those who already have urinary problems, the risk of urinary side effects may be 
higher. Men with large prostate glands are not good candidates for brachytherapy 
because it might not be possible to place the seeds into all of the correct locations. 
Typically Iodline-125 or Palladium-103 are used as isotopes, and the sources are placed 
transperineally with ultrasound guidance (Figure 1.12). Approximately 100 of these 4-
mm to 5-mm sources are used to treat the entire prostate. Low dose-rate brachytherapy 
has excellent results, with single-institution series reporting 10-year disease-specific 
survival rates greater than 95%  (43).  
Permanent brachytherapy as monotherapy is indicated for patients with low-risk cancers 
(cT1c–T2a, Gleason grade 2-6, PSA <10 ng/mL) and selected patients with low volume 
intermediate-risk cancers. Patients with high-risk cancers are generally considered poor 
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candidates for permanent brachytherapy alone. Given the good local control achieved 
with brachytherapy attempts have been made to combine with EBRT with or without 




Figure 1.12. Brachytherapy in prostate cancer.  
 
Low dose-rate brachytherapy consists of placement of permanent seed implants in the 
prostate. High dose-rate brachytherapy, which involves temporary insertion of a 
radiation source, is a newer approach that provides a “boost” dose in addition to EBRT 
for patients at high risk of recurrence. This approach allows for the treatment of higher 
risk features, such as extracapsular extension. Typically delivered over fewer than 10 
fractions, several single-institutional series have demonstrated both excellent disease 
control and modest acute urinary and gastrointestinal side effects  (45). In the RTOG 
00-19 trial 45 Gy were delivered with external beam radiation followed by 
brachytherapy to an additional 108 Gy  (46). With 4 years of follow-up, 15% of patients 
had a grade 3 or higher GU or GI toxicity, and biochemical control was similar to that 
reported using external beam radiation alone.  
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Androgen deprivation is used as an adjuvant to external-beam radiotherapy for higher-
risk disease (Table 1.3).  In a randomised trial of 415 patients with locally advanced 
disease, 3 years of androgen deprivation added to radiotherapy improved 10 year overall 
survival from 40% to 58% (HR 0.60, 95% CI 0.45–0.80; p=0.0004)  (47). Due to the 
excellent prognosis of low risk, the use of ADT offers no advantages in this group of 
patients. The optimum duration of adjuvant androgen deprivation is uncertain.  
TROG 96.01 compared none, 3 months or 6 months of neoadjuvant androgen 
deprivation in 818 men undergoing radiotherapy for localised and locally advanced 
disease (48).  The use of 6 months, not 3 months, neoadjuvant androgen-deprivation 
significantly improved overall mortality (43% versus 29% at 10 years, HR 0.63, 95% CI 
0.48–0.83; p=0.0008). So 6 months should be considered the minimum duration of 
adjuvant treatment. EORTC 22961 randomised 970 men between 6 months and 3 years 
of adjuvant treatment  (49). Overall mortality at 5 years was 19% and 15% (HR 1.42, 
95% CI 1.09–1.85), respectively. This survival benefit comes at the cost of a substantial 
prolongation of treatment-related morbidity.  
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2.2 Metastatic disease.  
Despite the excellent results achieved with surgery and radiotherapy unfortunately, 
approximately 30% of with prostate cancer patients will develop advanced disease. 
Metastatic prostate cancer patients are treated with hormonal therapy, chemotherapy, 
radiation therapy and/or other treatments.  
Hormone treatment may control advanced prostate cancer for long periods by shrinking 
the size or limiting tumor growth, thus helping to relieve pain and other symptoms. 
Androgen deprivation therapy achieves disease control in about 90% of these men, for a 
median of 18 months, but most of them eventually will develop progressive disease, a 
status called castration-resistant prostate cancer (CRPC).  
In 2004 the combination of docetaxel and prednisone demonstrated an improvement in 
overall survival (OS) (50,51). Since then, several new treatments such as 
immunotherapy, new hormonal manipulations, modern chemotherapy agents and bone-






Figure 1.13. Metastatic prostate cancer treatment.  
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Castration sensitive metastatic prostate cancer.  
Hormonal treatment.  
Androgen deprivation is considered the primary approach to the treatment of metastatic 
prostate cancer  (52). Prior to the development of newer therapies, overall survival for 
patients with metastatic prostate cancer ranged from 24-36 months. In recent years the 
introduction of new agents have allowed prolong survival after failure of hormonal 
treatment. 
ADT can be accomplished using bilateral orchiectomy (surgical castration) or a 
luteinizing hormone-releasing hormone (LHRH) agonist or antagonist (medical 
castration), which are equally effective. The addition of an antiandrogen to LHRH 
agonist treatment can minimize the risk of the flare response (ie, temporary rise in 
testosterone levels) that can occur with LHRH treatment  (53). No initial flare is 
associated with LHRH antagonists and no coadministration of anti-androgen is 
necessary.  
Medical or surgical castration combined with an antiandrogen is known as combined 
androgen blockade (CAB). No prospective randomized studies have demonstrated a 
survival advantage with CAB over the serial use of an LHRH agonist and an anti-
androgen  (54). Meta-analysis data suggest that bicalutamide may provide an 
incremental relative improvement in overall survival by 5% to 20% over LHRH agonist 
monotherapy, but a clinical trial is necessary to test this hypothesis (55). One 
explanation for many of the negative studies is the antiandrogen withdrawal 
phenomenon, in which a tumor that has started to grow despite antiandrogen treatment 
regresses when antiandrogen treatment is stopped. If the PSA level begins to rise in a 
patient who is receiving CAB, the antiandrogen should be discontinued before other 
therapy is initiated. Generally, 1-2 months are needed following antiandrogen 
withdrawal to see whether the patient will improve. The optimal interval varies with 
different antiandrogens. Antiandrogen monotherapy appears to be less effective than 
medical or surgical castration and is not recommended as primary ADT.  
In the years following the introduction of hormone therapy for prostate cancer it was 
debated whether the late onset of ADT could maintain survival benefit delaying the 
onset of side effects (56). Laboratory studies developed with LHRH antagonist and 
LHRH agonists demonstrated that early hormone therapy does not confer early 
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resistance. Moreover, clinical trials found that it provided significantly longer survival 
with fewer complications (eg, pathologic fractures, spinal cord compression, ureteral 
obstruction) than did deferred treatment  (57,58). 
Intermittent androgen suppression has been assessed in prospective, randomized 
studies as a possible means of minimizing the side effects of ADT. Two phase III trials 
found that intermittent androgen suppression resulted in better quality of life and it was 
noninferior to continuous therapy with respect to overall survival  (59,60).  However, 
according to a large study of 770 men treated with intermittent therapy and 765 men 
treated with continuous therapy survival may be shorter when androgen deprivation 
therapy is given intermittently rather than continuously (average survival, 5.1 vs 5.8 
years, a 10% higher relative risk for death). Intermittent therapy was associated with 
better erectile function and mental health at month 3 but not thereafter. 
Docetaxel in hormone-sensitive prostate cancer. 
 Two studies have tested the role of docetaxel in addition to ADT in patients with 
hormone-sensitive prostate cancer. The GETUG-AFU 15 phase III trial randomized 385 
patients with metastatic castration sensitive prostate cancer to receive ADT or ADT plus 
docetaxel (75 mg/m2 iv every 3 weeks, up to 9 cycles)  (61). After a median follow-up 
50 months, median OS was 58.9 months for the ADT plus docetaxel arm, versus 54.2 
months for patients receiving only ADT (HR 1.01, 95% CI 0.75-1.36). However, 
secondary objectives were met: clinical and biochemical progression free survival were 
statistically significant higher for the docetaxel plus ADT arm. 
 The E3805 (CHAARTED) study enrolled 790 mCRPC patients between July 2006 
and November 2012. They were randomized to receive ADT versus ADT plus 
docetaxel. In this case, the primary endpoint was met: after a median follow-up of 29 
months, OS was statistically significant better for the combination arm (57.6 versus 44.0 
months, HR 0.61, 95% CI 0.47-0.80). Patients with high metastatic disease burden 
(visceral metastases and/or four or more bone metastases with at least one beyond the 
axial skeleton) increased their survival by 17 months (49.2 versus 32.2 months, HR 
0.60, 95% CI 0.45-0.81). In patients with a low metastatic disease burden, median OS 
has not been reached yet (HR 0.63, 95% CI 0.34-1.17). Secondary objectives (PSA <0.2 
ng/mL at 6 and 12 months, median time to become castration resistant and median 
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clinical and biological PFS were also statistically significant better for the ADT plus 
docetaxel arm (62). 
 The differences observed between the two studies may be related to the different 
populations included (more high-risk patients in the study CHAARTED), as well as 
variations in the use of treatments in subsequent lines. Results from the Stampede study 
have been shared at ASCO 2015, showing a clinical and statistically significant benefit 
in survival of 10 months from adding docetaxel to ADT (63). In this study, four arms 
were tested: hormone therapy for > =3 years, hormone therapy plus docetaxel, hormone 
therapy plus docetaxel and zoledronic acid, and hormone therapy plus zoledronic acid 
alone (no benefit from adding zoledronic acid was observed). 
Castration resistant metastatic prostate cancer. 
Castration resistant prostate cancer is defined as disease progression (increase in PSA in 
serum, new clinical metastases, or progression of existing metastases) despite the 
administration of ADT. The Prostate Cancer Clinical Trials Working Group 2 (PCWG2) 
defines CRPC as patients with serum castration levels of testosterone (testosterone <50 
ng/dL or <1.7 nmol/L), PSA progression and/or clinical progression to castration, or 
progression despite anti-androgen withdrawal for at least 4–6 weeks  (64). 
Since the introduction of docetaxel in the treatment of mCRPC, designed randomized 
trials with new drugs have established two large categories: chemonaive and 
chemotherapy pretreated patients. The following sections briefly discusses the main 
therapeutic options currently available (Table 1.4). 
Hormonal treatment. New agents.  
When disease progresses, discontinuation of LHRH analogs therapy can result in an 
increase in serum testosterone and, thus, promoting tumor growth. There are currently 
no prospective trials demonstrating the impact of discontinuing ADT, and retrospective 
analysis provide conflicting results (65,66) . Despite the lack of strong clinical data, the 
current recommendation is to continue androgen suppression in all patients as an 
eligibility criterion for phase III trials in the androgen-resistant setting.  
Antiandrogen withdrawal should be considered in most patients with CRPC, except in 
symptomatic patients or in those who are showing rapid and aggressive progression  
(67). After the failure of the classical hormonal treatment we can consider for using 
Clinical application of circulating tumor cells in patients with metastatic castration-resistant prostate cancer 
48 
different therapies introduced in recent years (Figure 1.14). Here we focus on the two 
drugs with more data of phase III trials: abiraterone and enzalutamide.  
 
Table 1.4. Phase III trials evaluating agents which have been demonstrated activity in patients with 
mCRPC. 
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Abiraterone acetate (AA) is a selective, irreversible, and potent inhibitor of 17-
[alpha]-hydroxylase/17,20-lyase (CYP17), a critical enzyme in testosterone synthesis. 
This agent can block androgen synthesis developed in the adrenal glands, testicles and 
prostate cancer cells, to reduce blood testosterone levels below detectable limits (< 1 
ng/dL). Recently, abiraterone has demonstrated activity in castration resistant prostate 
cancer patients prior to and after docetaxel administration.  
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In the COU-AA-301 phase III study, 1195 patients who failed to one or two lines of 
chemotherapy were randomized to receive abiraterone 1000 mg daily plus prednisone 
5mg bid versus placebo plus prednisone  (68,69). Primary objective was met: median 
survival in patients treated with abiraterone was 15.8 months in comparison to 11.2 
months in placebo treated patients (p<0.0001). Secondary objectives were time to PSA 
progression, radiographic progression-free survival (rPFS) and PSA response. Patients 
treated with abiraterone also obtained higher PSA response rate (29.5% vs 5.5%; 
p<0.0001).  
In the predocetaxel setting, a phase III trial has evaluated the clinical benefit of AA vs 
prednisone in mildly symptomatic or asymptomatic chemo-naïve patients with 
progressive metastatic CRPC (70). In the COU-AA-302 study 1088 pts were 
randomized 1:1 to AA 1000 mg plus prednisone 5 mg bid versus placebo plus 
prednisone. Radiographic PFS was 16.5 and 8.3 months for AA and placebo, 
respectively (HR 0.53; 95% CI 0.45-0.62; p < 0.0001). In the final analysis median 
overall survival was significantly longer in the abiraterone acetate group than in the 
placebo group (34.7 months [95% CI 32·7–36·8] vs 30.3 months [28.7–33.3]; hazard 
ratio 0.81 [95% CI 0.70–0.93]; p=0.0033)  (71).  
Abiraterone has an excellent tolerance profile although it needs administration of 
prednisone in order to prevent the toxicity derived from the excess of mineralocorticoids 
(due to the CYP17 blockade). Most frequent grade 3-4 toxicities were edema and fuid 
retention (less than 3% severe), hypokalemia (<4%), hypertension (4%) and 
hypertransaminemia (3-5%)  (68,70). 
 Enzalutamide (MDV3100) inhibits nuclear translocation of the androgen receptor, 
DNA binding, and coactivator recruitment (72). Compared to the currently available 
antiandrogen agents enzalutamide has a greater affinity for the receptor, induces tumor 
shrinkage in xenograft models and has no known agonistic effects. 
 In the double-blind AFFIRM trial, 1199 men with castration resistant prostate cancer 
after chemotherapy were randomly assigned (2:1 ratio), to receive oral enzalutamide at 
a dose of 160 mg per day or placebo. Unlike abiraterone corticoesteroids administration 
was optional in both arms. Enzalutamide was superior to placebo in the primary end 
point, overall survival (HR=0.63 [0.53, 0.75], p<0.001) (73). Enzalutamide was also 
superior to placebo in all secondary end points: reduction in PSA level by 50% or more 
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(54% vs. 2%, P<0.001), the soft-tissue response rate (29% vs. 4%, P<0.001), the quality 
of life response rate (43% vs. 18%, p<0.001), the time to PSA progression (8.3 vs. 3.0 
months; HR 0.25; p<0.001), radiographic progression-free survival (8.3 vs. 2.9 months; 
HR 0.40; p<0.001), and the time to the first skeletal-related event (16.7 vs. 13.3 months; 
HR 0.69; P<0.001). 
 
Figure 1.14. Interaction between testosterone and its receptor in the prostate cell. Adapted from 
González del Alba, León et al, “Targeted therapies for prostate cancer” (74). 
 Enzalutamide has a good toxicity profile, with fatigue (6% grade 3), hypertension 
(6.6%) and hot flushes (20%) as the main side effects. Cardiac events were observed in 
6% of patients with enzalutamide versus 8% in the placebo arm. Seizures were reported 
in five patients (0.6%) receiving enzalutamide  (73). 
 The  PREVAIL phase III study, tested enzalutamide in chemotherapy-naive patients 
with mCRPC. A total of 1,717 men were randomized 1:1 to enzalutamide 160 mg/day 
or placebo  (75). Median OS was 32.4 months (95% CI, 31.5–upper limit not yet 
reached [NYR]) in the enzalutamide arm vs 30.2 months (95% CI, 28–upper limit 
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NYR) in the placebo arm, with a 30% reduction in risk of death (OS: HR 0.70; 95% CI: 
0.59-0.83; P< 0.0001). Median rPFS was not yet reached in the enzalutamide arm vs 3.9 
months in the placebo arm, with an 81% reduction in risk of rPFS (HR 0.19; 95% CI: 
0.15-0.23; P< 0.0001). 
 Chemotherapy.  
 Currently docetaxel based schemes are the standard treatment of patients with 
metastatic CRPC. In the SWOG 9916 trial, Petrylak et al compared docetaxel plus 
estramustine  every 21 days and dexamethasone 20 mg x 3 doses versus mitoxantrone 
day 1 every 21 days with prednisone 5 mg every 12 hours  (51). The median survival 
was 17.5 months and 15.6 months in the docetaxel and the mitoxantrone arm, 
respectively (p = 0.01). Docetaxel plus estramustine increased gastrointestinal toxicity 
(20% vs. 5%, p <0.001), metabolic disorders (6% vs. 1%, p <0.001), cardiotoxicity 
(15% vs 7%, p = 0.001), neuropathy (7% vs 2%, p = 0.001) and neutropenic fever (5% 
vs 2%, p = 0.01) without providing any benefit in pain control or quality of life. 
 In the TAX 327 trial 2 docetaxel schemes (weekly or every 3 weeks) were compared 
against the standard combination of mitoxantrone and prednisone (50). The primary 
endpoint was overall survival. The median survival was 16.5 months in the 
mitoxantrone group, 18.9 months in the group given docetaxel every three weeks and 
17.3 months in the group given weekly docetaxel. As compared with the men in the 
mitoxantrone group, patients in the group given docetaxel every three weeks had a 
hazard ratio for death of 0.76 (95 % CI, 0.62 to 0.94; p=0.009) and those given weekly 
docetaxel had a hazard ratio for death of 0.91 (95 %CI, 0.75 to 1.11; p=0.36). Docetaxel 
given every 3 weeks caused 32% of grade 3-4 neutropenia, with only 2.7% of febrile 
neutropenia and no toxic deaths. Mitoxantrone and weekly docetaxel caused a 22% and 
1.5% grade 3-4 neutropenia, respectively. There were no differences between the three 
schemes in non-haematological toxicity. Since the use of estramustine only caused more 
toxicity, docetaxel every 3 weeks plus prednisone was establihed as the standard 
chemotherapy regimen for the first line setting in metastatic CPRC (76).  
 Secondary objectives of the TAX 327 were pain response, PSA response, measurable 
response and quality of life. Docetaxel given every 3 weeks improved pain response 
when compared to mitoxantrone (35 vs 22%; p <0.01). The two docetaxel schemes 
(weekly or every three weeks) obtained higher response rate in the PSA compared to 
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mitoxantrone (45 vs 48 vs 32%, respectively). 
 In the TAX 327 and SWOG trials 99-16 docetaxel treatment was initiated without 
excluding patients according to the presence of symptoms or kind of progression. 
Asymptomatic patients have better overall survival, but it is unknown what is the 
consequence of delaying the start of cytotoxic therapy in these patients. Some men with 
asymptomatic metastatic CRPC can continue with no pain for long periods of time, 
while others have symptoms within a few weeks or months. In the first group we could 
delay the start of chemotherapy, while in the second group, with a survival rate around 
one year, it would be advisable not to delay treatment. 
 There is consensus that chemotherapy should not be delayed in symptomatic patients 
with visceral or bone progression, but in clinical practice often we consider these 
questions: 
- Asymptomatic (or minimally symptomatic) patients do benefit from docetaxel use? 
- All patients with asymptomatic CPRC should begin treatment with docetaxel? 
 To answer this question we should conduct a clinical trial in which asymptomatic or 
minimally symptomatic patients were randomized to early treatment or chemotherapy 
when symptoms worsen. In the absence of this phase III trial we need to find parameters 
that can help us in the decision making. Both in the original publication and updating of 
the TAX 327 trial can be observed that patients without pain at baseline showed an 
overall survival greater than those symptomatic (14.2 vs 21.3 months), but docetaxel is 
beneficial in both subgroups (50,77). In another analysis of the TAX 327 110 minimally 
symptomatic men were identified  (78). Median survival in these patients were 28.4, 
25.9 and 22 months for groups of docetaxel given every 3 weeks, docetaxel given 
weekly  and mitoxantrone, respectively. Although these differences were not 
statistically significant due to the small sample size these data indicate that 
asymptomatic or minimally symptomatic patients benefit from the use of chemotherapy, 
and should not be excluded from treatment. 
 Cabazitaxel, a second generation taxane, is approved for men with mCRPC previously 
treated with a docetaxel-containing regimen, and it is recommended for patients with or 
without visceral metastases (79). The TROPIC trial randomized 755 men with 
progressive disease to receive cabazitaxel 25 mg/m2 or mitoxantrone 12 mg/m2, each with 
daily prednisone. Cabazitaxel achieved an improvement in OS up to 2.4 months (HR 
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0.72; p <0.0001). A higher toxic death rate was seen in men who received cabazitaxel (4.9 
versus 1.9%). Febrile neutropenia was observed in 7.5% of cabazitaxel-treated men 
versus 1.3% of mitoxantrone-treated men. The incidences of severe diarrhea (6%), fatigue 
(5%), nausea/vomiting (2%), anemia (11%) and thrombocytopenia (4%) also were higher 
for cabazitaxel (80). These data suggest that cabazitaxel should be used with caution in 
patients with pre-existing bone marrow toxicities. A strict haematologic toxicity follow 
up, and prophylactic G-CSF could be recommended.  
 Inmunotherapy. 
 In the last years, immunotherapy has shown promising efficacy in the treatment of many 
solid tumors. Several different approaches with vaccines in prostate cancer have been 
evaluated in both the preclinical and clinical settings. 
 Sipuleucel-T, an autologous active cellular immunotherapy agent, was the first FDA-
approved therapeutic cancer vaccine and other agents alone or in combination are being 
explored. In the IMPACT study, sipuleucel-T prolonged OS among asymptomatic or 
mildly symptomatic men with mCRPC, before or after docetaxel treatment, with a 
relative reduction of 22% in the risk of death as compared with the placebo group (HR: 
0.78; 95% CI: 0.61-0.98; p=0.03)  (81). This reduction represented a 4.1 months 
improvement in median survival (25.8 months vs. 21.7 months). The most common 
associated adverse events were chills (51%), fever (22%), fatigue (16%), nausea (14%) 
and headache (11%). 
 A phase 2 trial of PROSTVAC has shown an improvement of 8.5 months in overall 
survival (HR 0.56)  (81). Accrual is ongoing to include 1200 patients in a phase III trial 
with three arms: ProstVac-VF, ProstVac-VF þ GM-CSF, or an empty vector control. 
Check-point inhibitors (ipilimumab, nivolumab) have shown impressive results in 
various types of tumors, but results in prostate cancer have been disappointing. 
Ipilimumab showed no survival improvement in a randomized phase 3 trial, but a subset 
analysis revealed a benefit in those patients without visceral metastases  (82). A deeper 
understanding of the mechanisms of checkpoint inhibitor function and failure will lead 
to improvements in clinical trial design and subsequent better clinical results. 
Bone targeted therapies. 
Bone metastases occur in more than 80% of patients with advanced prostate cancer. 
Bone metastases in prostate cancer are related to osteoclast-mediated resorption. 
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Zoledronic acid was evaluated in a phase III trial compared with placebo (83,84). 
Median time to the first skeletal related event (SRE) was longer in patients treated with 
zoledronic acid (488 vs. 321 days; p = 0.01). Besides significantly more patients 
receiving placebo displayed SREs compared with those receiving zoledronic acid 4 mg 
(44% vs. 33%; difference:−11%; 95% CI: −20% to −2%; p = 0.021). Zoledronic acid 
requires monitoring for renal function, and is not recommended in patients with creatine 
clearance lower than 30 mL/min. Osteonecrosis of the jaw is a rare complication but it 
causes a serious deterioration in the quality of life. 
Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) is involved in 
osteoclast function, formation and survival. Denosumab is a human monoclonal 
antibody directed against RANKL that inhibits osteoclast-mediated bone destruction. In 
a randomised, double blind study, subcutaneous denosumab was compared to 
intravenous zoledronic acid in 1904 patients with metastatic CRPC  (85). The median 
time to first on-study SRE was 20.7 months (95% CI: 18.8–24.9) for denosumab 
compared with 17.1 months (95% CI: 15.0–19.4) for zoledronic acid (HR: 0.82; 95% 
CI: 0.71–0.95; p = 0.0002 for non-inferiority; p=0.008 for superiority). Adverse events 
were similar in both arms, but hypocalcemia and osteonecrosis of the jaw occurred more 
frequently in the denosumab group. Denosumab had no effect on renal function and 
there is no need for renal monitoring. 
Radium is a calcium mimetic bone seeker alpha-particles emitter able to replace areas of 
increased bone turnover. Radium 223 (223Ra) has been introduced recently, 
representing the first alpha-emitter drug available for the treatment of patients with 
CRPC, with symptomatic bone metastases and no known visceral metastases. The 
ALSYMPCA trial was an international, randomized, double-blind, phase 3 study 
conducted in men with symptomatic mCRPC comparing 223Ra with placebo  (86). The 
trial enrolled patients progressing on, not eligible for, or refusing prior docetaxel-based 
chemotherapy. 
Radium 223 significantly improved OS compared with placebo (14.9 months vs. 11.3 
months, respectively; HR: 0.70; 95% CI: 0.58–0.83; p<0.001). Time to first SRE was 
significantly prolonged (median 15.6 months versus 9.8 months, respectively; HR = 
0.66; 95% CI, 0.52-0.83; p <0.001).  
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Table 1.5. Selected Ongoing clinical trials of targeted therapy for patients with metastatic CPRC. 
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Targeted therapies.  
 Besides AR mediated pathways, several alternative signaling pathways may also be 
involved in the disease progression of prostate cancer. Prostate cancers are often 
characterized by abnormalities in a variety of growth factor signaling pathways that 
control cell cycle and apoptosis. As these pathways are being understood, new 
therapeutic drugs are being developed directed against related targets. The review of 
each of these agents is beyond the scope of this thesis. Table 1.5 summarizes several 
agents at different stages of development in the treatment of mCPRC. 
 Several of these agents have demonstrated promising activity in early stages, not 
confirmed later in randomized trials. Again, the absence of biomarkers to select the 
most appropriate drug for each patient is a barrier that must be overcome to improve 
current results. 
3. Evaluation of response and progression criteria in metastatic castration resistant 
prostate cancer.  
A significant proportion of patients diagnosed with prostate cancer will progress after 
the initial treatment, which will inevitably lead to the appearance of metastasis and 
subsequent resistance to androgen deprivation therapy. Traditionally, the assessment of 
the response to the therapeutic agents of this disease has been particularly complicated 
due to the absence of easily measurable lesions, the prevalence of bone spreading and 
the relatively prolonged natural history in a significant number of patients. 
In 1999, the Prostate-Specific Antigen Working Group (PCWG1) defined the 
eligibility criteria and treatment benefit in clinical trials and proposed specific criteria 
for the use of prostatic specific antigen  (87).  The Response Evaluation Criteria in Solid 
Tumours (RECIST) and subsequently the modified RECIST criteria 1.1 tried to 
establish standards for the response evaluation in solid tumours, although they are often 
difficult to apply alone in the case of prostate cancer (88,89). Subsequently, the Prostate 
Cancer Clinical Trials Working Group (PCWG2) established a number of progression 
criteria to address the inclusion of patients in clinical trials and the evaluation of 
effectiveness of new treatments (64). These criteria, with some modifications, currently 
remain in force. However, controversies over the methods and more appropriate criteria 
for the best evaluation of castration-resistant prostate cancer progression remain. 
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As previously mentioned following the establishment of the docetaxel-prednisone 
regimen as the first-line standard of care in patients with metastatic CRPC, several 
agents have been shown to increase overall survival in patients participating in phase III 
trials  (50)( (68-71,73,75,80,86). Therefore, given the difficulty in assessing the disease, 
as well as the availability of new treatments that affect its survival and the nature of the 
various agents involved, the progression criteria to be used in clinical trials and in the 
clinical practice for all the phases of mCRPC need to be defined. Given the limitations 
in the assessment of response by PSA and imaging methods, the use of CTC in this 
scenario can be really useful. 
Progression criteria in CRPC. 
The definition of castration resistance in patients with prostate cancer involves 
biochemical (PSA) and/or clinical progression under adequate castration conditions. 
Therefore, CRPC requires two essential conditions: (1) adequate castration defined as 
serum testosterone levels < 50 ng/dL, and (2) evidence of progression  (90). 
As mentioned above, the definition of progressive disease in patien ts with mCRPC has 
been the subject of multiple considerations and continues to be an unresolved issue. In 
2008, the PCWG2 criteria established a consensus for the progression criteria 
assessment and the disease status in these patients  (64). Modification of the old criteria 
should allow the selection of the most suitable patients for clinical trials and the 
evaluation of the effectiveness of new treatments. 
One of the most important concepts introduced by the PCWG2 is the definition of five 
patterns of spread, each one with a different natural history and prognosis. The OS 
varies between 9 to 48 months, depending on pattern of tumour spread, which include 
the following: (1) locally progressing tumors and no metastatic disease, (2) biochemical 
progression (rising PSA-castrate) and no detectable metastatic disease (median OS 4 
years), (3) nodal spread and no evident bone or visceral disease (median OS between 18 
and 24 months), (4) bone disease with or without nodal disease and no evident visceral 
spread (median OS 18 months), and (5) visceral metastases (median OS between 9 and 
16 months). 
PSA progression is defined as three consecutive increments in the PSA value, at a 
minimum interval of one week, resulting in two increments of, at least, 50% of the nadir 
value, provided the PSA value is > 2 ng/mL. Radiological progression is defined as the 
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appearance of two or more new lesions in bone scintigraphy (conclusive proof) or 
progression by RECIST 1.1 criteria (in the case of soft tissue lesions). Finally, clinical 
progression is defined as pain progression or development of skeletal events (e.g., 
pathological fracture, medullar compression, palliative radiation or bone surgery). 
 In addition to defining the patterns of spread, the PCWG2 divided the aims of 
treatment of patients with mCRPC into the following two categories: (1) control, 
alleviate or eliminate the symptoms of the disease once treatment is started and (2) 
prevent or delay symptoms of the tumour in the future. For this reason, it´s 
recommended focusing on time-to-event objectives, advising to document pain at the 
start of treatment and every 3-4 weeks, monitor symptoms and quality of life and ignore 
early changes in pain (< 12 weeks) in the absence of progression, and confirm response 
or progression of symptoms after ≥ 3 weeks. Monitoring symptoms, such as pain, is an 
important therapeutic goal and should be considered an independent objective due to the 
poor correlation between PSA response and pain response, since the presence of pain 
constitutes an adverse prognostic factor for survival  (78). 
What is the role of PSA doubling time (PSA-DT)? 
In a retrospective study, Oudard et al. evaluated the usefulness of the PSA-DT prior to 
chemotherapy as a subrogated marker of survival in CRPC. They observed that the 
median survival was significantly lower if the PSA-DT was less than 45 days compared 
to PSA-DT values above 45 days (16.5 months vs. 26.4 months, respectively)  (91).  
Various published studies confirmed that the PSA response rate to chemotherapy in the 
CRPC is correlated with survival and is an acceptable measure of the potential benefit to 
the patient  (92,93) . Hussain et al. reported results of a retrospective study of 1015 
patients, in which PSA progression, defined by PCWG 1 and 2 criteria, was correlated 
with survival, both in the hormone-sensitivity and in the CRPC phase  (94). Therefore, 
PSA progression is a powerful predictor of survival, and thus can be considered a good 
primary endpoint for phase II trials. For this reason, the evaluation of PSA kinetics is 
currently recommended in order to assist in the decision-making, especially in those 
cases with no clear indication of when to start chemotherapy. 
When should treatment start in patients with mCRPC? 
Among the treatment options for patients with mCRPC who experienced progression 
despite an androgen deprivation therapy (surgical or chemical castration with luteinizing 
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hormone-releasing hormone analogues plus an anti-androgen agent), there is a wide 
variety of “classic” second-line hormonal approaches, including discontinuation of the 
anti-androgen therapy, high doses anti-androgen, adrenal inhibition with ketoconazole 
(although this has been withdrawn due to the risk of hepatotoxicity) or the use of 
corticosteroids  (95-97)  . 
According to the recommendations published by the Spanish Oncology Genitourinary 
Group (SOGUG), classic second-line hormonal approaches should be reserved for 
patients with a slow progression of the disease, as well as those who are asymptomatic 
or mildly symptomatic and those in which chemotherapy is contraindicated  (67,98) . 
However, none of these classic second-line hormonal therapies had an impact on 
survival, obtaining only short-term responses  (11).  
When should treatment with docetaxel, abiraterone or enzalutamide start? 
The final results of the COU-AA-302 study confirm the anticipated clinical efficacy in 
the preliminary analysis (71). The established criteria to determine progression were 
clinical (e.g., pain, need for radiotherapy or chemotherapy, or worsening of the 
performance status) and radiological (i.e., the PCWG2 criteria adapted to the trial). Both 
COU-AA-302 and PREVAIL included patients with progressive, asymptomatic or 
minimally symptomatic mCRPC (75). The patients included had PSA progression 
according to the PCWG2 criteria or radiological progression. According to the results of 
these trials, abiraterone-prednisone and enzalutamide can be considered the alternatives 
of choice in this group of patients.  
On the other hand, patients with symptomatic mCRPC or with objective progression of 
visceral metastases, as well as those at a greater risk of a rapid progression, should be 
considered candidates to receive chemotherapy. In patients with these conditions in 
which an increased risk of hematologic toxicity is expected or with an initial worsening 
of the performance status, a treatment with docetaxel administered weekly might be 
appropriate, due to its lower expected hematologic toxicity. 
The asymptomatic patient is defined in pre-chemotherapy studies as one that does not 
require the use of opiates nor radiotherapy for pain control and, in general, presents 
increased PSA as the only progression criterion. In the TAX 327 study, patients without 
pain at the study start had a greater OS than symptomatic patients (21.3 vs. 14.2 months, 
respectively), although the benefit of docetaxel was maintained in both subgroups. For 
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this reason, treatment with docetaxel for these patients should be considered based on 
their characteristics, especially if they are not candidates to receive abiraterone or 
enzalutamide (78). 
As mentioned above, asymptomatic patients have better OS, but the potential 
consequences of delaying the onset of treatment in these patients should be taken into 
account. Some patients with mCRPC may be asymptomatic for long periods of time, 
while others will have symptoms in a few weeks or months. Given the short OS in the 
latter group (approximately one year), delaying treatment initiation would not be 
recommended, especially considering that there are several drugs that have shown 
benefit in phase III trials. Therefore, patients with mCRPC should always be closely 
monitored, including regular clinical assessments and frequent PSA measurements. 
Taking into account all the variables and the available evidence already described, 
abiraterone plus prednisone or enzalutamide could be the first treatment for patients 
with minimally symptomatic mCRPC without visceral metastasis. Similarly, it seems 
advisable to give chemotherapy with docetaxel as the first therapy especially to the 
group of patients with symptomatic mCRPC with visceral metastases. 
Due to the toxicity profile of chemotherapy, one of the controversial issues in mCRPC 
is the optimal time to start treatment. In general, the evaluation of clinical and biological 
parameters, such as the PSA-DT, is considered when selecting patients. In this sense, a 
multidisciplinary team should take the decision, and the potential benefit and side 
effects of the treatment proposed should be discussed with each patient. 
What information can be obtained from prognostic nomograms? 
Several nomograms have been published based on the prognostic variables analyzed in 
groups of patients with CRPC treated with first-line chemotherapy  (99-101). For 
example, the nomogram described by Armstrong et al. incorporated PSA kinetics to 
predict survival at 1, 2 and 5 years in patients with CRPC treated with docetaxel in the 
TAX 327 trial and included new independent clinical factors (92). Thus, it has become a 
useful tool for stratifying patients who might be candidates for inclusion in clinical 
trials. However, in the routine clinical practice, the use of nomograms is not 
generalized; thus, their usefulness would be limited with respect to deciding the best 
timing to start chemotherapy. 
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Criteria to start a second-line treatment (post-docetaxel). 
Apart from meeting several criteria to define disease progression, and with various 
effective drugs in the postdocetaxel setting of CRPC, it is important to know the 
prognostic factors of such a progression. Armstrong et al. identified prognostic 
variables for OS pre- and post-chemotherapy, useful in deciding when to start treatment 
(Table 1.6). Given their impact on survival, it is important to know the percentages of 
patients included in clinical trials with any of these clinical manifestations, which are 
shown in Table 1.7. 
 
Table 1.6. Multivariable model for overall survival after disease progression used for the 
construction of the nomogram (modified from Armstrong et al.  (102)). 




>2 metastatic foci 
Worst performance status (KPS ≤ 70) 
Time from diagnosis (y) 
Presence of anaemia (Hb < 13) 
Alkaline phosphatase, IU/dL (<200 vs. 200-
1000) 
Alkaline phosphatase IU/dL (<200 vs. > 1000) 
Post-chemotherapy variables 
Duration of first-line chemotherapy (months) 
Number of progression factors (2 vs. 1) 
Number of progression factors (3 vs. 1) 











































Note: The corrected c-index for confidence intervals is 0.7049, n=640. 
Abbreviations: HR, hazard ratio; CI, confidence interval; KPS, Karnofsky Performance Status; Hb,    
haemoglobin.  
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There is no absolute consensus on the criteria to be used in deciding when to start 
treatment after progression on docetaxel. However, based on the inclusion criteria of 
published studies, patients with an Eastern Cooperative Oncology Group (ECOG) 
performance status ≤ 2, with clear progression, with or without the presence of 
symptoms associated with cancer and without relevant co-morbidities should be 
considered candidates for treatment. As a general consideration we recommend that 
these data should be evaluated by the medical oncologist and discussed with the patient, 
to take a consensus decision considering the benefits and toxicity associated with 
treatment. 
 
Table 1.7. Clinical manifestations of CRPC progression (%). 
Manifestation 
MSKCC 
(N = 124) 
SWOG9916  (51) 
(N= 770) 
TAX 327  (88) 
(N=1,106) 
Increased PSA 94 90 87 
Bone 84 88 93 
Significant pain 35 36 36 
Soft tissue lesions 
   Lung /liver 










Prostate/prostate bed 2 Not specified Not specified 
 
Abbreviations: MSKCC, Memorial Sloan-Kettering Cancer Center; SWOG, Southwest Oncology Group; PSA, 
prostate-specific antigen. 
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4. Clinical applications of circulating tumors cells in patients with prostate 
cancer. 
Currently, histopathological analysis (Gleason score) and PSA levels are key 
determinants of therapeutic decision. However, PSA analysis have some weaknesses as 
a biomarker, because it is also increased in benign prostatic hyperplasia, their levels 
could be similar in indolent and aggressive cancers and often fails to indicate accurately 
the patient`s response to a given treatment. In addition, the histopathological analysis is 
not enough to predict the disease evolution (103). Therefore, the clinical application of 
new surrogate markers will provide the opportunity for improving patient management 
and the therapeutic selection and monitoring.  
For its clinical use, a novel biomarker should provide relevant information to the 
clinicians in a cost-effective way. Therefore, new biomarkers need to improve the 
standards or at least improve their accuracy. The ideal biomarker should be determined 
through a blood test providing evidence about a patient’s outcomes (prognosis marker) 
or predicting the likelihood of response/benefit to a specific therapy (predictive marker)  
(104).  
During the process of haematogenous spread in prostate cancer tumor cells travel 
through the blood vessels and, after extravasation, colonize distant target organs, 
typically the bone. As circulating tumor cells (CTCs) are an intermediate between the 
primary tumor and metastasis, they are candidates to act as a surrogate markers 
measurable in blood  (105). The quantification of these CTCs has experienced a rapid 
technological development in last years, allowing the accumulation of important data to 
establish the potential clinical value of CTCs as early detection, diagnostic, prognostic, 
predictive, surrogate, stratification, and pharmaco-dynamic biomarkers in different 
carcinomas.  
CTCs are widely recognized as a biomarker in PCa. Numerous studies have 
demonstrated the association between CTCs baseline levels and clinical outcomes in 
metastatic patients  (106-108). In addition, drops in CTCs levels within the therapy has 
been associated with higher overall survival, similar to the benefit correlated to a 
substantial PSA decrease or radiographic response  (107,109,110). Besides, changes in 
CTCs levels usually precede PSA fluctuation being their monitoring of even greater 
value when changes in PSA or bone disease are difficult to evaluate  (108). Despite of 
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all the promising data regarding the value of CTCs as a disease marker in prostate 
cancer, their clinical utility should be carefully interpreted. 
Current and new approaches for CTCs detection: application in prostate cancer. 
CTCs occur at very low frequency in the bloodstream, generally estimated at 1 CTC per 
million of leukocytes. Because of the low concentration of CTCs in blood, extremely 
sensitive and specific strategies are required to process the blood samples in a short 
period of time. CTCs enrichment methods are based on physical or biological cell 
properties such as size or specific marker expression (Table 1.8). Immunocytochemical 
enrichment is the most employed strategy to isolate CTCs from blood cells. Affinity 
techniques normally use antibodies which recognize antigens expressed by CTCs but 
not by blood cells. The antigen mostly used is EpCAM, an epithelial marker 
overexpressed in some carcinomas  (111,112) .  
Table 1.8. CTCs enumeration platforms for prostate cancer. 
Assay Enrichment Detection 
Cellsearch system Immunocapture         
(EpCAM) 
IF for CK, CD45, and DAPI 
MagSweeper Immunocapture          
(EpCAM, CD45) 
PCR for PSA, KLK3, 
TMPRSS2, CD45 
EPISOT assay Immunocapture             
(CD45, CXCR4) 
Secretion of proteins; 
CK19, MUC1, PSA 
ISET Cell size ICC for CK 
ApoStreamTM Dielectrophoretic device ICC for EpCAM and CK 
CTC Membrane Microfliter Cell size IF for CK 
DEPArray Microfluidics Image-based selection 
Nanodetector (GILUPI) Immunoisolation        
(EpCAM) 
IF ofr CK, EpCAM, CD45 
Ficoll-Paque Cell Density ICC for CK, PSA PCR 
Vita-Assay (Functional Collagen 
Adhesion Matrix) 
Marker independent isolation ICC or flow cytometry 
(EpCAM, CK, CD44, CD34, 
CD45, Vimentin) 
GEDI microfluidic device Microfluidic/Immunocapture 
(PSMA) 
ICC for CD45, PSMA, EpCAM 
RosetteSep Deplection of CD45 PCR, ICC, cell culturing 
CTC-iChip CD15, CD45 +/- EpCAM Immunofluorescence, 
cytopathologic, FISH 
Magsweeper Immunoisolation        
(EpCAM) 
PSA, KLK3, TMPRSS2, CD45 
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However, CTCs undergo changes in their epithelial signature during the metastatic 
process interfering with the use of EpCAM as an universal marker (113,114) . 
Therefore, big efforts are focused on characterization and identification of additional 
markers able to distinguish CTCs from their counterparts in blood. Moreover, it is 
important to distinguish viable from apoptotic CTCs and to detect and profile the most 
relevant metastasis-initiating CTCs.  
Other methods for CTC enrichment or isolation are based on size, density, electric 
charges, or deformability. In this sense, several platforms using size as the isolation 
method to detect CTCs from blood were reported in recent years (115-117). An example 
of theses commercial available devices is ISET or ScreenCell®  (115,116,118,119). The 
handicap of these systems is that they provide low CTCs purity requiring in most cases 
further enrichment, and the fact that leucocytes could overlap in size with CTCs. An 
alternative approach is enrichment of cells by their density, such Ficoll–Hypaque 
method (120). This principle allows a marker-independent cell selection but leads to a 
high loss of tumor cells conducting to false-negative results in clinical samples. 
Microfluidics have been demonstrated to be valuable platforms for CTCs analyses that 
can be integrated to other processing steps to fully automate sample processing. These 
systems could combine both physical and biological strategies. Microfluidic devices 
based on affinity selection typically show higher purities compared to size-based 
selection but at the expense of throughput  (112,121,122). For example, “CTC-chip” 
isolates viable CTCs by affinity to anti-EpCAM-coated microspots under controlled 
laminar flow conditions. This approach demonstrated higher sensitivity, selectivity and 
yield compared with techniques based only on immunomagnetic beads in prostate 
cancer patients (112,123) .  
CellSearch (Veridex) is the only technology approved by the US Food and Drug 
Administration (FDA) for the CTCs quantification in metastatic breast, prostate and 
colon cancer. This technology uses magnetic beads coated with an anti-EpCAM 
antibody for the CTCs isolation; the identification is mainly based on cytokeratin-
positive expression. Although CellSearch is an accepted platform with high value for 
cancer prognosis and monitoring, its limitation to some cancer types reinforce the need 
of more effective technologies for the CTCs analysis (124,125) .  
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Recently, many new technologies have been presented for CTCs detection and 
molecular profiling but the clinical utility of most of them have to be demonstrated. 
There is a big interest in developing microdevices that can process smaller volumes of 
blood decreasing the assay time and the cost. Opposite, some technologies are now 
directed to analyse larger blood volumes, particularly in early-stage tumors where CTCs 
presence is even more unfrequently (126). Overall, efforts are directed to develop 
devices for live cancer cell detection with single cell sensitivity, high selectivity and 
reproducibility, easy fabrication and low cost. A strict clinical validation of the new 
devices is now required before their introduction into the management of cancer 
patients. 
Application in prostate cancer. 
Given the difficulty to acquire biopsies from patients with only bone metastasis and the 
value of providing new biomarkers (which improve PSA information) that could be 
used as surrogates for survival in clinical trials, prostate cancer represents the ideal 
disease for CTC research and clinical development. Importantly, prostate cancer cells 
display tissue-specific antigens, such as PSA and PSMA usually absent in non-epithelial 
cells. In addition, prostate cancer CTCs express epithelial markers such as EpCAM and 
several cytokeratins (8-9-19) in a higher degree that CTCs originating from other 
tumors even if the cells are heterogeneous and some of them display with EMT-like 
characteristics  (127).  
Chronologically the first approaches for CTC detection in prostate cancer were based on 
RT-PCR analysis to detect prostate-specific or epithelial specific markers in non-pre 
enriched blood samples (128,129). The results of these studies showed the possibility to 
distinguish patients from controls based on the levels of mRNA, but were often unable 
to show a direct prognostic relationship. Potential limitations of this approach are the 
low sensitive due to white blood cells contamination, the variability in the number of 
copies of a given mRNA between cancer cells and the use of heterogeneous inclusion 
criteria and small size numbers in confirmatory trials.  
The next step for CTC research development in prostate cancer was the use of complex 
methods with a selection step previous the cell identification. Using the CellSearch 
technology, as we commented before, tumour cells are first positively selected based on 
the EpCAM expression and then the identification depends on morphology 
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characteristics and the presence of cytokeratins expression  (125). 
This has permitted to find specific mutations such as the TMPRSS2-ERG translocation, 
the loss of PTEN and overexpression of markers such as the androgen receptor, also 
found in primary tumors, confirming that these cells are not only epithelial but 
originated in the tumor (130-132). Interestingly, there are also subtle differences 
favoring a more mesenchymal-like phenotype in the CTCs, perhaps reflecting that only 
a subset of cancer cells is able to intravasate and become a CTC  (127). 
Although EpCAM is the most widely used marker for positive selection of CTCs, other 
prostate cancer markers such as PSA and PSMA have been used with promissory 
results. Negative selection methods and methods that use physical properties offer the 
potential advantage of capturing cells that have lost the expression of epithelial and 
cancer specific markers, and have also showed some efficacy in prostate cancer  (133-
135). 
In last years, new CTC methodologies in prostate cancer have focused on offering a 
high sensitivity and the potential to conduct molecular characterization studies. Some of 
these technologies combine antibody specific binding and physic properties in 
microfluidic systems that may offer higher sensitivity and also more purity for cells 
with lower EpCAM expression  (136,137) . 
Clinical development of CTCs as a biomarker in prostate cancer. 
Requirements for biomarker validation. 
The first effort to standardize the requirements for the clinical validation of biomarkers 
was the development of common guidelines for reporting the results of studies with 
tumor markers, REMARK consensus (reporting recommendations for tumor MARKER 
prognostic studies) following the recommendations of the NC-EORTC (First 
International Meeting on Cancer Diagnostics in 2001)  (138). 
In 2004 the FDA Critical Path Iniciative identified the lack of adequate biomarkers as 
an obstacle for drug development and promoted the foundation of a ACCR-FDA-NCI 
backed Cancer Biomarkers Collaborative (CBC), a new consortium founded to 
“accelerate the translation of cancer therapeutics into the clinic by shaping the processes 
for the effective development of validated biomarkers and their use in clinical trials”. In 
2010 the CBC committed to 27 recommendations for the clinical validation of new 
molecular biomarkers (139). These recommendations focus on eight different areas to 
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improve biomarker development:  biospecimens, analytic performance, standardization 
and harmonization, bioinformatics, collaboration and data sharing, stakeholder 
education and communication, regulatory issues, and science policy. 
More clear is the proposal of the Evaluation of Genomic Applications in Practice and 
Prevention (EGAPP) working group, which consists in three successive requirements: 
analytic validity, clinical validity, and clinical utility  (140). While analytical validity 
refers to the reproducibility, accuracy and reliability of a test, clinical validity entails 
that the test can identify the phenotype, disease or the subgroup of patients of interest. 
Therefore, clinical validity encompasses analytical validity but has also to take into 
account the specificity and the disease prevalence to calculate the positive and negative 
predictive value. Finally, clinical utility requires that the use of a test provide with an 
added benefit for patient management-making. 
Although the level of evidence for each of these components can be evaluated 
objectively based on pre-specified benchmarks it is important to note that clinical utility 
requires both clinical and analytical validity  (141). In this sense, a test validated in a 
randomized controlled trial has also to perform reliably in external quality assessments 
in order to be useful for clinical use. 
Finally, a recent document redacted by the European Group on Tumor Markers, 
established a four phase model for biomarker validation, analogous to the pathway for 
therapeutic trials in oncology  (104). This pathway clarifies the strategies and objectives 
in each step of the process and provides several recommendations to guide trial design 
for the validation of a tumor biomarker. 
Obstacles for the clinical use of CTCs. 
Analytical validation. 
From an analytical point of view a validated method has to show high reproducibility of 
results in different measures from the same patient, but this is not always possible for 
CTCs enumeration. One of the main sources of variation is the low concentration of 
CTCs in blood, up to 30-40% of metastatic patients and more of 90% of patients with 
localized disease fail to have more than 5 CTCs (142). Thus, differences of one CTC 
between different measures could involve the classification of patients in the group of 
good vs. poor prognosis. A potential way to improve CTC yields, even without 
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improving sensitivity, would be the use of larger samples of blood, increasing the 
number of expected CTCs. 
The sensitivity of the different methods is normally tested using culture tumour cells 
mixed with blood. It is known that patient derived CTCs are smaller, more 
heterogeneous and may express different markers that cancer cells in culture, and 
probably a better surrogate -such as cells from primary tumors- should be employed  
(143). In this sense, the absence of epithelial markers in CTC samples due to EMT 
impairs recovery rate in patients with a potential poorer prognosis. 
Another critical source of error is the variability in the analytical method chosen. In this 
regard, data with the CellSearch method in 14 different laboratories showed that, 
although the inter-instrument and inter-assay reproducibility of the assay was high, the 
inter-laboratory reproducibility was low, due to inter-observer variation (35). This 
finding has been reproduced in other studies (144).  
Recent studies comparing different methodologies in paired samples from the same 
patient have shown that microfluidic systems and other methods that do not depend on 
EpCAM expression can isolate a higher number of CTC compared with CellSearch, 
even in samples that are negative for the CTC counting using the reference method. It is 
important to conduct additional studies focusing in quality control and benchmarking 
the performance and reliability of this methods. 
Clinical validation. 
Although most methodologies for CTC isolation and quantification require a 
prospective collection of samples, many studies have been designed using cohorts 
without a clinically significant pre-specified primary endpoint or a preplanned sample 
size calculation. As a result, many series may be underpowered (1-B<80) to verify a 
clinically relevant prognostic effect or confused by too permissive inclusion criteria  
(145). Other potential issue is the fact that although CTC isolation techniques are highly 
specific (over 98% for most techniques), sensitivity is still poor. Regarding this issue, 
CTC fragments have demonstrated to have prognostic value even in patients with no 
conventional CTC, suggesting a critical impact of sensitivity for the clinical validation 
of new technologies  (146,147) .  
Even considering these limitations, the hazard ratio related with high count of CTC 
presented a proper magnitude to be clinically significant, mainly in prostate cancer patients. 
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Actual evidences supporting the clinical use of CTCs in prostate cancer. 
Localized disease. 
Some investigators have evaluated the number of CTC in patients with localized 
prostate cancer. In a study performed in 37 patients (only 8 had non-metastatic disease) 
the authors related a cut-off of 5 or more CTCs/7.5 ml with poorer survival  (148). The 
main limitations of this study were the small number of patients with localized disease, 
the wide range of PSA (from 0.2 to 22.6 ng/mL) and the absence of pathologic 
confirmation of staging.  
Gewanter et al. detected circulating prostate cancer cells using PSA levels analysis by 
RT-PCR in the serum of 161 patients with localized Prostate cancer treated with 
radiotherapy (149). The median follow-up was 29 months. The pretreatment RT-PCR 
result was not predictive of biochemical relapse-free survival or clinical disease-free 
survival. Only in 25 patients with T3-4 prostate cancer the pretreatment negative RT-
PCR was associated with better outcomes. 
Berg and collaborators analyzed retrospectively the impact of disseminated tumor cell 
(DTCs) in biopsy material from bone marrow by immunohistochemical techniques in 
272 patients with prostate cancer (cT1-4 pN0M0) treated with radiotherapy (150). The 
presence of DTCs in bone marrow at diagnosis was associated with the histological 
differentiation of the primary tumor and an increased risk of developing distant 
metastases after radiotherapy.  
Advanced disease.  
In 2008 de Bono and colleagues conducted the IMMC38 study in 231 metastatic CRPC 
patients treated with chemotherapy  (107). Patients with more than 5 CTC/7.5mL blood 
were associated with worse overall survival (11.5 v 21.7 months; HR: 3.3; P < .001), 
distinguishing patients into favorable and unfavorable groups. CTC count showed even 
greater prognostic value than PSA levels. This study led to the approval by the FDA of 
the quantification system CellSearch CTC for advanced prostate cancer. A follow-up 
study of the same cohort analyzed only those patients receiving first-line therapy and 
showed that absolute CTC count and changes in CTC count measured as continuous 
variables were prognostic for survival in this group  (108). In another study conducted 
in 162 mCRPC patients who received docetaxel, CTC levels at baseline (cut-off 5 cells / 
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7.5 ml) and  at 2-5 weeks (< or ≥ 5 cells/7.5 mL) correlated with survival, while the 
decline in PSA (30 or 50%) did not  (151). 
The prognostic value of ≥ 5 CTCs/7.5 mL of blood was confirmed in the randomized 
COUAA-301 phase III study of abiraterone acetate in docetaxel-refractory mCRPC  
(152). In this study, CTCs were enumerated at baseline and during the first three cycles. 
CTC conversion from ≥ 5 CTCs to < 5 CTCs, along with changes in serum LDH, was 
strongly predictive for OS. Similar results were recently observed in a phase III study 
using Docetaxel with or without Lenalidomide  (153). Blood samples for CTC analysis 
were collected from 208 patients: 105 received docetaxel plus lenalidomide (DL) and 
103 received docetaxel (D). Baseline CTC counts were <5 cells/7.5 ml in 87 pts and ≥5 
cells/7.5 ml in 121 pts. Overall, 2-year OS was lower in patients with baseline CTC ≥5 
in both arms (DL, HR 3.63, p=0.0044; D, HR 3.41, p=0.0459). An increase in CTC 
between baseline count and cycle 4 was associated with significantly shorter OS (HR 
5.24; p=0.0251).  
The phase III SWOG 0421 trial compared the effectiveness of docetaxel plus atrasentan, 
versus docetaxel alone  (154). The study failed to meet its co-primary end-points of 
improved OS and progression-free survival with the addition of atrasentan. As part of 
the study, CTCs were enumerated at baseline and 21 days after the first dose of 
treatment. The authors showed that baseline CTC counts were correlated with 
recognized prognostic markers, including PSA, alkaline phosphatase, hemoglobin, liver 
disease and bone pain. Unfortunately, relationship with LDH was not assessed.  
Nowadays, there are no robust data supporting the surrogacy of CTCs enumeration and 
patient´s outcome using different methods than CellSearch, in spite of the promising 
results in terms of sensitivity demonstrated by the new technologies. 
Challenges to improve CTC use in clinical and preclinical scenarios. 
To introduce the use of CTC and derived biomarkers in the day-to-day management of 
prostate cancer, we can not forget the necessity to prove the cost-efficient of their 
analysis to be reimbursed in many health systems. It is important to remark that 
although having the FDA approval since 2006, CellSearch is still considered 
investigational by many insurance providers, and has not been evaluated by agencies 
such as NICE or others. To improve the cost-effectiveness ratio of the CTC analysis the 
cost of the CTC enumeration should be reduced and the molecular characterization 
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upgraded to increase the value of doing a CTC enumeration in terms of quality-
adjusted-years gained. 
There are clinical scenarios where the prognostic information provided by a CTC 
analysis could change the clinical practice. For example, when clinicians have to 
determine if a patient will survive enough to derive benefit from an immunotherapy that 
needs three to six months to be effective, or weather a surgical palliation of a spinal cord 
compression is guaranteed. In these cases clinicians use prognostic estimators based in 
clinical and analytic parameters, but there is evidence that CTCs improve the predictive 
value, specially to decide phase I enrolment  (155). 
Even more important is the relationship between CTC increases and decreases within 
the course of the disease. The CTC levels could help oncologist to distinguish an early 
PSA and radiographic flare from a real progression, or when a clinical deterioration 
without PSA changes is observed suggesting switch of the tumour to a neuroendocrine 
pathology. This is supported by a high correlation found between CTCs changes and 
survival in several phase III trials  (107,108,154). In fact PSA changes after treatment 
were not always prognostic alone in these studies and should not be used to make 
treatment changes. 
Currently, there are clinical studies exploring the value of the CTC count to be used as 
decision guidelines: NCT01710605 in breast cancer or NCT01640444 and 
NCT01640405 in colorectal cancer. In these trials the underlining hypothesis is that 
patients with high CTCs levels have a more aggressive disease and need to be treated 
with less conservative therapies. Although it has not been proved that the adverse 
prognosis of having more CTCs is affected by a more aggressive treatment, patients 
who change from a high number of CTC to a low number of CTCs after treatment, live 
as long as patients with low basal number of CTCs  (107). 
One interesting clinical application of these differences in tumor biology between the 
high and the low CTC group is the evaluation of new treatments, especially for 
strategies that may be associated with more toxicity only in the high CTC subgroup. 
With this approach the potential toxicities could be minimized, the number of patients to 
show a benefit would be reduced and the patients could be treated according to their 
underlining biological profile. Examples of studies limited to this CTC high 
subpopulation are the NCT01499043, where only patients with more than 10 CTC 
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detected by basal CellSearch analysis are included in the study and  treated with the 
multi-targeted tyrosine kinase inhibitor PLX3397. A 10 CTC threshold is also used in 
the NCT00887640 trial that studies the effect of Temsirolimus in CPRC, and a more 
conventional >5 CTC cut-off point is used in the NCT01682772 trial that explores the 
use of Olaparib also in the CPRC subpopulation. 
Other potential application of CTC in a clinical scenario is as a predictive marker for 
targeted treatments, in a similar way than KRAS mutations for colon cancer or EGFR 
mutations in lung cancer. This is the case of the NCT01961843 trial that investigates 
whether the AR status in CTCs can be used to predict response to Abiraterone. The 
NCT02012296 attempts the same goal for Enzalutamide and Mifepristone while the 
NCT01385293 study evaluates the association with the PI3K inhibitor BMK120. 
CTC studies have also found a place as surrogate biomarkers in preclinical testing. CTC 
enumeration has the appeal of providing an early and straightforward test for activity, 
and also the potential of providing pharmaco-dynamic information  (156). A pharmaco-
dynamic biomarker provides information “that there is a direct pharmacological effect 
of a drug”, but it does not necessarily provide prognostic or predictive information  
(157). The value of this test is that it allows the measure of the treatment effect on its 
targets, if a reliable pharmaco-dynamic test is not affected by treatment, the treatment 
will be ineffective.  
This ability to predict the non-efficacy early in the clinical development of a drug 
candidate, and the possibility of repeating CTCs at different time points within the 
development of the disease without the problems associated with repeated biopsies, has 
the potential of reducing costs, timelines and improve the success rate of the next 
generation of clinical trials  (158,159). 
Molecular profiling.  
CTC were a strong predictor for overall survival and have predictive value in mCRPC 
patients.  Nevertheless, the majority of the trials have focused on the clinical utility of 
CTC enumeration, using platforms that detect CTCs expressing epithelial markers. This 
approach is somewhat simplistic, since excludes tumor stem cells, CTC clusters, and 
CTCs with mesenchymal or anaplastic phenotypes, which may have important 
prognostic and predictive implications (160). CTC isolation techniques that select CTCs 
in a marker-independent manner are under active investigation.  
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Previous works demonstrated the feasibility of transcriptional and genomic profiling in 
CellSearch-detected CTC from Prostate cancer patients (111,161) . The molecular and 
genomic profiling of CTCs may identify novel mutations, shed light on mechanisms of 
resistance to therapy, and help to predict the likelihood of response to a given therapy, 
in real time and for a particular patient. In fact, CTCs are entirely different from almost 
all other biomarkers because they represent a sampling of a patient’s tumor, and then 
can reflect the heterogeneity of metastatic sites.  
In this sense, androgen receptor chromosomal amplifications have been detected in CTC 
from mCRPC patients by FISH. Importantly, the impact of TMPRSS2-ERG 
rearrangements has also been studied using CTC. FISH detection of ERG 
rearrangements had a significant association with the magnitude of PSA decline in 
chemotherapy naïve patients treated with Abiraterone acetate (131). In other study 
Dittamore et al. analyzed 48 samples from 21 mCRPC patients treated with abiraterone 
plus prednisone (43%) or enzalutamide (57%). No responses were seen in patients with 
high AR expression on CTC, while 53% of patients with low AR had a PSA decline and 
stable radiographic disease. Salvi et al. studied the role of copy number variations of 
CYP17A1 and AR genes as predictive biomarkers for outcome of abiraterone treated 
CRPC patients (162). Those men with both genes amplification had a lower overall 
survival. In the multivariable analysis both AR and CYP17A1 copy number variations 
(CNV) independently predicted PFS and AR CNV did it for OS.  
AR splice variants lacking the canonical ligand-binding domain are known to be 
responsible for development of CRPC. Antonarakis et al. prospectively determined the 
presence of AR splice variant 7 messenger RNA (AR-V7) in CTC from patients with 
CRPC treated with abiraterone (31 pts) or enzalutamide (31 pts). No PSA responses 
were seen among AR-V7-positive patients either for enzalutamide or abiraterone-treated 
patients compared to PSA responses in 53% and 68%, respectively, among AR-V7-
negative patients (163). PSA, clinical and rPFS and overall survival were also 
significantly shorter in AR-V7-positive groups.  
In a second study the same investigators prospectively enrolled 37 patients with 
metastatic CRPC initiating docetaxel or cabazitaxel (164). Detection of AR-V7 in CTCs 
from these men was not associated with primary resistance to chemotherapy. In AR-
V7–positive men, taxanes appear to be more efficacious than enzalutamide or 
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abiraterone therapy, whereas in AR-V7–negative men, chemotherapy and abiraterone or 
enzalutamide may have comparable efficacy. The authors suggest that circulating tumor 
cell–based AR-V7 detection could serve as a treatment selection biomarker in CRPC. 
These results lead to believe that not only count but also the molecular characterization 
of CTCs may be of value for response monitoring and drug selection in patients with 
metastatic prostate cancer. 
CTC culture in prostate cancer. 
One of the main challenges in the field of CTCs development is the possibility to 
expand these cells in vitro. This would permit a better characterization of CTCs from 
patients to progress in individualized anti-tumour therapies. Although the CTCs culture 
in vitro remains difficult to achieve, some promising results are emerging and 
supporting the idea of a new era in the oncology field  (165). For example, it has been 
described that prostate cancer cells are recoverable in murine models using CTC-chip 
and then able to be cultured in vitro (166). Kirby et al. captured using GEDI 
microfluidic CTCs from CRPC and analysed the microtubule response to chemotherapy 
providing a new strategy for guiding drug selection and the development of 
individualized treatment (167). 
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Patients with metastatic prostate cancer were treated until recent years with hormonal 
therapy and docetaxel after becoming resistant to hormone deprivation. With the 
introduction of new agents such as abiraterone, enzalutamide, cabazitaxel or 
immunotherapy there is an increasing need of novel clinical tools to distinguish patients 
who will benefit from different therapies. In an ideal environment we would need 
biomarkers associated with response probability to select which is the most appropriate 
drug for each patient and in each specific time. 
To date, level of prostate-specific antigen have been the most used biomarker to assess 
the progression in patients with prostate cancer. However, in many cases, blood levels 
of PSA does not accurately reflect the state of progression of the disease or the risk for 
new metastasis development. In addition, radiological evaluation is difficult and largely 
unhelpful in patients with mCRPC. Therefore, effective treatment of metastatic disease 
requires clinical tools to select and monitor therapy. 
Taking into account this scenario, there are two priorities to improve the clinical 
management of metastatic CPRC patients: the characterization of prognostic, follow-up 
and therapy response predictors to guide the clinical intervention and the identification 
of new therapeutic targets to increase the treatment options of these man. 
Due to the continuous evolution of tumors, which involves genetic and epigenetic 
alteration of cancer cells and tumor heterogeneity, it is well accepted that primary 
tumors and individual metastases provide a limited information of the molecular status 
of cancers. In this sense, CTCs provide a real-time and sequential ‘‘liquid biopsy’’ for 
metastasic cancer patients. These cells can provide significant information for a better 
understanding of tumor biology and tumor cell dissemination.  
Into this context of knowledge, our hypothesis is that, in addition to the clinical value of 
CTCs counting to predict mCRPC patient outcome, the molecular characterization of 
the CTC population from these patients offers a unique source to obtain important 
information on:  
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1)  Patients prognostic. 
2) Patients monitoring to be able to determine early response, anticipating and 
improving the biochemical and radiological evaluation. 
3)  Therapy selection, identifying the mechanisms of resistance to current therapies. 
4)  Therapy development, providing information of the main actors for mCRPC 
progression and aggressiveness. 
 
Chapter 3. Objectives 
 





The objectives of this thesis are set to try to explore the possibilities for the use of CTCs 
in the management of patients with cancer metastatic castration-resistant prostate. We 
have established three main objectives: 
 
1. The assessment and quantification of CTCs in a cohort of patients with 
metastatic CRPC and treated with docetaxel/cabazitaxel in order to evaluate 
the role of CTC count as an independent prognostic and monitoring marker. 
 
2. The application of a new methodology for CTCs analyses in CRPC, with 
high sensibility and versatility to provide a robust alternative to the 
CellSearch, the actual reference system.  
 
3. The molecular characterization of  CTCs present in patients with mCPRC 
using a global gene expression approach in order to identify new specific 
CTCs markers and potential genes related to resistance to chemotherapy. 
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1. Study design.  
We conducted a prospective, longitudinal study in order to analyse the number and the 
biology of CTCs from peripheral blood of mCRPC patients treated at first line 
chemotherapy with either intravenous docetaxel 75 mg/m2 or cabazitaxel 25 mg/m2 
every 3 weeks. The study was approved by the research ethics committee and was 
performed in accordance with the ethical standards of the Declaration of Helsinki.  
Informed consent was signed by all patients previously the inclusion in the study. The 
informed consent model and the ethical research committee approval are shown in 
Annex 2 y 3. 
CTCs counts were assessed using CellSearch system at baseline, before the 3rd cycle 
and the 6th cycle during the chemotherapy treatment. Two additional samples for CTCs 
molecular characterization were taken before starting chemotherapy and when PSA or 
radiological progression was established (Figure 4.1). Treatment was continued until 
progression, unacceptable toxicity, death or when the number o preplanned cycles of 
chemotherapy was completed (minimun of 6 or maximum of 9 cycles).  
 
 
Figure 4.1. Study design.  
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2. Patient inclusion.  
A total of 29 mCRPC patients and 15 healthy individuals were prospectively enrolled in 
this study from January 2012 to April 2014 at the Medical Oncology Department in the 
Hospital Universitario de Santiago de Compostela, Spain. The inclusion and exclusion 
criteria are listed in Table 4.1. Control group included 15 healthy men with similar ages 
range to patients and no previous cancer episodes. 
A radiologist independently reviewed the imaging datasets, blinded to CTC results. 
According to RECIST 1.1 criteria, patients with non-measurable disease only at 
baseline, e.g., bone lesions were allowed. Response was determined by biochemical 
(PSA values), radiological (CT scan, bone scan) and clinical criteria, evaluated by a 
genitourinary oncology physician. 
Table 4.1. Study inclusion and exclusion criteria.  
Inclusion criteria 
Patients with metastatic prostate adenocarcinoma 
Progression to hormonal therapy. Indication of chemotherapy 
Patients with serum castration levels of testosterone (testosterone <50 ng/dL or <1.7 nmol/L), PSA 
progression and/or clinical progression to castration, or progression despite anti-androgen withdrawal 
for at least 4–6 weeks 
No measurable disease is required 
ECOG PS 0-2 
Ability to understand the procedures of the study and informed consent 
Estimated overall survival > 3 months 
Exclusion criteria 
 
Non-adenocarcinoma prostate cancer 
PSA progression but no evidence of metastases 
CNS metastases 
ECOG PS> 2 
Inability to understand the study procedures and to signed an informed consent 
Estimated overall survival <3 months 
 
3. Blood sampling and CTC analyses.  
3.1 CTC isolation and quantification using CellSearch system. 
CTC analyses were performed using CellSearch (Veridex LLC, Raritan, NJ, USA) 
technology. Samples were drawn into 10 mL evacuated blood drawtubes (CellSave 
Preservative Tubes, Veridex LLC, Raritan, NJ, USA), maintained at room temperature 
and processed within 96 h after collection. 7.5 mL of peripheral blood, together with 6.5 
mL of sample buffer (Veridex LLC, Raritan, NJ, USA), were centrifuged at 800xg, 10 
min at room temperature. After centrifugation, cells expressing EpCAM were 
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immunomagnetically enriched and fluorescently labelled with DAPI, CD45-APC, and 









Figure 4.2. CTC analysis with the CellSearch system. A. Representative scheme of CTC isolation and 
characterization process that CellSearch system applies to blood samples from patients. B. CTC image 
obtained after the analysis of a blood sample from a mCRPC patient with the CellSearch system. Cells 
were considered CTC when they have round-oval morphology, nucleated (DAPI+, ≥ 4μm), lacking CD45 
and expressing CK-PE (CK8, 18 and 19). C. Leucocyte, showing DAPI and CD-45 expression (CK-PE 
negative). 
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Then the images of stained cells were acquired by a semiautomatic fluorescence 
microscopy system, CellTrack system (Veridex LLC, Raritan, NJ, USA). Finally, two 
experimented reviewers selected the morphological intact CTC, defined as round-oval 
morphology, nucleated (DAPI+), lacking CD45 and expressing CK, from the gallery of 
objects proposed by the system.  
Concomitantly, PSA, lactate dehydrogenase and alkaline phosphatase were analyzed as 
routine markers at the clinical site. 
3.2 CTC isolation using CELLection and molecular characterization by RT-qPCR. 
Gene expression analysis was carried out on blood samples extracted prior to initiating 
chemotherapy (Figure 4.3). The protocol combines an EpCAM-based CTC 
inmunoisolation and a RT-qPCR analysis of a previously pre-amplificated genetic 
material (168). CTC isolation was made with CELLectionTM Epithelial Enrich system 
(Invitrogen, Dynal, Oslo, Norway) that contains beads coated with EpCAM antibodies. 
15 ml of Buffer 2 were added to 7.5 ml of peripheral blood (PBS 1x, BSA 0,1%, EDTA 
2 mM). After sample centrifugation at 1250xg during 15 min at room temperature 
plasma fraction was discarded. Then, 7.5 ml of Buffer 2 were added to 100 l of 
EpCAM-conjugated beads. They were incubated at 4ºC, 30 min at constant rotation. 
After that, cells linked to the magnetic beads were recovered using a magnet. The 
recovered fraction was then washed three times with Buffer 1 (PBS 1x, BSA 0,1%, 
pH7.4) to decrease the unspecific isolation. Finally, isolated cells were re-suspended in 
100 l of RNA later (Ambion®, Austin, USA) to avoid RNA damage and were stored 
at -80ºC until use. 
  




Figure 4.3. Representative scheme of CTC isolation and the different steps required to perform the 
gene expression analysis by RT-qPCR.  
 
Total RNA from CTC was extracted with the QIAmp viral RNA mini kit (Qiagen, 
Valencia, CA, USA), designed for very low cellularity samples following the 
manufacturer´s instructions. cDNA was synthesized by using Superscript III reverse 
transcriptase (Invitrogen, Carlsbad, CA, USA)  and subjected to a preamplification for 
14 cycles with TaqMan® PreAmp Master Mix kit (Applied Biosystem, Foster City, CA, 
USA) prior to  RT-qPCR (TaqMan Gene Expression Assays; Applied Biosystems), to 
maximize detection rates.   
We analyzed in the CTCs fraction the expression of 15 candidates genes selected in 
basis on their relevance for prostate cancer biology plus the house-keeping gene 
GAPDH as total cellular load marker and CD45, a specific gene for hematopoietic cells, 
to estimate non-specific isolation. The genes selected for this study have been 
previously related to androgen-regulation (AR, CYP19A1 and CYP17A1), stem cell 
phenotype (CD133, CD44, ALDH1A, ABCG2 and CD49f) and prostate cancer 
aggressiveness and/or resistance to taxanes (BIRC5, CLU, GDF15, RAB7A, SPINK1, 





29 CRPC patients 
15 healthy 




Figure 4.4. General fuctions of candidate genes analyzed by RT-qPCR. 
 
RT-qPCR was performed using TaqMan® Gene Expression Assays and StepOnePlus 
Real-Time PCR System (Applied Biosystem, Foster City, CA, USA). cDNA was 
diluted at 1:20 with TE1X. Then, 5 l of this dilution were added to 10 l TaqMan® 
Master Mix, 1 μl TaqMan® Gene Expression Assay, 4 μl RNase free water.  PCR 
conditions were: 50ºC, 2min; 95ºC, 10 min; (95ºC, 15 sec; 60ºC, 1min) x 40 cycles. 
Data were analyzed using StepOne Software v.2.1. (Applied Biosystems) and 
expression values were normalized to CD45. The same protocol was applied to healthy 
volunteer’s blood. 
3.3 Whole gene expression analysis of CTCs.  
Whole gene expression analysis was carried out on blood samples extracted from 9 
patients prior to initiating chemotherapy and when progression was confirmed. In 
parallel, the same protocol was applied to blood samples from 6 healthy donors stablish 
the baseline of background from unspecific immunoisolation (Figure 4.5). CTCs 
isolation and RNA extraction were made as described above in section 3.2 of Material 
and Methods. 
Gene expression arrays. Total RNA extraction, complete Whole Transcriptome 
Amplification (WTA2, Sigma Aldrich, Sant Louis, USA) and gene expression array was 
performed as described  (168). Briefly, total RNA was extracted with the QIAmp viral 
Hormon pathway 
Stem like phenotype 







BIRC5, CLU, GDF15, 
RAB7A, SPINK1, 
TUB1A1, MDR1 
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RNA mini kit (Qiagen, Valencia, CA, USA) specifically designed for very low 
cellularity samples.  
 
 
Figure 4.5. Schematic representation of the procedure used for CTCs gene expression profiling. Taken 
from Mariscal et al. (under review). 
 
Subsequent pure RNA was then subjected to Complete Whole Transcriptome 
Amplification PCR for 20 cycles using the maximum amount of RNA; Cy3 labeling and 
hybridization onto Agilent 4x44k gene expression arrays. Upon hybridization, signal 
was captured and processed using an Agilent scanner (G2565B, Agilent Technologies). 
The scanner images were segmented by the Agilent Feature Extraction Software (v9.5) 
with the protocol GE1-v5_95.   
4. Statistical analysis. 
Data were analysed using SPSS (Chicago, version 15.00 for Windows) and GraphPad 
Prism 4.00 software (GraphPad Softwares Inc, San Diego, CA, USA). p values <0.05 
were considered statistically significant. For the collection and analysis of clinical data 
in the patient group a database was designed. The main variables collected are 
summarized in annex 1. 
Regarding the experimental variables, CTC counts obtained by CellSearch are presented 
as number per 7.5 ml of blood while the expression of the candidate markers analysed in 
CTCs by RT-qPCR are presented as 40-Ct normalized by CD45 expression (40-Ct). The 
cut-off value to categorize the expression levels of the markers was calculated on basis 
of percentile that best grouped patients into good and poor evolution groups. 
 CTC CHARACTERIZATION 
 6  healthy 
 9 CRPC 
patients
CTC 
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The association between categorical variables were done using 4x4 tables and the Chi-
square test for significance or the Fisher exact test if the expected values in each group 
were <5. T-test for independent samples was used to compare the mean of the different 
clinical and experimental groups. For multivariate analyses, biochemical response was 
defined as PSA decrease of ≥50 %. Bivariate correlation analysis was carried out 
according Pearson statistic. 
Regarding survival analyses, PFS and OS were analyzed using Kaplan-Meier analysis 
and differences were examined by log-rank test. Univariate and multivariate analyses 
were performed using Cox regression statistics.  
Gene expression arrays analysis. Extended dynamic range implemented in the Agilent 
software was applied to avoid saturation in the highest intensity range. The Agilent 
feature extraction was used as raw data for further pre-processing. The processed signal 
(gProcessed-Signal) value was chosen for the statistical analysis instead of the signal 
with substracted background (gBGSubSignal) since it produces lower average 
coefficient of variation (CV) in Spike-In and gene replicates (169,170). Spatial Detrend 
correction was applied using the Agilent Feature Extraction algorithm. The following 
features and/or genes which did not conform to the established quality criteria were 
filtered: (a) non-uniform pixel distributed outliers and population replicate outliers 
according to the default Agilent feature extraction criteria; (b) spots not differentiated 
from background signal; (c) spots in the range of negative controls. 
After this filtration, we considered CTC-associated genes those non detected in any 
control and detected in at least 5 patients at baseline and progression. In order to 
compare the profile expression in CTC fraction at baseline and progression 
normalization between microarrays was carried out using the Quantile method 
implemented in the Limma package of the R statistical software version 3.2. After 
normalization, the two quantiles 0.25 (Q1=361.78) and 0.75 (Q3=2953.91) of all gene 
signals in all experimental conditions were computed. The resulting list contains all 
genes which expression was lower than Q1 at baseline and higher than Q3 at 
progression. 
Finally, gene set characterising CTC population was analysed with Ingenuity Pathway 
Analysis software (IPA; Qiagen, Redwood City, CA, USA) for networks generation and 
the identification of the main signalling pathways involved in CTCs biology.   
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5.1. Patient characteristics and treatment efficacy.  
 
Between January 2012 and April 2014 29 mCRPC patients were prospectively enrolled 
at the Medical Oncology Department in the Hospital Universitario de Santiago de 
Compostela. Samples were acquired from 15 healthy controls using the same 
institutionally approved protocol.  Patient baseline demographics and clinical 
characteristics are described in table 5.1 and table 5.2. Twenty seven percent of patients 
debuted as stage IV disease. Those with local or locoregional prostate cancer were 
treated by prostatectomy (20%) or radiotherapy (41%). Most of patients received 2 or 3 
hormonal maneuvers, including at least complete blockade and antiandrogen 
withdrawal. Mean serum PSA at initial diagnosis was 258 ng/mL (range 2-2327). 
 
Table 5.1 Patient demographics and clinical characteristics I. 
 
Comorbidities, n (%) 
  COPD 
  Hypertension 
  Diabetes mellitus 
  Hypertension + Diabetes 










  Stage, n (%) 
    I 
    IIA 
    IIB 
    III 
    IV 
 
  PSA, ng/mL  
    Mean, range 










258 (2-2327)  
11 (2-2327) 
 
Initial treatment, n (%) 
  Radical prostatectomy 
  Radiotherapy 
    Radical 
    Adjuvant 








Previous Hormonal  
Maneouvers, n (%) 
  1 
  2 
  3 








COPD: Cronic Obstructive Pulmonary Disease. 
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Gleason score was >7 in 37.9% of cases. All patients had bone metastases; 
approximately one-third of the study population had  lymph nodes metastases, and 13% 
in the lung. Twenty-six men received docetaxel and 3 cabazitaxel. Since our center 
participated in the phase III FIRSTANA trial, comparing the efficacy of cabazitaxel 
versus docetaxel in first line mCRPC, we decided to allow the inclusion in our study of 
3 patients randomized to the cabazitaxel arm. 





























Disease site, n (%) 
Bone  
Bone only 
Lymph node + Bone 
Lymph node + Bone + Lung 







Biphosphonates, n (%) 27 (93.1) 
Radionuclides, n (%) 1 (3.4) 
PSA, ng/mL  
    Mean, range 




AP, IU/L  
    Mean, range 





    Mean, range 





Docetaxel, n (%) 
Cabazitaxel, n (%) 
Number of cycles, median 






















PSA: Prostate specific antigen; AP: Alkaline phosphatase;  
LDH: lactate dehydrogenase. 
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Treatment summary and efficacy. 
Median number of chemotherapy cycles was 6. Most patients had no dose reductions 
while 3 participants in the study had chemotherapy dose delays. About 80% of patients 
received additional post-study therapy. The most frequent types of post-study therapy 
received were abiraterone (48.2%) and chemotherapy (30.9%). 
The median PFS was 7.4 months (95% CI, 5.9–8.7) (Figure 5.1). Median OS was 
27.3 months (95% CI, 16–38.7) (Figure 5.2). A PSA decline of ⩾50% from baseline 
occurred in 55.2% of patients (Table 5.3). In the subset of men with measurable disease 
the disease control rate (defined as CR + PR + SD) for all patients was 48%. 
 
 
Figure 5.1. Kaplan-Meier plot for PFS of all the patients included in the study. 
 
Table 5.3. Efficacy results. 
 













Partial response, % 
No changes, % 









Partial response, % 
No changes, % 
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Figure 5.2. Kaplan-Meier plot for OS of all the patients included in the study. 
 
Safety.  
Regardless of causality, fatigue (any grade) was the most frequent adverse event (Table 
5.4). Among the non-haematologic adverse events (AE), the only grade 3-4 toxicity 
corresponded to dacryocystitis in one patient. The incidence of diarrhoea, neuropathy 
and nausea occurred in 34.4 %, 31% and 24.1% of patients, respectively (Table 5.4).  
 
  Table 5.4. Chemotherapy toxicity.  
 Any G , (%) G3, (%) G4, (%) 
Non-haematologic AE 
Fatigue 26 (89.7) 0 0 
Alopecia 20 (69) 0 0 
Dacryocystitis 1 (3.4) 1 (3.4) 0 
Onycholysis 8 (27.5) 0 0 
Cutaneous 1 (3.4) 0 0 
Peripheral edema 3 (10.3) 0 0 
Anorexia 4 (13.8 ) 0 0 
Diarrhoea 10 (34.4) 0 0 
Nausea 7 (24.1) 0 0 
Vomiting 3 (10.3) 0 0 
Neuropathy 9 (31) 0 0 
Haematologic AE 
Anaemia 24 (82.8) 2 (6.9) 0 
Neutropenia 7 (24.1) 1 (3.4) 3 (10.3) 
Thrombocytopenia 2 (6.9) 2 (6.9) 0 
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Regarding hematological side effects anemia was the most common, but mostly grade 
1-2. Seven and four patients had grade 1-2 and grade 3-4 neutropenia, respectively. 
5.2 Clinical value of CTC counts monitoring for mCRPC management. 
CTC counts were analyzed in a total of 78 samples. CTCs were detected in 93.1 %, 
55.1% and 31% of patients at baseline, at 3 rd and at 6th cycle, respectively. At the time 
of this analysis, all patients had progressed and 44.8 % (n = 13) of them had died. 
Concomitant serum PSA and radiological assessments were evaluable in 28 and 21 
patients, respectively. Table 5.5 summarize the number of patients in whom CTC were 
analyzed at baseline, at 3rd and at 6th chemotherapy cycle as well as the mean, median 
and range of these counts. 
 
Table 5.5. Description of CTC values during treatment. 
Characteristic Baseline CTC 
(CTC0) 
CTC cycle 3 
(CTC3) 
 CTC cycle 6 
(CTC6) 
N        Valid 







Mean  159.38 57.3 9.5 
Median 12 4 0 
Typical deviation 561 261.8 19.9 
Range 0-3000 0-1392 0-66 
 
 
Many authors have previously described that patients with high CTC counts have higher 
frequency of visceral metastases, high Gleason score and other unfavorable clinico-
pathological features. In these studies, a cutoff of 5 CTC was chosen to be correlated 
with variables such as age, Gleason score, site of metastasis, etc ... (Table 5.6). Despite 
the limitations associated with the small size of our group of patients, we conducted a 
description of the clinicopathological features in patients with < 5 or ≥ 5 CTCs per 7.5 
ml of blood (Table 5.6 and Figure 5.3).  
We found higher number of CTCs in patients diagnosed with locally advanced disease 
(28 vs 263; p=0.054), nodal invasion (33 vs 443; p=0.03), and also in patients that were 
responsive to hormonal therapy for less than 24 months (18 vs 311; p=0.04). Mean 
levels of serum alkaline phosphatase and PSA were significantly higher in the CTC high 
subpopulation. 
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Table 5. 6 Clinical characteristics of the CTC high and CTC low subpopulations (CTC0). 
 
Characteristic < 5 CTC ≥5 CTC  p 
N 10 19  
Age  71.4 68.74 0.433 
Age at diagnosis 66.0 63.9 0.325 
Locally advanced disease 
at diagnosis 
44% 70% 0.212 
Nodal  invasion (cN) 22% 41% 0.012 
Gleason score >7 33% 47% 0.40 
Hormonal therapy, years 3.41  2.26  0.221 
Visceral disease 11% 23% 0.187 
Baseline PA, mean 207 765 0.03 
Baseline LDH, mean 396 558 0.216 



























1 0 0 0
2 0 0 0
3 0 0 0





















1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0





























1 0 0 0
2 0 0 0
3 0 0 0




Figure 5.3. CTC counts acording to:  
(A) lymph node metastases;  
(B) Gleason score;  
(C) duration of hormonotherapy. 
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Association of CTC counts with OS. 
The prognostic value of categorical CTC counts (<5 vs. ≥5 CTCs) to predict OS was 
analyzed in a landmark analysis at each time point of CTC assessment. Kaplan–Meier 
analyses revealed significant differences in median OS times for all time points. Median 
survival times were 16 months (95 % CI 9.4-24.7) for those patients with ≥5 CTCs at 
baseline versus not reached for those < 5 CTCs (Figure 5.4 and Figure 5.5). 
 
Figure 5.4. Kaplan–Meier analyses for overall survival according to categorical CTC counts  
(log-rank =0.007). 
 
In the analysis of Receiver Operating Characteristic (ROC) curves, baseline CTCs count 
was the risk factor with higher AUC for predicting the possibility of having an above 
mean overall survival (AUC=0.784). At the same time higher CTC counts were  
inversely proportional to the probability of biochemical response (AUC=0.321). There 
was only a weak association between CTCs and PFS. Phosphatase alkaline 
(AUC=0.727) and LDH (AUC=0.636) levels had better correlation with survival than 
PSA (AUC=0.530).  
We also evaluated the number of CTCs present before and after chemotherapy (before 
3rd cycle and before the 6th cycle) in patients that showed early progressive disease, to 
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see if the early increase in CTCs can anticipate tumor progression. We found that 
patients with CTCs ≥ 5 at 3rd cycle had a very high risk of being in biochemical 
(HR=5.571; p=0.055) or radiological progression (HR=10.679; p=0.01). Patients with ≥ 
5 CTCs at the 6th cycle had 28 (p=0.04) and 12.35 (p<0.01) more risk of biochemical 
and radiological progression, respectively (Table 5.7).  
To find out whether this fact was related to tumor progression, we analyzed the CTCs 
levels during chemotherapy. All patients who progressed during treatment had ≥ 5 CTC 
at baseline determination, allowing discard this assumption. By contrast patients who 
started from a baseline count ≥ 5 CTC, but after chemotherapy became < 5CTC 
achieved a PFS (8 months) and OS (38 months) similar to the group that started with < 
5 CTC at baseline determination. 
Table 5.7 Association between CTC values and biochemical and radiological progression. 
≥ 5 CTCs 
 
 




5.2 0.196 1.66 0.367 
After 3 cycles 
 
 
5.57 0.055 10.769 0.01* 
After 6 cycles 28 0.04* 12.35 <0.01* 
Bq: biochemical; Rx:radiological. *p< 0.05. 
 
 
Figure 5.5. Kaplan–Meier analyses for PFS according to the CTC status at baseline (log-rank=0.73)   
Chapter 5. Results 
105 
CTC count and chemotherapy. 
Mean number of CTCs decreased after treatment from 159.38 to 57.3 before the 3rd  
cycle and to 9 before the 6th cycle. The overall rate of biochemical response was 55% 
(47% in the ≥5CTC baseline subgroup vs 70% in the <5CTC baseline CTC subgroup), 
but those patients that converted to <5CTC after chemotherapy had similar response 
rates to those with <5CTC at baseline (73% vs  38%) (Figure 5.6 and Figure 5.7).  
Patients with ≥5CTC at baseline had a higher risk of progression at 12 weeks (36%, 
compared to 10% for those men with <5CTCs) and a lower mean PFS and OS. On the 
other hand patients with early conversion from ≥5CTC to <5CTCs after 3 cycles of 
docetaxel had similar PFS and OS to those patients with low baseline CTC counts. 
Patients with higher baseline CTC counts could represent a heterogeneous subgroup 
with a subset of chemosensitive patients that derive the most benefit from docetaxel 
treatment. 
 
Figure 5.6. Kaplan–Meier analyses for overall survival according to categorical CTC counts       
(<5CTCs baseline; from ≥5CTCs to < 5CTC after chemotherapy; from <5 CTCs to ≥ 5 CTCS after 
chemotherapy; ≥ 5 CTCs baseline). 














Figure 5.7. Kaplan–Meier analyses for progression free survival according to categorical CTC counts        
(<5CTC baseline; from ≥5CTC to <5CTC after chemotherapy; from <5 CTCs to ≥5 CTCS after 
chemotherapy; ≥5 CTCs). 
5.3. A new approach for CTCs analysis in mCRPC patients based on 
immunoisolation and RT-qPCR. 
CTCs immunoisolation from peripheral blood in mCRPC patients. 
Immunoisolation of CTC from peripheral blood samples was performed with magnetic 
beads coated with EpCAM antibodies, as a well accepted strategy for prostate 
carcinomas  (107,171). After CTCs immunoisolation we analysed the enriched fraction 
by q-RT-PCR. For that, after RNA extraction we performed a pre-amplification step to 
increase the detection rate of the PCR. First, we evaluated the expression levels 
of GAPDH as a marker of cellularity, which includes both CTC and unspecific blood 
cells, normalized to the background of CD45expression as specific marker for cells of 
hematopoietic origin (168). As shown, GAPDH levels were significantly higher in the 
group of patients compared to controls (Figure 5.8 A) indicating the presence of an 
extra population of cells isolated from the blood of CRPC patients.  
 




Figure 5.8. Validation of the CTC isolation approach in mCRPC patients. Box plots indicate median 
values in the control group compared with the group of mCRPC patients for GAPDH (A) CD45 (B) and 
KLK3 (C) normalized to CD45. CD45, used as a marker of unspecific blood cells isolation showed no 
differences between both groups, while GAPDH and KLK3 demonstrated optimal accuracy for CTC 
detection (**p< 0.01; *** p< 0.01). (D) ROC-curve showing the high sensitivity and specificity of KLK3 to 
detect the presence of CTCs in our mCRPC cohort. CD-45: cluster of differentiation 45; GAPDH: 
Glyceraldehyde-3-phosphate dehydrogenase; KLK3: kallikrein 3; AUC: area under curve.  
In addition, CD45 did not present differences between both groups (Figure 5.8 B), 
demonstrating that the unspecific background resulting from the process of 
immunoisolation was similar in the group of patients and controls. Importantly, when 
we compared the expression of KLK3, as a specific marker for prostate cells, no positive 
cases were found in the group of controls while 93.1 % of patients were positive for 
KLK3, reinforcing the high specificity of our strategy for CTCs detection and analysis 
(Figure 5.8 C and D). Globally, these results demonstrated the presence of CTC in our 
cohort of CRPC patients.   
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CTCs profile in CRPC patients. 
Once demonstrated the efficiency of the CTCs isolation strategy, we explored the gene-
expression profile of CTCs in samples from CRPC patients. For this, we analyzed 
relevant genes for prostate cancer progression related to androgen-regulation (AR, 
CYP19 and CYP17), stem cell phenotype (CD133, CD44, ALDH1A, ABCG2 and 
CD49f) and prostate cancer aggressiveness and/or resistance to taxanes (BIRC5, CLU, 
GDF15, RAB7A, SPINK1, TUB1A, MDR1). We analyzed the expression levels of these 
genes in the whole set of patients and controls, and identified those genes with a 
significant expression in CTC from the group of patients compared to the background of 
unspecific isolation from the controls (Figure 5.9).  
 
Figure 5.9. Gene expression profiling in CTCs from mCRPC patients. Significant expression levels of 
genes involved in relevant signalling pathways for PCa biology: (A) hormone pathways (B) stem cell 
features and (C) associated with prostate cancer progression and chemotherapy resistance. White boxes 
represent the gene expression levels in the group of healthy controls, grey boxes correspond to patients 
(Mann Whitney test, *p<0.05; **p<0.01***p<0.001). 
 
CD133 and ABCG2 were expressed in less than 30% of patients and 20% of controls, 
therefore, they were discarded for further analyses. Among the remaining genes, we 
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GDF15, RAB7 and SPINK1. All of them are considered to characterize the population 
of CTC in our cohort of patients. This concern was reinforced after the analysis of ROC 
curves, showing all the validated genes high areas under the curves or AUROC ranged 
from 0.70 (BIRC5) to 0.87 (GDF15) (Table 5.8). 
TABLE 5.8.  Diagnostic value to detect disseminated disease in mCRPC patients.  
Receiver Operating Characteristic (ROC) curves 
GENES AUC p-value CI 95% 
AR 0.76 0.002 0.62-0.90 
CYP19 0.74 0.006 0.59-0.80 
TUB1 0.83 <0.001 0.72-0.95 
GDF15 0.87 <0.001 0.76-0.98 
BIRC5 0.70 0.024 0.54-0.86 
RAB7 0.81 0.001 0.68-0.94 
SPINK1 0.79 0.001 0.66-0.92 
 
Taking into account these results, the CTC population of our mCRPC cohort is better 
characterized by genes implicated in hormone synthesis and signalling together with 
genes strongly associated with proliferation, cell adhesion, immune system evasion and 
also the response to treatment based on taxanes. Importantly, the global CTC population 
of mCRPC was not found positive for the stem like markers analyzed. 
Association between the CTCs profile and clinical parameters. 
We analysed the possible association between standard clinical parameters and the 
levels of our CTC-markers and we found the results summarized in Table 5.9. Patients 
with PS = 0 had significant lower levels of AR, SPINK1 and GDF15. Patients with 
Gleason score ≥7 were characterized by higher levels of TUB1 while the presence of 
lymph node metastasis was not correlated with higher levels of these CTC-markers.  
Patients who received fewer treatments before docetaxel or cabazitaxel administration had 
higher levels of some markers, reaching statistical significance for CYP19 and GDF15. 
Interestingly, serum PSA levels at baseline correlated with PSA (KLK3) levels analysed 
in CTC population. On the other hand, patients with high levels of LDH and PA at 
baseline were those with high levels of GDF15 marker. Overall, these results seem to 
reflect the presence of greater number of CTCs in patients with poor clinical status before 
the treatment onset, in terms of PS, Gleason score and biochemical markers. 
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       Table 5.9. Correlation between baseline characteristics and CTCs profile 
















ECOG          
    0 (n=7) -7.69 -7.16* 3.28 -11.44 1.53 3.59 -16.55* -13.43* 
    1-2 (n=22) -5.17 -3.49* 1.75 -9.42 1.98 2.93 -11.92* -6.85* 
Gleason score          
    ≤7 (n=15) -3.86 -5.33 1.24* -9.80 1.44 2.39 -12.37 -8.78 
    >7 (n=11) -5.53 -6.23 3.34* -10.09 2.60 3.98 -13.91 -9.10 
Nº of prior Tx         
    1-2 (n=15) -4.69 -3.14 2.23 -8.78* 2.52 3.57 -11.74 -5.97* 
    > 2 (n=14) -6.93 -5.70 2.01 -11.12* 1.18 2.58 -14.43 -11.08* 
PSA baseline         
    <122 (n=15) -6.23** -4.92 2.02 -10.07 1.60 2.87 -12.95 -9.41 
    ≥122 (n=14) -4.33** -2.66 2.44 -9.40 2.72 3.80 -13.32 -5.38 
LDH baseline         
    <454 (n=12) -6.40 -5.03 1.76 -9.44 1.62 3.21 -12.78 -9.12** 
    454 (n=12) -4.49 -2.85 2.44 -9.60 2.64 3.21 -11.80 -6.08** 
PA baseline         
    <320 (n=14) -7.28 -5.62** 2.09 -9.98 1.80 3.27 -13.68 -11.20** 
    ≥320 (n=14) -4.43 -3.24** 2.10 -10.05 1.97 2.94 -12.09 -5.58** 
       
*P≤0.05 according to T-test; **p≤0.05 according to Pearson test 
 
 
Prognostic value of the CTCs markers. 
In addition to the diagnostic value of our CTC-panel, we studied the prognostic impact 
of these markers to determine their real clinical interest for the management of patients 
with mCRPC. For that, we defined two groups of patients, those with low or high levels 
of each marker, using a cutoff defined as the 50, 60 or 70% percentile depending of 
each marker.  
We first investigated the prognostic potential of these CTC markers by Kaplan–Meier 
survival analyses for PFS and OS. As Table 5.10 shows, high levels of KLK3, AR, 
CYP19 and GDF15 were statistically associated with shorter PFS rates. For OS we 
found that patients with high levels of KLK3, AR, GDF15 and BIRC5 presented poorer 
survival rates that those with low levels (Figure 5.10). Thus, patients into the group of 
bad prognosis according to AR-CTC levels presented 16.6 months of OS while the good 
prognosis group reached a mean OS of 31 months.  
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Table 5.10. Kaplan-Meier analysis for clinicopathological parameters and CTCs markers 
 Overall survival (OS) Progression free survival (PFS) 
 mean (95% CI) p mean (95% CI) p value 
Performance status      
PS0 31.2 (22.7-39.8)  
0.12 
8.1 (5.6-10.6) 0.92 
PS1/PS2 22.9 (16.5-29.2) 7.6 (5.8-9.4) 
Gleason Score      
≤7 24.4 (17.8-30.6)  
0.70 
8.7 (6.3-11,1) 0.14 
>7 27.7 (17.8-37.5) 6.7 (4.8-8.7) 
Lymph node metastases      
no 30.7 (23.4-38.1) 0.05 8.7 (6.7-10.7) 0.12 
yes 18.9 (11.4-26.5) 6.3 (4.3-8.4) 
Nº of prior treatments 
i
    
≤2 22.03 (13.9-30.1)  
0.17 
6.5 (4.9-8.2) 0.09 
>2 28.4 (22.3-34.6) 9 (6.6-11.4) 
Baseline PSA serum levels      
≤122 25.7 (18.5-32.9)  
0.68 
7.6 (5.8-9.4) 0.83 
>122 24.4 (16.7-32.1) 7.9 (5.4-10.36) 
Baseline LDH levels      
≤320 24.3 (17.3-31.4) 0.67 7 (5.2-8.8) 0.71 
>320 22.9 (13.3-32.6) 6.8 (4.6-8.9) 
Baseline PA levels      
≤454 28.4 (22.3-34.6) 0.15 8 (6.5-9.5) 0.84 
>454 22.8 (14.4-31.4) 7.7 (5.1-10.9) 
KLK3      
low 29.65 (23.4-35.9) 0.04 9.4 (7.2-10.6) 0.012 
high 20.4 (12.8-28) 5.9(4.4-7.4) 
AR      
low 31 (26.3-35.7) 0.002 9.3(7.2-11.5) 0.002 
high 16.6 (8.8-24.4) 6 (4.3-7.7) 
CYP19      
low 26.6 (21.3-31.95) 0.12 8.9 (7,2-10.6) 0.015 
high 20.6 (9-32.2) 5.2 (3-7.3) 
TUB1      
low 21.5 (16-27) 0.18 8.5 (6.7-10.2) 0.09 
high 30 (17.8-31.2) 5.7 (3.2-8.2) 
GDF15      
low 31.1 (24.9-37.2) <0.00
1 
8.6 (6.7-10.3) 0.043 
high 10.6 (6.8-14.5) 5.6 (3.5-7.7) 
BIRC5      
low 30.5 (23.7-37.3) 0.013 7.7 (6.2-9.3) 0.94 
high 15.8 (9.4-22.2) 7.7 (4.2-11.2) 
RAB7      
low 19.9 (14.2-25.7) 0.11 8.5 (6.1-11) 0.22 
high 30 (21.8-38.3) 6.9 (5.3-8.6) 
SPINK1      
low 23.1 (17.3-28.9) 0.58 8.5 (6.7-10.3) 0.12 
high 28.4 (17.3-39.5) 6 (3.7-8.29) 
HR: hazard ratio; CI: confidence interval.  
 





Figure 5.10. Kaplan Meier analysis for overall survival (OS) of validated CTC markers in mCRPC 
patients. Low/high expression defined based on the 50% (KLK3 and AR) and 70% (BIRC5 and GDF15) 
percentile. 
Univariate Cox regression analysis confirmed the prognosis value of KLK3, AR and 
CYP19 to predict PFS. AR, GDF15 and BIRC5 were confirmed as good predictors for 
OS. As Table 5.11 shows, patients with high GDF15 levels presented a 2.5 and 15.7 
fold increased risk of progression and death compared to patients with low GDF15 
levels. It is important to remark that only CTC count and these CTC-markers, among all 
the other factors including in the study were validated as prognostic markers after the 
univariate analyses. In fact, KLK3 (PSA)-CTC associated levels were found as a good 
prognostic marker for PFS and almost reached statistical significance for OS while 
Log-Rank=0,002  Log-Rank=0.04  
Log-Rank=0.013  Log-Rank< 0.001  
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serum PSA levels at baseline did not show any value to predict the response to the 
chemotherapy and the patient evolution (Table 5.11).  
We believe that this panel of markers identified in the population of CTC can provide 
useful prognostic information in our cohort of mCRPC patients and even play a role as 
an alternative to CellSearch for detection of CTCs. 
 
Table 5.11. Univariate Cox regression analysis for clinicopathological parameters and CTCs 
markers 
 
 Progression free survival 
(PFS) 
Overall survival (OS) 
 HR (95% CI) p 
value 
HR (95% CI) p 
value 
Performance status (PS0 vs. 
PS1/PS2) 
1 (0.43-2.4) 0.92 4.3 (0.55-34.2) 0.16 
Gleason Score (≤7 vs. >7) 1.8 (0.8-4.3) 0.15 0.78 (0.21-2.8) 0.7 
Lymph node metastases (no vs. yes) 1.8 (0.83-3.89) 0.13 3.08 (0.91-10.3) 0.06 
Nº of prior treatments regimens (≤2 
vs >2) 
0.5 (0.2-1.15) 0.10 0.44 (0.13-1.5) 0.18 
Baseline PSA serum levels  
(≤122 vs >122) 
0.92 (0.42-1.9) 0.83 1.26 (0.4-4) 0.68 
Baseline LDH levels (≤320 vs >320) 0.85 (0.37-1.9) 0.7 1.3 (0.39-4.2) 0.67 
Baseline FA levels (≤454 vs >454) 0.92 (0.42-2) 0.84 2.4 (0.69-8.6) 0.16 
KLK3 (low vs high) 2.7 (1.2-6.1) 0.016 3.52 (0.94-13) 0.06 
AR (low vs high) 2.5 (1.1-5.58) 0.027 6.7 (1.7-25.6) 0.005 
CYP19 (low vs high) 2.7 (1.16-6.24) 0.020 2.42 (0.75-7.76) 0.13 
TUB1 (low vs high) 2 (0.87-4.8) 0.09 0.36 (0.08-1.7) 0.2 
GDF15 (low vs high) 2.4 (1-5.8) 0.05  15.7 (3.1-79.7) 0.001 
BIRC5 (low vs high) 1(0.44-2.35) 0.94 3.96 (1.2-12.7) 0.02 
RAB7 (low vs high) 1.62(0.73-3.6) 0.22 0.39 (0.11-1.3) 0.12 
SPINK1 (low vs high) 1.9 (0.8-4.3) 0.13 0.69 (0.18-2.56) 0.58 
Hazard ratios, 95% confidence intervals (CI) and p-values values are shown. Statistically significant p-
values (p < 0.05) are highlighted with bold letters. Marker high and low levels were calculated based on 
50, 60 and 70 percentile depending on each marker. HR: hazard ratio; CI: confidence interval.  
 
The independent prognostic value of CTCs counts, PSA, LDH and CTCs markers for 
OS was assessed by multivariate Cox proportional hazards regressions. We included 
baseline PSA and baseline LDH as clinical variables studied extensively in the 
literature. We also included the CTCs levels analyzed by CellSearch as the standard for 
CTCs analyses. For this analysis we only considered those markers with statistically 
significant p-values in the univariate analysis (we also include KLK3, bordering on 
significance). Comparing different assessment methods, only CTCs counts (HR 1.003;  
p = 0.046) showed independent prognostic significance (Table 5.12).  
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Table.5.12 Multivariate Cox proportional hazards regression for OS  
   Hazard ratio  95% CI   p 
CTC BASAL 1.004  1.001-1.007  0.018 
PSA basal  0.677  0.143-3.192  0.622 
LDH basal  6.583  0.803-53.966  0.079 
AR   0.297  0.045-1.937  0.204 
KLK3   0.095  0.007-1.283  0.076 
BIRC5   0.701  0.163-3.017  0.634 
GDF15   0.111  0.012-1.061  0.056 
5.4. Global genome expression characterization of CTCs from mCRPC. 
CTC Immunoisolation and global gene expression analysis. 
The strategy for CTC immunoisolation, RNA extraction and amplification for 
hybridisation onto cDNA microarrays was previously validated by Barbazan et al  for 
colorectal cancer patients (168). Briefly, CTC were immunoisolated from 7.5 ml of 
peripheral blood from mCRPC patients (n=9; Table 5.13) at baseline and when patients 
progressed. Magnetic beads were used, which were coated with a monoclonal antibody 
towards EpCAM  (171). RNA from isolated CTC was purified using a kit specifically 
designed for low abundance samples. In parallel, the same protocol was applied to 
blood samples from healthy donors (n=6) to establish the baseline of background from 
unspecific non-CTC immunoisolation. Prior to gene expression analysis, the presence of 
isolated CTC was confirmed by CellSearch system quantification and/or the presence of 
KLK3 transcripts in the CTC fraction by RT-qPCR. 
 
Table 5.13. Clinicopathological parameters of patients analyzed by global gene expression arrays 















 2  64 1 6 yes Bone and lung 3 Docetaxel 196 55 7 
 5 80 1 8 yes Bone 2 Docetaxel 139 0 9 
 6 65 1 6 yes Bone 2 Docetaxel 1.929 59 6 
9 52 1 - no Bone 3 Docetaxel 409 78 4 
11 73 0 8 no Bone 3 Docetaxel 233 12 10 
13 79 1 9 no Bone 4 Docetaxel 715 12 6 
17 71 1 8 no Bone 2 Docetaxel 3.115 199 9 
21 68 1 9 yes Bone 2 Docetaxel 347 239 11 
 24 74 1 7 yes Bone 1 Docetaxel 279 21 6 
*analyzed by CellSearch technology; PFS, progression free survival; CT: chemotherapy; Id: identification 
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In order to characterize the CTC population from mCRPC patients, after the 
immunoisolation, purified RNA was further treated with DNaseI, amplified using the 
WTA2 whole transcriptome amplification method, and complementary DNA was 
labeled and hybridized onto Agilent expression arrays (Gene Expression Omnibus, 
GEO. Accession number: GSE31023). After the initial pre-processing of raw data, an 
average of 21,273 spots were filtered according to the criteria described in Materials & 
Methods, which represented  47.81 % of the spots in the microarray with a maximum of 
28,867 (64.88%) and a minimum of 15,629 (35.12%). Normalization among all 
microarray data was performed by the Quantile method implemented in the Limma 
package of the R statistical software. This method ensured that the A values (average 
intensities) had the same empirical distribution across microarrays whilst leaving M 
values (log-ratios) unchanged. 
First, to identify the genes specifically expressed in the CTC population of mCRPC 
patients from the background of contaminating blood cells isolated together with the 
CTC population we consider signals obtained in our 6 healthy controls as the 
background from non-specifically isolated blood cells, mainly lymphocytes. Therefore 
we consider as non specific CTC genes those genes with positive expression in healthy 
controls. After discarding the genes expressed in healthy samples, the list of genes 
specifically expressed in  CTCs was composed by those genes present in at least 5 
patients at baseline and progression (Table 5.14).   
This strategy led to the identification of a final set of 54 genes, 50 of them were 
annotated genes that were specific to the CTC population in our patients. It is important 
to remark the presence in this list of KLK3 (PSA) as the broad accepted prostate cancer 
marker and EpCAM, the molecule used for the isolation of CTCs in our appoach and the 
one classically used for CTC isolation in carcinomas. In addition, BIRC5 was also found 
as member of this list.  
On the other hand, we aimed to identify those genes with increased levels at the moment 
of progression that could be participating in the tumor expansion and the development 
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analized genes with low expression (lower signal than 361.78=Q1) at baseline and high 
expression at progression disease (signal higher than 2953.91=Q3). After proccesing the 
data the list obtained from this analysis was composed by 16 genes and was 
characterized by the presence of genes such as CYP3A4 and CSAG2 strongly associated 
with resistance to chemotherapy (Table 5.15).  
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Bioinformatic analysis with Ingenuity Pathway Analysis (IPA). 
The analysis of molecular pathways, gene networks and biological functions associated 
with the list of genes specifically expressed in CTC immunoisolated from mCRPC 
patients was performed using IPA. Genes expressed in at least five patients and not 
expressed in any of the controls were considered for IPA analysis. This analysis 
proposed a number of cellular functions related to the list of 50 CTC genes, all of them 
highly altered in cancer (Table 5.16).  
 
Table 5.16. Main cellular functions associated with the list of genes specifically expressed in CTC 
immunoisolated from mCRPC. 
CELLULAR FUNCTIONS GENES 
Cell proliferation BIRC5, CCNL2, CREM, EFNA1, EPCAM, FOSL1, GHRL, 
HOXB13, NGEF, THPO, TP53TG5 
Cell death/apoptosis BIK, BISC5, CCNL2, CREM, EFNA1, EPCAM, FOSL1, GHRL, 
HOXA3, HOXB13, KLK3, MAOA, NLRP4, NUMBL, NUPL1, 
QKI, ROM1, THBS4, THPO, ZMYM2 
Cell cycle progression BIRC5, EPCAM, FOSL1, QKI, THPO, ZBTB49, ZMYM2 
Cell differentiation ARL4A, BIK, EFNA1, EPCAM, FOSL1, GHRL, XOXB13, KLK3, 
MINOS1-NBL1/NBL1, NUMBL, QKI, SDK1, THPO, TRIM15, 
ZMYM2 
Cellular movement/cell invasion BIRC5, EFNA1, EPCAM, FGD4, FOSL1, GHRL, HOXB13, 
KLK3, NUMBL 
Cellular assembly and 
organization/microtubule 
dynamics 
BIRC5, EFNA1, FGD4, GHRL, MAOA, MINOS1-NBL1/NBL1, 
NUMBL, SDK1, THBS4 
Cell morphology/formation of 
cellular protrusions 
FGD4, EFNA1, GHRL, MINOS1-NBL1/NBL1, NUMBL, SDK1, 
THBS4 
Cellular attachment/adhesion EPCAM, KLK3, EFNA1 
Reproductive system disease/ 
hypodiploidy of prostate cancer 
BIRC5 
Reproductive system 
disease/familial prostate cancer 
HOXB13 
 
Next, we found cell proliferation and cell death together with cell cycle and cellular 
differentiation as important functions that could illustrate the process CTCs might 
experience to adapt and survive in the hostile environment of blood stream. Of note, 
cellular movement and cell invasion was highlighted as a principal biological function 
defining the prostate cancer-CTC, concordant with the events of CTC homing and 
extravasation. Moreover, genes associated with microtubule dynamics as main actor 
during cell migration as well as the formation of cellular protrusions and cell 
attachment/adhesion, point to an active role of the isolated CTC during the generation of 
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micrometastasis. 
IPA analysis also identified insulin, estrogen receptor 2 (ESR2) and beta-estradiol 
signaling as upstream regulators of these cellular functions, suggesting these signaling 
pathways as potential therapeutic approaches specifically targeting the subpopulation of 
CTC in mCRPC patients. Likewise, the analysis of gene-gene interactions and gene 
network identified ERK, PI3K/Akt and NOTCH signaling pathways orchestrating the 
biological features of prostate cancer CTC (Figure 5.11), and therefore are also potential 




Figure 5.11. Gene network generated with the list of genes specifically expressed in CTC from 
mCRPC. Signaling pathways at the core of the network are candidate pathways orchestrating the 
biology of CTCs and potential therapeutic targets. 
Regarding the analysis of differential gene expression at disease progression compared 
to paired samples at baseline from the same patients, we focused on those genes poor 
expressed at baseline and presenting maximal expression at progression. IPA analysis of 
the 16 genes obtained with this strategy pointed to apoptosis as the main cellular 
function related with these genes (C8orf4, CYP3A4, MAGEA3/MAGEA6, OMA1, PLAT, 
TDRD1), indicative of a modulated response to therapy. Gene network analysis pointed 
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to beta-estradiol as a key molecular actor in the biology of prostate-cancer CTC at 







Figure 5.12. Gene network generated with the list of genes specifically expressed in prostate 
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Clinical value of CTC counts monitoring for mCRPC management. 
 
Prostate cancer is one of the most common cancers in industrialized countries. Despite 
the excellent results obtained with surgery or radiotherapy in initial stages, 
unfortunately 30% of these patients will develop metastatic disease, usually in the bone. 
Androgen deprivation has been the therapeutic strategy with more effective response, 
with disease control in 80% of cases, although almost all patients eventually develop 
resistance to hormone deprivation, a state known as metastatic castration-resistant 
prostate cancer (mCRPC).  
Classically the key elements determining the prognosis and the decision on when to 
start or finish treatment in mCRPC patients are: clinicopathological features, serum PSA 
and radiological evaluation (67). Histopathological analysis allows us to know data on 
the extent of the tumor and other features (such as Gleason score, vascular and 
lymphatic invasion) that will be useful but do not allow to predict the disease evolution. 
Serum PSA is currently used as biomarker to measure disease burden and to monitorize 
treatment response. One of the disadvantages of PSA is that it can be increased both in 
PCa as in benign prostatic hyperplasia. Besides, their levels could be similar in indolent 
and aggressive cancers and often fails to indicate accurately the patient’s response to 
treatment. The PSA flare phenomenon after the onset of chemotherapy in patients with 
mCRPC may also complicate this situation (172). PSA flare is not related with 
progression and has not a negative impact in patients outcomes negatively. However, 
we can not know before 12 weeks if an elevated PSA corresponds to a PSA flare or a 
real progression (172). For this reason PSA is not accepted for regulatory purposes for 
the approval of new drugs. 
Radiological progression is defined by PCGW2 as the appearance of two or more new 
lesions in bone scintigraphy (conclusive proof) or progression by RECIST 1.1 criteria 
(in the case of soft tissue lesions) (64). Limited lymph node and visceral tumor 
involvement restrict the value of the standard imaging test for evaluation of response. 
Besides bone metastases are measured with difficulty by bone scans. Although in a 
recent study Morris et al. have showed a correlation between the radiographic PFS and 
OS (using a modified form of RECIST 1.0), evaluation of bone disease remains a 
dilemma in this tumor (173). A high percentage of men experienced bone scan flare in 
the absence of confirmed bone scan progression over time. This fact complicates 
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treatment decisions and may lead to the suspension of a treatment that was actually 
proving effective. Therefore, the clinical application of new surrogate markers will 
provide the opportunity for improving patient management and the therapeutic selection 
and monitoring.  
During the process of haematogenous spread in PCa, tumor cells travel through the 
blood vessels and, after extravasation, colonize distant target organs, typically the bone. 
As circulating tumor cells (CTCs) are consider an intermediate between the primary 
tumor and metastasis, they are candidates to act as surrogate markers measurable in 
blood. Taking into account that bone metastases in patients with prostate cancer are 
difficult to biopsy, CTCs from these patients might serve as a “liquid biopsy” reflecting 
tumor burden and progression at real time. Moreover, serial monitoring of CTCs could 
provide information concerning not only tumor burden over time, also about the 
molecular characteristics of tumour cells evolving under the treatment pressure and 
being the best tumour source to identify response biomarkers (105). 
CTCs occur at very low frequency in the bloodstream, generally estimated at 1 CTC per 
million of leukocytes. Because of the low concentration of CTCs in blood, extremely 
sensitive and specific strategies are required to process the blood samples in a short 
period of time. A considerable number of technologies have been developed to isolate, 
quantify and characterize CTCs in last years, but only CellSearch platform have been 
cleared by FDA for clinical use in metastasic breast, colorectal and prostate cancers  
(124,125,174).  
Several studies have established the prognostic value of CTCs for OS in patients with 
PCa (108,152,154). In the SWOG S0421 study 238 men with mCRPC were treated with 
docetaxel, and the median OS was 26 months for the group of CTCs<5 versus 13 
months for those patients with CTCs≥ 5 per 7.5 mL at baseline. In addition, the group of 
Bono and collaborators found LDH concentration and CTC counts (better measured as a 
continuous variable) as the most predictive factor for survival in the IMMC38 trial.  
We decided to explore whether the same approach was applied to men with mCPRC 
treated in our hospital. In this cohort of 29 mCRPC patients the median PFS was 
7.4 months and median OS was 27.3. The CTCs count showed prognostic value being 
the median survival time 16 months for those patients with ≥5 CTCs at baseline versus 
not reached for those<5 CTCs. This means that only a patient into the favorable CTCs 
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count died at the end of the follow-up. Importantly, we found higher number of CTCs in 
patients diagnosed with locally advanced disease, nodal invasion, and also in patients 
that were responsive to hormonal therapy for less than 24 months, all factors associated 
with adverse clinicopathological features. But this fact alone justifies the introduction of 
CellSearch platform in daily clinical practice? Does eliminate CTC count the value of 
other factors such as PSA or LDH? 
Beyond the value of a single baseline measurement kinetics we believe that CTC 
quantification should also provide predictive information about therapeutic response, 
and help clinicians with the selection of the most appropriate treatment for each patient 
at each moment. Thus, drops in CTCs levels within the therapy has been associated with 
higher OS, similar to the benefit correlated to a substantial PSA decrease or 
radiographic response  (109,110,154,174). Goldkorn et al. described that changes in 
CTCs levels from day 0 to 21 were prognostic being any increase in CTC counts, as a 
continuous variable, from day 0 to 21 associated with reduced OS. However, drops in 
CTC count showed only a trend towards improved OS (154). Authors suggest that 
perhaps an early drop at day 21 after treatment onset could not be maintained over time 
and therefore, it makes difficult to know the real prognostic implications of this CTCs 
reduction, while an early rise after therapy initiation may reflect primary resistance and 
constitutes a prognostic factor associated with a poor outcome. 
Our data are aligned with those described in literature, since patients with CTCs ≥ 5 
before the 3rdcycle and 6thcycle had a very high risk of being in biochemical or 
radiological progression. Another important point which enhances the usefulness of the 
CTCs counting is that patients who moved from a baseline count ≥ 5 CTC, to CTCs 
levels <5 after chemotherapy achieved a mean PFS (8 months) and OS (38 months) 
similar to the group that started with <5 CTC at baseline determination. 
Regarding evaluation of response changes in CTCs levels usually precede PSA 
fluctuation being their monitoring of even greater value when changes in PSA or bone 
disease are difficult to evaluate (108). Scher et al. have described the lack of association 
between the time to a single rise in PSA and survival (and a second determination 
improves results) but in contrast a single rise in CTCs was moderately associated to 
survival time (108). Though still very preliminary, there are examples of the use of CTC 
in the evaluation of response in patients with prostate cancer. In this sense, Mateo and 
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collaborators in a study of 50 patients treated with olaparib, considered RECIST 1.1, or 
PSA level reduction or a confirmed reduction in the CTCs count from ≥5 cells per 7.5 
ml of blood to < 5 cells per 7.5 ml for the assesment of response (175). 
One limitation of the CellSearch system is the low detection of CTC in mCRPC 
chemotherapy-naïve patients, a stage where we need to have new intermediates 
surrogates for OS. Indeed although the survival times of patients with high CTC 
numbers are uniformly poor, those with favorable counts vary excessively. Therefore 
we need methods to detect more cells in a higher percentage of patients and help refine 
the prognosis of patients with favorable cell counts (108).  
Another limitation of the Cellsearch platform is that it can only isolate prostate tumor 
cells expressing EpCAM. Therefore this platform misses those populations of cells that 
have low or absent EpCAM expression, including those who have undergone epithelial-
mesenchymal transition and tumor stem cells. This is of special interest in patients with 
prostate cancer because androgen deprivation therapy may promote epithelial- 
mesenchymal transition (176). Furthermore CellSearch does not allow to select cells for 
ex vivo culture or for genomic analysis. Some of these limitations could be overcome by 
using other methods to detect not only the stem or epithelial-mesenchymal 
subpopulations but also CTC clusters  (177). 
To this regard, Ma et al. have confirmed in a meta-analysis the strong prognostic value 
of CTCs (178). They demonstrated that detection of CTCs by immunohistochemistry 
was less accurate than using CellSearch or RT-PCR. Though only the Cellsearch system 
has been approved by the FDA, RT-PCR could perform as well as the Cellsearch 
system in many cases. Notwithstanding, any method can still missed EMT phenotype 
cells or CTC clusters. However, the complexity and the heterogeneity of the CTC 
population requires the application of more versatile methods with allow a deeper 
molecular characterization than CellSearch. 
A new approach for CTCs analysis in mCRPC patients based on immunoisolation 
and RT-qPCR. 
Nowadays it is well accepted that CTCs provide a uniquely accessible source of tumor-
derived material for molecular analyses, even more important in tumors such PCa where 
the inaccessible metastatic lesions not allow individualize therapies according to the 
mechanism of drug resistance, which appear during the evolution of the disease  
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(179,180). In addition to the CTC enumeration, the molecular characterization of CTCs 
could provide important insights into disease progression and might allow adaptation of 
therapeutic strategies, mainly in CRPC patients, since the optimal use of chemotherapy, 
enzyme inhibitors or AR antagonists require the application of precision molecular 
medicine. 
Our group and others previously demonstated that combination of CTC-
immunoenrichment and the analysis of CTC-transcriptome by RT-q-PCR provide an 
alternative and high sensitivity method for CTCs detection and characterization  
(131,168,181). Here we use this approach to characterize the CTC population from   
mCRPC men progressing despite castrate levels of testosterone and after at least one 
hormonal manipulation. The goal of this study was to identify CTC-markers with 
clinical impact for the management of these patients starting chemotherapy based on 
docetaxel or cabazitaxel. 
First, we evaluated the expression levels of GAPDH normalized to the background 
of CD45 expression. GAPDH levels were significantly higher in the group of 29 
patients compared to controls indicating the presence of an extra population of cells 
isolated from the blood of CRPC patients. Then we found a CTCs transcriptome 
phenotype mainly characterized by the expression of two group of genes; those related 
with androgen signaling pathway such as AR and CYP19 and those implicated in 
relevant functions for PCa progression and resistance such as BIRC5, TUB1A, GDF15, 
RAB7 and SPINK1.  
Androgen stimulation is essential for prostate gland development and homeostasis and a 
main actor in PCa evolution. From 2-18% of prostate tumors harbour AR mutations, 
and 5-52% present AR amplification  (182,183). In a recent study in 150 prostate cancer 
patients, 71% of cases presented AR pathway aberrations, the majority of wich were 
directed alterations affecting AR through amplification and mutation (183). Nowadays, 
it is widely accepted that AR pathway is active when patients relapse despite castrate 
levels of androgens (testosterone and dihydrotestosterone).  
The analysis of AR in CTCs was attempted by various groups with promising results 
(176,184). Miyamoto et al. determined the AR signalling status in CTCs from patients 
under androgen deprivation therapy as a possible indicator for therapy efficacy (132). 
Reinforcing the value of AR analysis, recent studies proposed the evaluation of AR 
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modifications in CTCs, including detection of AR-V7 and point mutations as an 
accessible and valuable tool for treatment selection (163,164,185). Detection of AR-V7 
in CTCs from men with metastatic CRPC is not associated with primary resistance to 
taxane chemotherapy. In AR-V7-positive men, taxanes appear to be more efficacious 
than enzalutamide or abiraterone therapy, whereas in AR-V7-negative men, taxanes and 
enzalutamide or abiraterone may have comparable efficacy (164).  
Crespo et al have evaluated AR expression in CTC of patients treated with enzalutamide 
or abiraterone (186). Using the CellSearch platform the authors analyzed AR, CK, and 
CD45 expression and demonstrated that AR nuclear expression is mantained in CTC at 
progression to novel endocrine agents. Although it is not currently available, a 
conjugated antibody for the detection of AR splice variants in the CellSearch platform 
could be incorporated in the 4th channel to automate the detection of ARV7 in this 
scenario.  
Besides the AR alterations, the overexpression of enzymes responsible for androgen 
synthesis and metabolism have been also proposed to explain the persistence of 
hormone-mediating signalling in prostate tumor cells under hormone deprivation state  
(187). We found that CYP19A1 (Cytochrome P450, Family 19, Subfamily A, 
Polypeptide 1) was present in the CTC population of our mCRPC patients. This enzyme 
catalyzes the conversion of androstenedione to estrone, and testosterone to estradiol and 
has been suggested to be involved in prostate cancer risk and survival by affecting the 
serum sex hormone milieu (188). Although no previous data exists to this concern, the 
expression of CYP19A1 in CTCs from patients progressing after androgen deprivation 
could represent an adaptative mechanism to maintain the hormone stimulation of 
prostate tumor cells. 
On the other hand, we identified BIRC5, TUB1A, GDF15, RAB7 and SPINK1 as genes 
characterizing CTCs of mCRPC patiens. They conform a diverse group of genes with a 
common role promoting tumor agresiveness and the development of resistance to 
taxanes-based treatment. BIRC5 or survivin is a member of the inhibitor of apoptosis 
protein family which mediates tumourigenesis suppressing tumor apoptosis and 
promoting angiogenesis (189). Its expression in PCa tissues has been related with high 
Gleason score, chemoresistance and cancer progression (190). Serine Protease Inhibitor 
Kazal Type 1 (SPINK1) is secreted in the prostate gland and its principal role is the 
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inhibition of serine proteases such as trypsin. Due to their strong association with ETS 
rearrangement negative prostate cancers, SPINK1 positive tumors have been proposed 
as a distinct prostate cancer subtype (191). Its overexpression has also been associated 
with an increased risk of biochemical recurrence in hormonally and surgically treated 
prostate cancer cohorts (192). RAB7 is a regulator of intracellular endocytic/membrane 
trafficking involved in many diseases including prostate cancer and several infectious 
diseases. In addition to its recognized role in vesicle trafficking, this protein has recently 
described as a regulator of apoptosis in response to growth factors. 
GDF15 (Growth differentiation factor-15), most known as MIC-1 (Macrophage 
Inhibitory Cytokine1), is a cytokine commonly overexpressed in many cancers, 
including PCa patients, where serum levels are an independent predictors for overall 
survival and bone metastasis formation (193). Enhanced level of GDF-15 in prostate 
tumor cells has been associated with their acquisition of epithelial-mesenchymal 
transition phenotype and docetaxel resistance, even in prostate cancer stem/progenitor 
cells (194). Finally, Tubuline alpha 1 (TUBA1A) has not been studied before in PCa, 
although its upregulation was described in breast cell lines resistant to paclitaxel and in 
breast cancer patients progressing to taxanes-based therapy  (195). 
Ideally the study of a panel of genes in the CTC population from mCRPC patients 
allowed: 1) detect tumor cells by an alternative method to CellSearch; 2) obtain 
information on the prognosis of patients and 3) better understand the molecular 
mechanism of the disease, with possible involvement in the selection of therapies. So, in 
addition to provide more information about the biology of the specific subpopulation of 
CTC in mCRPC, our gene-expression profiling also permitted the identification of 
valuable prognostic biomarkers. Thus, high levels of AR, CYP19 and GDF15 were 
associated with poor PFS rates while AR, GDF15 and BIRC5 were also found as 
consistent predictors of OS in the univariate analysis. This molecular CTCs-signature 
could be useful both in the initial diagnosis and as a potential tool to monitor therapy or 
predict the clinical response. Further analysis in a large study including therapy 
monitoring should be done to determine the clinical value of these markers. 
In this sense different groups have explored the PCR mRNA expression in peripheral 
blood mononuclear cell fraction and its relationship with systemic disease and tumor 
load. Danila et al. have developed a validation of a prostate cancer-enhanced mRNA 
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detection assay in whole blood as a prognostic biomarker panel for survival  (196). 
They identified a 5-gene panel consisting of KLK3, KLK2, HOXB13, GRHL2 and 
FOXA1, and measured these markers in blood samples from 97 CRPC patients with 
progressive disease. Expression of at least 2 f the 5 genes was a strong predictor for 
survival, comparable with the CellSearch system. 
Dijkstras et al. analyzed KLK3, PCA3 and TMPRSS2-ERG mRNA in 20 CPRPC 
patients (197). KLK3 was detected in 89% of cases, a rate higher than described in other 
series, and which it is similar to our findings (93%) (198). Although it was a small 
exploratory study, the authors described that in most patients with positive biomarker 
expression at baseline a decrease in biomarker expression was detected after three 
cycles of docetaxel. Marín-Aguilera et al. analyzed  the molecular profiling of 
peripheral blood from 43 mCRPC patients. They selected 282 genes through a global 
gene expression and built a two-gene model (SELENBP1 and MMP9). The 
combination of the two-gene signature and CTC count showed a strong prognostic 
significance.  
One of the potential limitations of our strategy is that we focus exclusively on the 
fraction of circulating tumor cells, and we do not analyze the relationship between 
immune response and survival of our patients. Some groups have explored this 
relationship. Olmos et al. used whole-blood gene profiling to identify gene-expression 
signatures that stratify CRPC patients with castration-resistant prostate cancer into 
distinct prognostic groups  (199). During the process they managed to build a model 
with only 9 genes which provided prognostic information. The genes with altered 
expression in patients with worse prognosis were associated to early erythroid cells and 
B-cell and T-cell function. On the other hand Ross et al. described a six-gene signature 
(ABL2, SEMA4D, ITGAL, C1QA, TIMP1 and CDKN1A) that separated patients with 
CPRC into two risk groups: a low-risk group with a median survival more than 34.9 
months and a high-risk group with a median survival of 7.8 months (200). The authors 
concluded that the six-gene model suggests a possible deregulation of the immune 
system. 
In summary our study provide novel insights about the molecular profile of CTCs from 
mCRPC patients candidates to be treated with taxanes. We identified as specific CTC 
biomarkers genes highly related with the development of resistance to taxanes and 
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hormone regulation together with known PCa markers as AR and KLK3. Importantly, 
these markers showed value to predict the evolution of mCRPC patients and constitute a 
promising tool for therapy selection and monitoring. Unlike other groups studying 
panels of genes in peripheral blood without isolation of CTCs in our analysis we use 
beads coated with EpCAM antibodies to isolate CTCs and then extract the total RNA. 
Global genome expression characterization of CTCs from mCRPC. 
The interest of CTC population as the principal responsible for PCa dissemination and a 
valuable source to characterize tumor at real time, has increased exponentially in last 
years. In fact, changes on CTCs phenotype could reflect tumor evolution under the 
pressure of systemic therapies, providing a unique opportunity to go insight into the 
mechanisms regulating prostate cancer biology (177,201). 
In our study, after evaluating the CTC counts by CellSearch platform and analyze the 
genes described by RT-PCR, we performed a global gene expression approach to 
characterize the CTC population from mCRPC patients in order to identify main actors 
behind PCa aggressiveness. For that we combined CTC immunoisolation based on 
EpCAM expression, accurate RNA extraction from very low number of cells, whole-
genome amplification and a massive gene-expression profiling for the characterization 
and interpretation of the biology of CTC in mCRPC patients, as we previously 
described for colorectal cancer (168). Importantly, we analyzed the CTCs population in 
nine patients starting docetaxel treatment at baseline and when they progressed with the 
goal of monitoring possible changes in the CTCs population after therapy pressure and 
selection. 
The profiling approach allowed us the identification of 50 genes by subtracting the 
background of non-specific isolation of blood cells obtained in a group of healthy 
controls following the same procedure than patients. Validating our analytical strategy 
we found KLK3 and EpCAM as components of this list. Both genes are well accepted 
as specific markers of prostate cancer CTCs but also as molecules implicated in tumor 
behavior (146,197,202,203). Furthermore, the expression of many of the other CTC-
genes has been described above in the prostatic tissue. Most of them are involved in key 
steps of the prostate carcinogenesis such as PAGE2B (prostate-2B gene associated 
Protein), MAO (monoamine oxidase) and HOXB13 (homeobox B13) (204-206). 
Pomerantz et al. has shown that the androgen receptor cistrome undergoes extensive  
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reprogramming during prostate epithelial transformation in man (207). The marked 
redistribution of AR binding sites during tumorigenesis represents one of the mos 
recuerrent epigenetic or genetic alterations yet discovered in prostate cancer. The 
authors observed that FOXA1, a general pioneer factor, and HOXB13 colocalize at 
most tumor AR binding sites and they are sufficient to reprogram the AR cistrome. 
Danila, in the study cited previously, included these two genes within the panel related 
to prognosis (196). 
In our gene list we also found EFNA1, encoding a member of the Ephrin family of 
membrane receptors involved in cell migration, attachment and spreading that has been 
described as a potential marker of progression in prostate cancer and BIRC5, also 
known as Survivin, which has been strongly associated with PCa development, 
progression, and drug resistance  (208-210)  . 
The genes characterizing CTCs from our cohort of patients are paticipating in 
mechanisms such as cell proliferation and death, cell cycle and cellular differentiation, 
and cell migration and adhesion. These fuctions are consistent with a subpopulation of 
tumor cells that must acquire an aggressive and invasive phenotype allowing 
dissociation from the primary tumour, invasion of neighbour tissues and their 
intravasation and survival in the blood flow. For example, the activity of BIRC5 in 
CTCs could be important to prevent the mechanisms of cellular death induced by a high 
hostile environment such blood, since this molecule have a key role to inhibit apoptosis. 
In fact, it is known that regulation of apoptosis has a central role in the development of 
prostate cancer and its progression to an androgen-independent state, which is due, in 
part, to up-regulation of antiapoptotic genes such as Survivin (211,212). 
The challenges associated with CTC detection and analyses begin with the natural 
scarcity of CTCs therefore platforms for CTC detection with high sensitivity, 
specificity, and reliability are in need. One area of intense development is the single-cell 
analysis of CTC. Chen et al. have developed a method for the analysis of single CTC  
(213). They described  that many EpCAM-positive CTCs show loss of epithelial 
characteristics. These cells may not express PSA an other markers related with primary 
prostate tumors. Interestingly these cells become highly deformable by increasing 
elasticities of their membrane. In other work by Miyamoto et al established single-cell 
RNA-sequencing profiles of 77 intact CTCs isolated from 13 patients by using 
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microfluidic enrichment  (214). Single CTCs from each individual display considerable 
heterogeneity, including expression of AR gene mutations and splicing variants. CTCs 
from patients progressing under an AR inhibitor, compared with untreated cases, 
indicates activation of noncanonical Wnt signaling. 
In our study we performed an Ingenuity Pathway analyses of the list of genes 
specifically expressed in CTC immunoisolated from mCRPC patients. Genes expressed 
in at least five patients and not expressed in any of the controls were considered for IPA 
analysis. Interestingly, our CTC profiling before docetaxel treatment pointed out ERK, 
PI3K/Akt, NOTCH and insulin as relevant cell signaling pathways for CTC biology, all 
of them classical tumor driver pathways in cancer. We also found ESR2 and beta-
estradiol pathways as relevant for CTC biology in our cohort of mCRPC patients. In this 
sense, estrogens dependent  regulation of prostate cancer was described as an important 
mechanism promoting tumor progression when cancer cells become androgen 
independent (215). This effect may be related to: 1) estrogens interference with PI3K-
Akt signaling pathway, ultimately resulting in apoptosis inhibition and an increase in 
cell cycle progression, and 2) up-regulation of insulin-like growth factor receptor by 
17B-estradiol, with increased mitogenic and motogenic activities in response to IGF 
(216). Therefore, our CTC-profiling could provide a realistic picture of the main 
determinants in an androgen independent status.   
On the other hand, comparing the CTC gene expression profile before docetaxel and 
when the patients progressed we found a small number of differentially expressed 
genes. In this list CSAG2 and CYP3A4 stand out as regulators of chemotherapy activity 
(217). CYP3A4 encodes a member of the cytochrome P450 superfamily of enzymes 
that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, 
steroids and other lipids. It is nowadays established that cytochrome P450-3A  is a 
major determinant of the variability in docetaxel response being its inhibition a broad 
accepted strategy to improve docetaxel efectiveness in prostate cancer and other tumors  
(218,219). The higher presence of CYP3A4 transcripts in CTC population of mCRPC 
patients could reflect the expansion of a more resistant tumour population after 
docetaxel pressure. 
Finally, it is important to note that CTCs study has also been used to guide treatment 
selection in clinical trials. In breast cancer, HER2 protein expression on CTCs has been 
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assessed using the CellSearch technology, and other investigators are using CellSearch 
to monitor endocrine resistance in ER-positive HER2-negative metastatic disease 
(COMETI phase II trial, NCT01701050).  
In prostate cancer  various studies explore clinical applications of CTCs. CTCs baseline 
number will enable better risk stratification of patients at the time of inclusion in clinical 
trials. In addition one of the secondary objectives in the ongoing trial NCT02379390 is 
to analyze tumoral mRNA including AR-V7 as a biomarker in CTCs, an information 
with direct involvement in treatment selection. Another study (NCT02485691) 
evaluates the correlation of a signature of resistance to AR-targeted agents with clinical 
outcome via the analysis of CTC phenotypes as well as expression and localization of 
proteins including AR isoforms in CTCs. A similar strategy will implement the CTC 
analysis to select which patients will benefit from treatment (and will continue to) and 
which patients are in progress and should switch to a new agent. 
Overall, our global expression analysis described a specific molecular profiling of CTC 
isolated from mCRPC within docetaxel treatment. This approach allowed us to get a 
better picture of the principal actors for prostate cancer progression after androgen 
deprivation. We found a general stress-survival phenotype in the CTC population of 
mCRPC patients partially based on cell proliferation, apoptosis, adhesion and migration. 
Importantly we identify relevant therapeutic drivers when patients progressed that could 
represent potential monitoring markers and therapeutic targets after docetaxel treatment.  
Our results could be usefullness to improve the clinical management of of mCRPC 
patients but a deeper validation should be attempted in a bigger independent cohort. 
First, to determine the robustness of DNA microarrays we should perform a RT-qPCR 
of the selected group of 15 genes. The next step will be to develop a clinical trial in 
patients with mCRPC with serial blood samples to confirm the value of our panel of 
genes in the detection, prognosis and response evaluation. But that is another story. 
 
Chapter 7. Conclusions 

Chapter 7. Conclusions 
137 
1. In our cohort of 29 mCRPC patients starting chemotherapy CTCs levels 
analyzed using CellSerach showed prognostic value. The number of CTCs was 
higher in patients diagnosed with locally advanced disease, nodal invasion, and 
also in patients that were responsive to hormonal therapy for less than 24 
months. 
2. CTCs count showed value as a therapy monitoring marker. Thus, patients with 
CTCs ≥ 5 before the 3rdcycle and 6thcycle of chemotherapy had a very high risk 
of being in biochemical or radiological progression. On the contrary, man who 
moved from a baseline count ≥ 5 CTC, to CTCs levels <5 after chemotherapy 
achieved similar results to the baseline low risk group. 
3. Combination of CTC-immunoenrichment and the analysis of CTC-transcriptome 
by RT-qPCR provide an alternative and high sensitivity method for CTCs 
detection and characterization in mCRPC patients.   
4. KLK3 together with those genes related with androgen signaling pathway (such 
as AR and CYP19) and those implicated in relevant functions for PCa 
progression and resistance (such as BIRC5, TUB1A, GDF15, RAB7 and 
SPINK1) are specific CTCs markers. 
5. High levels of AR, CYP19 and GDF15 were associated with poor PFS rates 
while AR, GDF15 and BIRC5 were also found as consistent predictors of OS.  
6. Besides the prognosis value of the CTCs-signature identify by RT-qPCR this 
markers could be useful both in the initial diagnosis and as a potential tool to 
monitor therapy or predict the clinical response. 
7. The validity of our method combining CTCs immunoisolation based on EpCAM 
expression, accurate RNA extraction from very low number of cells, whole-
genome amplification and a massive gene-expression profiling for the 
characterization and interpretation of the biology of CTCs in mCRPC patients 
has been shown. 
8. A specific set of 50 genes was found to characterize the population of CTCs 
from our cohort of patients. These genes are paticipating in relevant mechanisms 
for cancer progression such as cell proliferation and death, cell cycle and cellular 
differentiation, and cell migration and adhesion. 
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9. After a bioinformatic analysis the CTCs profiling before docetaxel treatment 
pointed out ERK, PI3K/Akt, NOTCH and insulin as relevant cell signaling 
pathways for CTC biology, all of them classical tumor driver pathways in 
cancer. We also found ESR2 and beta-estradiol pathways as relevant for CTC 
biology in our cohort of mCRPC patients. 
10. The comparison of the CTCs phenotype between baseline and when patientes 
progressed provided us a list of genes, such as CYP3A4, that could be related 
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EL CÁNCER DE PRÓSTATA. 
El cáncer de próstata es el segundo tumor con mayor mortalidad en hombres de paises 
industrializados. A pesar de que generalmente presenta un pronóstico favorable existe 
un grupo de pacientes que desarrollan metástasis a distancia, habitualmente a nivel óseo, 
y que finalmente fallecen como consecuencia de esta enfermedad (1).  
El diagnóstico de cáncer de próstata se basa en tres elementos: prostate specific antigen 
(PSA) elevado, tacto rectal sospechoso y biopsia de próstata. La determinación de PSA 
en sangre ha jugado un papel fundamental en el aumento de detección de cáncer de 
próstata en estadios iniciales visto en las últimas décadas. El riesgo de cáncer de 
próstata aumenta con valores elevados de PSA, pero no existe un umbral de PSA por 
debajo del cual se pueda descartar definitivamente que no existe riesgo de padecer un 
tumor  maligno prostático. 
El sistema de estadificación se basa en el AJCC TNM, pero también tiene en cuenta el 
PSA sérico y Gleason. La enfermedad localizada se debe clasificar en grupos 
pronósticos para la toma de decisiones  (12). Siguiendo un modelo predictivo se puede 
determinar la probabilidad de control bioquímico a los 5 años después del tratamiento 
local (90%, 60% y 30%, respectivamente): 
- Bajo riesgo: PSA <10 ng/dL, Gleason ≤ 6 y T1c o T2a. 
- Riesgo intermedio: PSA 10-20 ng/dL, Gleason 7 y T2b. 
- Alto riesgo: PSA> 20 ng/dL, Gleason ≥ 8 y T2c. 
Los pacientes con grado de Gleason elevado tienen mayor probabilidad de invasión 
linfovascular, márgenes quirúrgicos positivos, mayor riesgo de extensión extraprostática 
y de aparición de metástasis. A pesar de su utilidad y de las mejoras introducidas en las 
revisiones de 2005 y 2014, el sistema de clasificación de Gleason todavía tiene 
importantes limitaciones. Epstein et al. han propuesto una adaptación con posibles 
beneficios: una estratificación más precisa que los sistemas actuales y una 
simplificación a cinco grados, con el potencial de reducir el sobretratamiento (10). 
La mayoría de los pacientes son diagnosticados con tumores confinados a la próstata. 
Las opciones de tratamiento varían según la edad, el grado de Gleason, comorbilidad, 
expectativa de vida y otras características clínicas. En el cáncer de próstata de bajo 
riesgo, el paciente debe decidir entre cirugía o radioterapia frente a la vigilancia activa. 
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La vigilancia activa es apropiada para muchos pacientes, especialmente hombres con 
tumores menos agresivos y edad avanzada. 
En el cáncer de próstata de riesgo intermedio se puede plantear prostatectomía radical 
con linfadenectomía extendida o radioterapia externa asociada a tratamiento hormonal 
adyuvante. La braquiterapia es también una alternativa en pacientes seleccionados.  
En aquellos pacientes con enfermedad de alto riesgo muchas veces es necesario plantear 
un tratamiento multimodal, idealmente decidido dentro de un comité multidisciplinar. 
Las alternativas son la prostatectomía radical con linfadenectomía ampliada (y 
radioterapia adyuvante si se precisa tras el análisis de la pieza quirúrgica) o la 
administración de radioterapia externa acompañada de 2-3 años de tratamiento 
hormonal.  
A pesar de los excelentes resultados obtenidos con cirugía o radioterapia, 
desafortunadamente un 30% de estos pacientes desarrollarán enfermedad metastásica. 
Historicamente la deprivación androgénica ha sido la estrategia terapéutica con una 
respuesta más efectiva, con mejoría y control de la enfermedad en el 80% de los casos, 
aunque practicamente todos los pacientes acabarán desarrollando resistencia a la 
deprivación hormonal (220). En pacientes asintomáticos se puede considerar la opción 
de una segunda maniobra hormonal aunque no está demostrado su beneficio en téminos 
de supervivencia. En pacientes con bloqueo hormonal completo y que presentan signos 
evidentes de progresión la retirada de antiandrógeno consigue respuesta en el 20 o 30% 
de los pacientes. 
En 2004, la combinación de docetaxel y prednisona demostró una mejoría en la 
supervivencia global en hombres con cáncer de próstata metastásico resistente a la 
castración (mCPRC) (50,51). Recientemente se han comunicado los datos de dos 
ensayos clínicos aleatorizados que anticipan el uso de docetaxel a los pacientes con 
enfermedad hormono sensible  (62,63) .  
Desde los ensayos iniciales de Tannock  y Petrylak abiraterona (AA), enzalutamida 
(ENZ), cabazitaxel, Radium-223 y sipuleucel-T han demostrado prolongar la 
supervivencia global en pacientes con mCPRC post docetaxel (69,73,80,81,86). 
Además, AA y ENZ también han logrado beneficio en supervivencia global en 
pacientes mínimamente sintomáticos quimio-naive, algo que sólo sipuleucel-T-había 
demostrado previamente (70,75,81). Sin embargo, el 10-20% de los pacientes son 
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refractarios primarios a AA o ENZ, de ahí que una caracterización adecuada de los 
pacientes evitaría retrasos indeseables de los tratamientos potencialmente más eficaces. 
Tradicionalmente, la evaluación de la respuesta a los agentes terapéuticos en el cáncer 
de próstata ha sido particularmente complicada debido a la ausencia de lesiones 
fácilmente medibles, a la prevalencia de la diseminación ósea y la historia natural 
relativamente prolongada en un número significativo de pacientes.  
Hasta la fecha, los niveles de PSA han sido el biomarcador más utilizado para evaluar la 
progresión tumoral en pacientes con cáncer de próstata. Sin embargo, en muchos casos 
los niveles en sangre de este marcador no reflejan fielmente el estado de progresión de 
la enfermedad o el riesgo de aparición de nuevas metástasis. En ocasiones no se 
consigue un manejo adecuado de la enfermedad debido a la falta de recursos precisos 
para su detección temprana o para evaluar la respuesta tumoral. Evitar la continuación 
de un tratamiento inefectivo posibilita reducir la toxicidad del mismo y que el paciente 
se pueda beneficiar de una nueva estrategia terapéutica. 
CÉLULAS TUMORALES CIRCULANTES EN CÁNCER DE PRÓSTATA.  
La diseminación temprana de células tumorales en pacientes con cáncer es 
generalmente indetectable mediante análisis histopatológico convencional o mediante 
técnicas de imagen de alta resolución. Esta circunstancia ha motivado el desarrollo de 
ensayos inmunocitoquímicos y moleculares que permiten la detección específica de 
células tumorales metastáticas en ganglios linfáticos regionales, sangre periférica o 
médula ósea, antes de que la metástasis tenga el tamaño suficiente para ser detectable 
macroscópicamente. La detección precoz de células tumorales diseminadas en linfa y 
médula ósea (DTC) o sangre periférica (CTC) presenta un gran valor para la 
identificación de pacientes que precisen tratamiento sistémico tras el abordaje local del 
tumor primario (221). 
Asworth en 1869 describió la importancia del estudio de las células tumorales 
circulantes, pero hasta hace pocos años no existía la tecnología adecuada para su 
identificación y aislamiento. Actualmente la detección de CTCs se puede realizar de 
modo directo o indirecto. La detección directa incluye  métodos citométricos, en los que 
se detectan células completas, y en la detección indirecta se utilizan métodos basados en 
la expresión de genes específicos de este tipo de células. Para intentar mejorar la 
sensibilidad de estas técnicas de detección, se han desarrollado métodos de 
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enriquecimiento celular mediante filtración, gradientes de densidad o aislamiento 
inmunomagnético.  
Actualmente el único sistema de detección y análisis de CTC aceptado para uso clínico 
por la Food and Drug Administration (FDA) y en distintos países europeos es el 
CellSearchTM (Veridex). Este sistema realiza un inmunoaislamiento de células 
epiteliales con partículas magnéticas unidas a anticuerpos anti-EpCAM (antígeno 
superficie de célula epitelial altamente expresado en carcinomas). Posteriormente estas 
células son identificadas por expresión positiva de las citoqueratinas 8 y 18 (marcadores 
de célula epitelial), expresión negativa de CD45 (marcador de leucocitos) y marcaje 
positivo para DAPI para demostrar la integridad nuclear y, por tanto, celular. Este 
sistema proporciona un método altamente reproducible y sensible para la identificación 
de CTCs  (125,222,223) .  
En varios estudios se ha relacionado el descenso de niveles de CTC con una mejor 
supervivencia global, de modo similar al beneficio relacionado con una disminución 
marcada de PSA o una respuesta radiológica (107,109,110,154). Además los cambios 
en los niveles de CTC habitualmente preceden las fluctuaciones de PSA y su 
monitorización es incluso de mayor valor cuando los cambios en el PSA o la 
enfermedad ósea son difíciles de evaluar (108). Con todo y a pesar del prometedor valor 
clínico de las CTCs en pacientes con cáncer de próstata, todavía existe una importante 
necesidad de mejorar los métodos de análisis, que permitan  una caracterización 
molecular adecuada de dichas células y mejoren la sensibilidad y coste-efectividad del 
CellSearch. Además del valor de la cuantificación de CTCs, el estudio de perfiles 
moleculares en pacientes con mCPRC puede permitir identificar marcadores con valor 
clínico en el manejo de estos pacientes.  
En nuestro planteamiento, combinamos el aislamiento de CTC basado en EpCAM y el 
análisis posterior con RT-qPCR de un panel de genes implicados en la vía de 
señalización mediada por andrógenos, en el fenotipo tumoral stem like, resistencia a  
drogas y en un  comportamiento tumoral más agresivo. Con este enfoque, previamente 
validado en cáncer colorrectal y endometrial por nuestro grupo (168,181), pretendemos 
identificar un panel de biomarcadores que nos permita identificar las CTC de pacientes 
con mCPRC, que aporte información pronóstica en supervivencia libre de progresión y 
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supervivencia global, y que nos proporcione información sobre las características 
moleculares de dichas células. 
HIPÓTESIS DEL ESTUDIO. 
Hasta la fecha, los niveles de PSA han sido el biomarcador más utilizado para evaluar la 
progresión en pacientes con cáncer de próstata. Sin embargo, en muchos casos, los 
niveles en sangre de PSA no reflejan con precisión el estado de la enfermedad o el 
riesgo de desarrollo de metástasis. Además, la evaluación radiológica es difícil. Por lo 
tanto, el tratamiento eficaz de la enfermedad metastásica requiere herramientas clínicas 
para seleccionar y monitorizar el tratamiento. 
Teniendo en cuenta este escenario, hay dos prioridades para mejorar el manejo clínico 
de los hombres con CPRC metastásico: la caracterización de biomarcadores 
pronósticos, de seguimiento y respuesta a la terapia para guiar la intervención clínica y 
la identificación de nuevas dianas terapéuticas mejorando las opciones terapéuticas de 
estos pacientes. 
Debido a la continua evolución de los tumores, que implica la alteración genética y 
epigenética celular y la heterogeneidad del tumor, se acepta que los tumores primarios y 
las metástasis individuales proporcionan una información limitada sobre el estado 
molecular del cáncer. En este sentido, las CTCs proporcionan en tiempo real y 
secuencialmente una '' biopsia líquida '' para pacientes con cáncer metastásico. Estas 
células pueden proporcionar información fundamental para profundizar en la 
comprensión de la biología del tumor y en los mecanismos de diseminación tumoral. 
Nuestra hipótesis es que, además del valor clínico del recuento de CTC para predecir la 
evolución del paciente con mCPRC, la caracterización molecular de su población de 
CTC ofrece una fuente única para obtener información importante sobre: 
1) El  pronóstico de los pacientes. 
2) La monitorización de los pacientes para poder determinar una respuesta precoz, 
anticipando y  mejorando la evaluación bioquímica y radiológica. 
3) La selección del tratamiento, identificando mecanismos de resistencia a las terapias 
actuales. 
4) Desarrollo del tratamiento, proporcionando información sobre los principales factores 
implicados en la progresión y agresividad del cáncer de próstata resistente a la 
castración. 
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OBJETIVOS DEL ESTUDIO.  
Pretendemos explorar las posibilidades de uso de las CTCs en el manejo de pacientes 
con cáncer de próstata metastásico resistente a la castración. Hemos establecido tres 
objetivos principales: 
1. La evaluación y cuantificación de CTCs en una cohorte de pacientes con CRPC 
metastático y tratados con docetaxel o cabazitaxel. Evaluar el papel del recuento de 
CTCs como un marcador independiente de supervivencia libre de progresión y la 
supervivencia global en este grupo de pacientes. Además, el muestreo secuencial a lo 
largo del tratamiento nos permitirá evaluar la utilidad de la CTCs como un marcador 
precoz de la respuesta o resistencia a la quimioterapia. 
2. El desarrollo de una metodología más sensible y versátil que constituya una 
alternativa al sistema de referencia para el análisis de CTCs. Esta metodología se basa 
en el análisis de un conjunto de marcadores expresados en la población de CTCs de los 
pacientes en la cohorte del estudio, con el fin de encontrar nuevos marcadores para el 
diagnóstico y pronóstico que guien la terapia en estos pacientes. 
3. La caracterización molecular de las CTCs presentes en pacientes con mCPRC usando 
un enfoque global de la expresión génica con el fin de identificar nuevos marcadores de 
CTCs específicos y genes potencialemente relacionados con la resistencia a la 
quimioterapia. 
AISLAMIENTO DE CÉLULAS TUMORALES CIRCULANTES.  
En primer lugar realizamos la evaluación y cuantificación de CTCs en una cohorte de 
29 pacientes con cáncer de próstata resistente a la castración metastásico, tratados con 
quimioterapia. La detección de CTC en sangre periférica se correlacionó con datos 
clínicos y patológicos, y se calculó el porcentaje de respuestas por PSA, imagen, 
supervivencia libre de progresión y supervivencia global. Se extrajeron 7,5 ml de sangre 
por paciente en cada muestra, y el recuento de CTC se realizó con el sistema Cellsearch, 
antes del 1er, 3er y 6o ciclo de tratamiento (docetaxel o cabazitaxel).  
La supervivencia libre de progresión (SLP) fue 7,4 meses (IC 95%, 5,9–8,7) (Figura 
5.1, apartado “results” ) y la supervivencia global (SG) 27,3 meses (IC 95%, 16–38.7) 
(Figura 5.2, apartado “results”). Se demostró respuesta por PSA en el 55,2% de los 
pacientes; en el subrupo de hombres con enfermedad medible no se observó ninguna 
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respuesta radiológica, y en un 48% de los participantes sí se consiguió estabilización del 
tumor. 
El numero de CTCs fue mayor en los pacientes diagnosticados con enfermedad 
localmente avanzada (28 vs 263; p = 0,054), con invasión ganglionar (33 vs 443; p = 
0,03), y que respondieron a tratamiento hormonal durante menos de 24 meses (18 vs 
311; p = 0,04). La superviencia global media fue 16 meses (IC 95 % 9,4-24,7)  para los 
pacientes con ≥ 5 CTCs en la extracción basal versus no alcanzada para  aquellos con 
<5 CTCs . 
En el análisis mediante curvas ROC, el recuento basal de CTC fue el factor de riesgo 
con mayor AUC para predecir la posibilidad de tener una supervivencia global por 
encima de la media (AUC = 0,784). Los pacientes con ≥ 5CTC al inicio del estudio 
tenían un mayor riesgo de progresión a las 12 semanas (36%, frente al 10% para los 
hombres con < 5CTCs) y una SLP y SG menor que aquellos con < 5CTC. Sin embargo 
los pacientes con conversión de ≥ 5CTC a < 5CTC después de 3 ciclos de docetaxel 
tuvieron una superviencia libre de progresión y supervivencia global similares a 
aquellos pacientes con niveles basales bajos de CTC. Nuestros hallazgos concuerdan 
con los datos publicados por otros autores,  describiendo que los pacientes que tienen 
más de  5 CTC/7,5 mL de sangre tienen un peor pronóstico.  De hecho este umbral se 
utiliza de modo generalizado para establecer el pronóstico de los pacientes con cáncer 
de próstata metastásico (grupo favorable y otro desfavorable) tratados tanto con 
quimioterapia como con otros agentes (107,108,152-154).  
Resulta especialmente importante el hecho de que los pacientes con ≥ 5CTC en el 
momento basal y que pasan a  < 5CTC durante el tratamiento tienen una supervivencia 
global similar a los pacientes de buen pronóstico inicial. La respuesta por CTC puede 
servir entonces no solo como factor pronóstico antes del inicio de tratamiento, si no 
también para comprobar la eficacia del mismo. En el ensayo SWOG S0421 se estudió la 
respuesta por CTCs 21 días tras el inicio de docetaxel (con o sin atrasentan). Mientras 
que el descenso de CTCs se asociaba a una tendencia en mejor supervivencia, pero sin 
alcanzar la significación estadística, cualquier aumento en los niveles de CTC sí se 
relacionó con peor pronóstico (154). Puede que los cambios precoces en CTC no 
discriminen una respuesta prolongada, mientras que su aumento indique pacientes 
refractarios primarios al tratamiento y con muy mal  pronóstico.   
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En nuestro estudio hemos podido comprobar que la extracción y análisis de muestras de 
sangre para recuento de CTCs en nuestro medio es factible, consiguiendo resultados 
similares a otros grupos. Hemos observado una relación entre el número de CTCs en la 
determinación basal y la supervivencia global y también hemos comprobado el valor 
pronóstico de la conversión de ≥ 5CTC a < 5CTC tras la adminsitración de 
quimioterapia.  
CARACTERIZACIÓN DE CTC EN mCRPC.  
Paralelamente en la primera extracción se recogió un tubo adicional de sangre para 
llevar a cabo la caracterización molecular de las CTCs presentes en estos pacientes. Las 
muestras recogidas para la caracterización molecular se procesaron mediante el sistema 
CELLection Epithelial Enrich, que se basa en el empleo de partículas magnéticas 
acopladas a anticuerpos anti-EpCAM para la purificación de CTCs. Estas muestras 
enriquecidas en CTC se utilizaron para extraer mRNA mediante un proceso optimizado 
para muestras con escasa carga celular junto con un proceso de preamplificación previo.  
La presencia de células inespecíficas en la muestra hizo necesario un proceso de 
selección para asegurar que realmente estábamos analizando el componente celular 
epitelial. Con esta finalidad primero evaluamos los niveles de expresión de GADPH 
como un marcador de celularidad, que incluye tanto las CTCs como células de la serie 
blanca, normalizado por la expresión de CD45 como un marcador específico de células 
de origen hematopoyético  (168).  
Tras el inmunoaislamiento analizamos la fracción enriquecida de la muestra mediante      
q-RT-PCR para el estudio de genes relevantes relacionados con regulación androgénica  
(AR, CYP19 and CYP17), fenotipo stem cell (CD133, CD44, ALDH1A, ABCG2, CD49f) 
y agresividad de cáncer de próstata y/o resistencia a taxanos (BIRC5, CLU, GDF15, 
RAB7A, SPINK1, TUB1A, MDR1). Se compararon los resultados de los 29 pacientes 
con un grupo control de 15 hombres sin diagnóstico de cáncer. Los niveles de GAPDH 
fueron mayores en el grupo de pacientes, confirmando la existencia de una población 
celular “extra” aislada en la sangre de estos pacientes. Además no se detectó expresión 
de KLK3 en los controles y sí en el 93,1 % de los pacientes, reforzando nuestra 
estrategia de selección y análisis de CTCs.  
De los genes estudiados observamos una expresión significativa de AR, CYP19, BIRC5, 
TUB1A, GDF15, RAB7 and SPINK, un panel que caracteriza la población de CTCs de 
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nuestros pacientes. Además de su significado diagnóstico exploramos posteriormente su 
valor pronóstico mediante análisis de Kaplan Meier para SLP y SG. Así, niveles 
elevados de KLK3, AR, CYP19 y GDF15 se asociaron de un modo estadísticamente 
significativo a peor SLP. Respecto a la supervivencia global los pacientes con niveles 
elevados de KLK3, AR, GDF15 y BIRC5 presentaron una supervivencia más corta que 
aquellos con niveles bajos. Por ejemplo, los pacientes de mal pronóstico según los 
niveles de AR-CTC presentaron una superviencia de 16.6 meses mientras que los del 
grupo de buen pronóstico alcanzaron una media de 31 meses.  
El análisis univariante de Cox confirmó el valor pronóstico de KLK3, AR, CYP19 y 
GDF15 para predecir PFS, mientras que solo AR, GDF15 y BIRC5 mostraron valor 
como predictores para supervivencia global. Posteriormente introdujimos estos 
marcadores en el análisis multivariante para SG, en el que también incluímos niveles 
basales de CTC analizados mediante CellSearch, PSA y LDH. Únicamente los niveles 
de CTC alcanzaron la significación estadística.  
En una tercera etapa se completó el estudio de expresión génica mediante microarrays, 
siguiendo el protocolo desarrollado en nuestro grupo de investigación (168).  La 
caracterización molecular de las CTC presentes en pacientes con mCPRC se realizó en 
9 pacientes y 6 sujetos sanos. Todas las muestra para el análisis de expresión se 
sometieron a un proceso de amplificación y los datos obtenidos tras este análisis 
comparativo entre los grupos establecidos se evaluaron a través de herramientas 
bioinformáticas (análisis de rutas funcionales y redes de genes a través de Ingenuity 
Pathway Analysis, IPA).  
Tras descartar los genes expresados en las controles sanos, la lista de los genes 
específicos de las CTCs estaba compuesta por los genes presentes en al menos 5 
pacientes al inicio del estudio y a la progresión. Esta estrategia condujo a la 
identificación de un conjunto final de 50 genes específicos de la población CTCs en 
nuestros pacientes. En este listado se encontraban KLK3 y BIRC5, ambos descritos 
previamente como marcadores CTCs en nuestra cohorte de 29 pacientes mCPRC cuyas 
CTCs se analizaron por RT-qPCR (ver sección 5.3). Estos resultados validan nuestra 
estrategia analítica para caracterizar la población de CTCs en mCRPC. 
Por otro lado, identificamos aquellos genes con niveles aumentados en el momento de la 
progresión y que podrían participar tanto en el crecimiento tumoral como en el 
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desarrollo de resistencia al tratamiento (docetaxel o cabazitaxel). Identificamos 16 
genes, entre los que destacan CYP3A4 y CSAG2, fuertemente asociados con la 
resistencia a la quimioterapia. 
En un último paso analizamos mediante Ingenuity Pathway Analysis (IPA) las vías 
moleculares, las redes de genes y las funciones biológicas asociadas con la lista de 
genes expresados específicamente en CTC de nuestros pacientes con mCRPC. 
Interesantemente nuestro perfil de CTC antes del tratamiento con docetaxel señaló a 
ERK, PI3K / Akt, Notch y a la insulina como vías de señalización celular relevante para 
la biología de las CTCs, todas ellas vías clásicas relacionadas con cáncer. También 
ESR2 y la vía de beta-estradiol resultaron elementos relevantes en la biología de las 
CTCs de esta cohorte de pacientes. 
En resumen, el análisis de expresión global describió un perfil molecular específico de 
CTCs aisladas en mCPRC en tratamiento con quimioterapia. Este enfoque nos ha 
permitido profundizar en los principales actores de la progresión del cáncer de próstata 
tras deprivación androgénica. Encontramos un fenotipo de una población de CTCs 
basado parcialmente en la proliferación celular, apoptosis, adhesión y migración. Estas 
vías relevantes en la progresión tumoral podrían representar marcadores de 
monitorización y potenciales dianas terapéuticas tras tratamiento con taxanos. Nuestros 
resultados podrían ser de utilidad para mejorar el manejo clínico de estos pacientes, 
aunque deben validarse un cohorte independiente de pacientes mCPRC con mayor 
tamaño muestral. 
CONCLUSIONES. 
1. En esta cohorte de 29 pacientes con mCRPC el recuento de CTC mostró valor 
pronóstico siendo la mediana de supervivencia de 16 meses para los pacientes 
con ≥ 5 CTC al inicio del estudio y no alcanzada en los pacinetes con < 5 CTC. 
2. Encontramos un mayor número de CTCs en pacientes diagnosticados con 
enfermedad localmente avanzada, invasión ganglionar, y también en pacientes 
que eran sensibles a la terapia hormonal durante menos de 24 meses, todos elos 
factores relacionados con características clínico-patológicas adversas. 
3. Los pacientes con CTC ≥ 5 antes del 3er y 6º ciclo de la quimioterapia tuvieron 
un alto riesgo de progresión bioquímica o radiológica. Por el contrario, los 
pacientes que pasaron de un recuento basal  ≥ 5 CTC a niveles de CTC <5 
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después de docetaxel o cabazitaxel lograron una SLP media y SG similares al 
grupo con <5 CTC en la determinación inicial. 
4. La combinación de enriquecimiento de CTCs y el análisis del transcriptoma de 
CTCs mediante RT-qPCR constituye un método alternativo y de alta 
sensibilidad para la detección y caracterización de las CTCs. 
5. Es importante destacar que cuando se comparó la expresión de KLK3, como un 
marcador específico de células prostáticas, no se encontraron casos positivos en 
el grupo de controles, mientras que el 93,1% de los pacientes fueron positivos. 
Este hecho refuerza la alta especificidad de nuestra estrategia para la detección y 
análisis de CTCs. La curva ROC mostró una alta sensibilidad y especificidad de 
KLK3 para detectar la presencia de CTCs en nuestra cohorte de pacientes 
mCRPC. 
6. El transcriptoma de las CTCs se caracteriza principalmente por la expresión de 
dos grupo de genes; los relacionados con la vía de señalización de andrógenos 
como (AR y CYP19) y los implicados en las funciones relevantes para la 
progresión y la resistencia del cáncer de próstata, como BIRC5, TUB1A, 
GDF15, RAB7 y SPINK1. 
7. Niveles altos de AR, CYP19 y GDF15 se asociaron con malos resultados de 
SLP mientras que AR, GDF15 y BIRC5 se mostraron  como predictores 
consistentes de SG en el análisis univariado. Este firma molecular de las CTCs-
podría ser útil en el diagnóstico inicial y como una herramienta potencial para 
monitorizar el tratamiento o predecir la respuesta clínica. 
8. Se ha demostrado la validez de nuestro método que combina el 
inmunoaislamiento de CTCs basado en la expresión de EpCAM, la extracción de 
RNA de muy bajo número de células, la amplificación de todo el genoma y un 
análisis global de perfil de expresión de genes para la caracterización e 
interpretación de la biología de las CTCs en pacientes mCRPC. 
9. Se ha descrito un conjunto específico de 50 genes para caracterizar la población 
de las CTCs de nuestra cohorte de pacientes. Estos genes participan en 
mecanismos tales como la proliferación y la muerte celular, el ciclo celular y la 
diferenciación celular, y la migración y adhesión celular. 
10. En el análisis IPA el perfil de CTCs antes del tratamiento con docetaxel señaló a 
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ERK, PI3K / Akt, Notch y la insulina como vías de señalización celular 
relevantes para la biología de las CTCs, todas ellas vías clásicas en cáncer. 
También ESR2 y la vías de beta-estradiol son elementos relevantes en la 
biología de las CTCs en nuestra cohorte de pacientes. 
 
List of abbreviations 
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3D-CRT: 3-dimensional conformal radiation therapy.  
AA: abiraterone acetate.  
ADT:androgen deprivation therapy. 
AE: adverse effect.  
AR: Androgen receptor. 
AR-V7: AR splice variant 7. 
BFS: biochemical-free survival.  
CAB: combined androgen blockade.  
CBC: Cancer Biomarkers Collaborative.  
CCP: cell cycle progression. 
CI: Confidence interval. 
CNV: copy number variations. 
COPD: Cronic Obstructive Pulmonary Disease. 
CRPC: castration resistan prostate cancer.  
CSS: prostate cancer-specific survival. 
CT: computed tomography. 
CTC: circulating tumor cells.  
CV: coefficient of variation. 
DAPI: 4,6-diamidino-2-phenylindole. 
DRE: Digital rectal examination. 
DTC: disseminated tumor cell. 
EBRT: external beam radiation therapy. 
ECOG: Eastern Cooperative Oncology Group. 
EGAPP: Evaluation of Genomic Applications in Practice and Prevention. 
EpCAM:epithelial cell adhesion molecule. 
ESR2: estrogen receptor 2. 
FDA: US Food and Drug Administration. 
HE: hematoxylin eosin.  
IMRT: Intensed Modulated radiotherapy.  
IPA: Ingenuity pathway analysis. 
MFS: metastasis-free survival. 
MRI: magnetic resonance imaging. 
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NCCN: National Comprehensive Cancer Network 
NED: Neuroendocrine differentiation. 
NYR: not yet reached.  
LH-RH: luteinizing hormone-releasing hormone. 
OS: overall survival. 
PCa: prostate cancer 
PCWG: Prostate-Specific Antigen Working Group. 
PFS: progression free survival.  
PLND: pelvic lymph node dissection. 
PPV: Predictive positive value. 
PSA: Prostatic specific antigen.  
RANKL: Receptor Activator of Nuclear Factor Kappa B Ligand. 
RECIST: The Response Evaluation Criteria in Solid Tumours. 
REMARK: Reporting Recommendations for tumor MARKER prognostic studies.  
ROC: Receiver Operating Characteristic. 
RP: radical prostatectomy. 
rPFS: radiographic progression-free survival. 
SBRT: Stereotactic body radiotherapy. 
SOGUG: Spanish Oncology Genitourinary Group. 
SRE: skeletal related events. 







Annex 1. Clinical Database.  
 
A. Age. 
B. Comorbidity.  
a. Hypertension. 
b. Chronic obstructive pulmonary disease. 
c. Diabetes mellitus. 
d. Heart disease. 
e. More than one of the previous. 
f. Other diseases. 
g. None of these. 
C. Initial treatment. 
a. Date of diagnosis.  
b. Initial stage. 
c. PSA.  
d. Gleason. 
e. Initial treatment. 
i. Surgery (yes/no). Date of surgery. 
ii. Radiotherapy (yes/no). Date of radiotherapy. Indication 
(adyuvant or radical). Median dose. 
D. Treatment of the metastatic disease, previous to chemotherapy.  
a. Hormonal treatment. 
i. Number and date of hormonal treatments.  
ii. Kind of maneuver:   
1. Complete blockade. 
2. Antiandrogen. 
3. LH-RH agonist. 




iii. Reason to hormonal treatment stop. 
1. Imaging progression. 
2. PSA progression. 
3. Clinical PSA. 
4. Progression by two factors. 
5. Progression by three factors. 
6. Toxicity. 
7. Others. 
b. Biphosphonates (yes/no). 
c. Radionuclide (yes/no). 
d. Paliative radiotherapy (yes/no). 
 
E. Treatment of the metastatic disease at the start of chemotherapy. 
a. Stage: TNM. 
b. LDH, Alkaline phosphatase, PSA.  
c. Chemotherapy. 
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i. Docetaxel or cabazitaxel. 
ii. Date of start and finish. 
iii. Total dose. Number of cycles. 
iv. Reduction (yes/no). Delay (yes/no). 
v. Toxicity: adverse event and grade.  
F. Evaluation of response. 
a. Clinical response.  
b. Biochemical response.  
c. Radiological response.  








h. Clinical trial. 
i. Others. 
j. None. 
H. Disease progression.  
a. Progression (yes/no). 
b. Date of progression. 








 More than one site.  
I. Survival. 
a. Exitus (yes/no). 
b. Date of death. 
c. Cause of death.  
i. Progression disease. 
ii. Toxicity. 
iii. Infection. 






Annex 2. Informed consent.  
 
HOJA DE INFORMACIÓN PARA EL PARTICIPANTE 
Análisis de tejido tumoral y sangre 
 
Código de Participante: ___________________ 
 
Título del estudio: “Estudio de las células tumorales circulantes de pacientes con cáncer de 
próstata resistente a deprivación androgénica” Código de Protocolo: CTC-PROST-01                                                 
Promotor: Dr. Rafael López López. CHU de Santiago de Compostela. 
 
Nombre del Investigador:       Tel.: ............................................... 
Dirección: ................................................................................................................................... 
 
¿En qué consiste este estudio? ¿Cuáles son sus objetivos?  
El Servicio de Oncología Médica de este Hospital está llevando a cabo un estudio para entender 
mejor los mecanismos que permiten que el cáncer de próstata progrese formando metástasis en 
otros órganos diferentes al de origen y que deje de responder a fármacos que se emplean para 
combatirlo, como el Docetaxel. Para ello se necesita aislar y estudiar las células tumorales que 
se encuentran en sangre de pacientes como usted. 
 
Para que las células del tumor se asienten en otros órganos, como por ejemplo los huesos, tienen 
que viajar por la sangre, donde pueden ser detectadas. Estas células tumorales detectadas en 
sangre también se denominan células tumorales circulantes o CTC. Se ha observado que el 
número y las características de las CTC varían una vez iniciado un tratamiento con 
quimioterapia. Estudiar estos cambios es de gran importancia para encontrar nuevas 
herramientas para seguir la evolución de su enfermedad y para comprender mejor el 
funcionamiento del cáncer de próstata y, por tanto, encontrar nuevas vías de tratamiento. Es por 
ello, por lo que solicitamos su consentimiento para la utilización de muestras de su sangre para 
hacer nuestro estudio. 
 
Este estudio ha sido aprobado por el Comité Ético de Investigación Clínica y se realizará 
siguiendo la Declaración de Helsinki y los requisitos establecidos en el Real Decreto 223/2004.  
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¿Cómo se realizará este estudio?  
 
Solicitamos su consentimiento para que durante la visita previa al primer tratamiento con 
Docetaxel se le extraigan dos tubos adicionales de sangre. Una de estas muestras de sangre se 
utilizará para estudiar características de estas células tumorales circulantes en sangre que se 
asocien a la resistencia al tratamiento o a la capacidad de formar metástasis en distintos órganos. 
La otra muestra servirá para ver los niveles de células tumorales circulantes presentes en su 
sangre.  
Estos niveles de células tumorales circulantes se cuantificarán además en una muestra que se le 
extraerá antes del   3er y 6º ciclo de tratamiento. 
En el momento en que consideremos que su tumor se ha vuelto resistente al tratamiento le 
solicitaremos 1 tubo adicional de sangre para estudiar características del tumor que se asocien a 
la resistencia al tratamiento. 
Tenga en cuenta que estas muestras son un valioso instrumento para la investigación, que podría 
permitir obtener información para nuevas terapias y estrategias para pacientes, que como usted, 
padecen esta misma enfermedad. 
 
Es importante que sepa que su médico dentro del estudio podrá informarle de los resultados de 
los análisis, si usted así lo desea.  
 
 
¿Cuáles son los beneficios esperables y los riesgos potenciales de este estudio?  
Usted no obtendrá ningún beneficio por permitir el análisis de sus muestras biológicas. En 
cualquier caso, la información que se obtenga por su participación en este estudio puede ser de 
gran ayuda para otras personas con su misma enfermedad. La cesión de muestras para 
investigación es voluntaria y altruista. Su único beneficio es el que corresponde al avance de la 
medicina en beneficio de la sociedad, y el saber que ha colaborado en este proceso. 
Las muestras no podrá ser objeto directo de actividades con ánimo de lucro. No obstante, la 
información generada a partir de los estudios realizados sobre su muestra podría ser fuente de 
beneficios comerciales. En tal caso, están previstos mecanismos para que estos beneficios 
reviertan en la salud de la población, aunque no de forma individual en el donante. 
Su participación en este estudio es completamente voluntaria. Si usted decide no participar 
recibirá todos los cuidados médicos que pudiera necesitar y su relación con los equipos médicos 




Las únicas molestias y riesgos de participar en este estudio están relacionados con la toma de la 
muestra de sangre de su brazo, que se realiza siguiendo el procedimiento habitual. Le puede 
ocasionar un pequeño hematoma o una leve inflamación, que desaparecerán en pocos días; más 
raramente, mareo o dolor en el momento de la extracción de sangre.  
 
¿Se dispone de otros tratamientos?  
En esta parte del estudio que ahora se le propone no se pretende evaluar ningún tratamiento 
adicional sino que simplemente queremos estudiar como afecta el tratamiento con Docetaxel a 
la población de células tumorales que circulan a través de su sangre y las posibles causas de 
resistencia a este fármaco. 
 
Su participación es voluntaria:  
Si desea participar en esta parte del estudio debe comunicárselo a su médico del estudio. Su 
participación es voluntaria. Si interviene en este estudio, debe saber que en cualquier momento 
puede decidir no seguir participando sin tener que manifestar razón alguna para ello.  
 
¿Qué sucederá con las muestras?  
La muestra de sangre fresca que se extraiga será almacenada en el Servicio de Oncología. Si 
usted nos da su consentimiento, dichas muestras serán trasladas al Laboratorio de Oncología 
Traslacional del Hospital Clínico Universitario de Santiago, para su posterior análisis. Durante 
este tiempo, dichas muestras se codificarán con su número de participación en el estudio, pero 
nunca con su nombre y apellidos o con cualquier otro dato que pueda identificarlo de manera 
directa.   
Las muestras se conservarán en el Laboratorio de Oncología Traslacional del Hospital Clínico 
Universitario de Santiago durante como máximo 5 años.  Pasado este tiempo, las muestras de 
sangre serán destruidas. Ninguna de las muestras recogidas se utilizará para otras 
investigaciones, ni serán compartidas con ningún otro equipo de investigación. 
 
Revisión de Documentos Originales, Confidencialidad y Protección de Datos de Carácter 
Personal:  
Usted comprende y consiente: con el fin de garantizar la fiabilidad de los datos recogidos en 
este estudio, será preciso que los miembros del equipo investigador, así como el promotor del 
estudio y eventualmente las autoridades sanitarias y/o miembros del Comité Ético de 
Investigación Clínica, tengan acceso a su historia clínica, comprometiéndose a la más estricta 
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confidencialidad, de acuerdo con la Ley 41/2002. Así mismo, se dará cumplimiento a la Ley de 
Investigación Biomédica 14/2007. 
El tratamiento, la comunicación y la cesión de los datos de carácter personal de todos los sujetos 
participantes se ajustará a lo dispuesto en la Ley Orgánica 15/1999, de 13 de diciembre de 
protección e datos de carácter personal y la transmisión de datos se hará conforme a la dicha ley 
y al R.D. 1720/2007.  De acuerdo a lo que establece la legislación mencionada, usted puede 
ejercer los derechos de acceso, modificación, oposición y cancelación de datos, para lo cual 
deberá dirigirse a su médico del estudio. En ninguno de los informes del estudio aparecerá su 
nombre y su identidad no será revelada a persona alguna salvo para cumplir con los fines del 
estudio y en el caso de urgencia médica o requerimiento legal. Cualquier información de 
carácter personal que pueda ser identificable será conservada y procesada por medios 
informáticos bajo condiciones de seguridad por el Promotor, o por una institución designada por 
el, con el propósito de determinar los resultados del estudio. El acceso a dicha información 
quedará restringido al personal del estudio designado al efecto o a otro personal autorizado que 
estará obligado a mantener la confidencialidad de la información. Los resultados del estudio 
podrán ser comunicados a las autoridades sanitarias y, eventualmente, a la comunidad científica 
a través de congresos y/o publicaciones.  
Sus datos se transferirán de forma codificada, no incluyendo iniciales, nombre, dirección u otro 
dato que le identifique directamente. Le será asignado un número que sólo el equipo médico del 
estudio podrá conectar con su nombre. De acuerdo con la ley vigente, usted tiene derecho al 
acceso de sus datos personales; asimismo, tiene derecho a su rectificación y cancelación. Si así 
lo desea, deberá solicitarlo al médico que le atiende en este estudio.  
 
Otra información que usted debe conocer:  
Los resultados del estudio podrán ser comunicados en reuniones científicas, congresos médicos 
o publicaciones científicas. Siempre se mantendrá una estricta confidencialidad sobre su 
identidad. 
Si usted lo desea, su médico de cabecera será informado de su participación en este estudio, para 
lo cual se le entrega a usted una carta informativa para que se la haga llegar.  
 
Ante cualquier eventualidad que pudiera surgir mientras participe en este estudio o para 
cualquier pregunta sobre el mismo que desee realizar tras leer este documento, por favor diríjase 
a: ________________________________________, en el teléfono _____________. 




Este documento se firmará por duplicado quedándose una copia el Investigador  




Análisis de CTC en sangre 
 
Yo, (nombre y apellidos)______________________________________________________ 
 
He leído la hoja de información que se me ha entregado.  
He podido hacer preguntas sobre el estudio.  
He recibido suficiente información sobre el estudio.  
 
He hablado con: (nombre del investigador) _______________________________________ 
 
He tenido tiempo suficiente para considerar de manera adecuada mi participación en el estudio.  
Comprendo que mi participación es voluntaria.  
Comprendo que puedo retirarme del estudio:  
1. Cuando quiera  
2. Sin tener que dar explicaciones 
3. Sin que esto repercuta en mis cuidados médicos  
 
Presto libremente mi conformidad para que se utilicen mis muestras y datos asociados como 




Afirmo haber obtenido información adecuada sobre la finalidad de la conservación, el lugar de 
la conservación, la seguridad y las garantías de cumplimiento de la legalidad vigente que me 
proporciona el centro encargado de conservar las muestras a los fines indicados tal efecto. 
 
Comprendo que sobre las muestras de este estudio NO se llevarán a cabo análisis genéticos. 
 
Autorizo a que se transfieran mis muestras y datos asociados, excepto los que me identifiquen, 







Fecha: ……. /……. /……….                                                  Fecha: ……. /……. /………. 
 






















Gracias a los pacientes y a sus familias. Su generosidad y colaboración en este estudio 
han sido absolutas. La ilusión por contribuir a profundizar en el conocimiento de su 
enfermedad, y la dignidad con la que se comportan en momentos tan difíciles merece 
toda nuestra admiración y respeto.  
Del mismo modo nuestro trabajo no habría sido posible sin el apoyo, paciencia y cariño 
de todo el personal del Hospital de Día y de la planta de Oncología del Hospital Clínico 
Universitario de Santiago. Para todos y cada uno de sus miembros, mi más sincero 
agradecimiento.  
Como persona y como médico he sido educado en el valor que aporta el equipo y el 
trabajo compartido. Resulta imposible, a pesar de la visión cortoplazista y gremial en la 
que en ocasiones  nos escudamos, no desarrollar nuestro trabajo dentro de un enfoque 
interdisciplinar, en colaboración con otros compañeros. De ahí que el mérito del 
presente trabajo sea compartido también con miembros de otros servicios del hospital: 
Anatomía Patológica, Unidad de Farmacia Oncológica, Medicina Nuclear, Oncología 
Radioterápica, Radiodiagnóstico o Urología, entre otros.  
En el laboratorio de Oncología traslacional del Hospital Clínico se realizaron los 
estudios de enumeración y caracterización molecular de las células tumorales 
circulantes. Lógicamente sin su participación no existiría esta tesis. Por su 
disponibilidad, conocimiento y capacidad inagotable de respuesta muchas gracias, en 
especial a Helena, Alicia, Miguel y Laura.  
María aportó siempre una visión original y disruptiva desde Canadá, además de batir el 
record mundial de número de variables en una base de datos. A Urbano le debo varias 
ilustraciones magníficas, una valiosísima ayuda estadística, y la revisión de parte del 
texto. Además Urbano ha participado en el cuidado de muchos de los pacientes que nos 
han cedido sus datos, y hemos compartido ideas, inquietudes. Hemos aprendido juntos y 
siempre ha estado a mi lado. 
Rafa e Ihab, mis directores de tesis, han encontrado tiempo (ese bien tan preciado) para 
poder dedicármelo y guiarme tanto en el diseño inicial del estudio como aconsejarme en 
el enfoque final del manuscrito. Han contribuido con sus sugerencias  a la revisión del 
texto. 
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Gracias también a Miguel por su contribución a la parte de arrays, y por la revisión de la 
discusión y conclusiones. Es especialmente motivador el que siempre esté receptivo a 
cualquier propuesta, y nos anime a seguir desarrollando proyectos.  
Gracias a Fernando, por su ánimo y por el cuadro que ilustra la portada y el inicio de 
cada capítulo. 
Antonio y Roberto también me han regalado parte de su tiempo, además de 
proporcionarme excelentes fotografías incorporadas en la introducción. Más allá y 
mucho más importante, comparto con ellos una profunda y estimulante amistad. 
Por su profunda y exhaustiva revisión del manuscrito, por su paciencia, por su claridad 
y extenso conocimiento del mundo de las CTCs estoy en completa e impagable deuda 
con Laura.  Ahora que deposito la tesis ganará mucho en calidad de vida.  
El ejemplo de mi padre y mi madre, su dedicación, profesionalidad y valores han sido 
siempre y siguen siendo un referente en mi vida. Es una gran suerte poder darles las 
gracias a mis padres...y seguro que se sorprenden, porque les parecerá que no han hecho 
nada. Solo ser padres. Todo.  
Javi, Sabela, Miguel y Pedro han sufrido directamente estos meses, el tiempo 
insuficiente que les he dedicado. A cambio solo he tenido sonrisas, alegría y palabras de 
ánimo. Ilusión. Para vosotros, por vuestra paciencia, por vuestra curiosidad insaciable, 
por transmitir tanta felicidad.  
A mis hermanos y al resto de mi familia.  
Bea me animó desde antes del primer momento, siendo consciente que sería la principal 
damnificada en este proceso. Ha sonreído en el cansancio, el estrés, los momentos de 
duda, y en  las dificultades. Me ha cuidado en todo momento. Ha participado también de 
la emoción, del progreso del texto, y ha acogido este proyecto como común. Ha 
esperado pacientemente y ha aprendido todo lo que no debe hacerse en el desarrollo de 
la tesis.  
Gracias por arriesgar, Bea, y por creer en nuestra vida juntos.  
